title page Title Pag
 
AN OPEN -LABEL, RANDO MIZED-SEQUENCE, MULT ICENTER, SINGLE -
CROSSOVER STUDY TO A SSESS THE RELATIVE B IOAVAILABILITY AND 
BIOEQUIVALENCE OF NI RAPARIB TABLET FORMU LATION  COMPARED TO 
NIRAPARIB CAPSULE FO RMULATION IN PATIENT S WITH ADVANCED SOLI D 
TUMORS  
Sponsor:  TESARO , a Glaxo Smith Kline 
Company  
980 Great West Road  
Brentford  
Middlesex, TW8 9GS  
UK  
Medical Monitor:  Reginald Ewesuedo , MD  
Senior Medical Director  
 
Sponsor Protocol No.:  
IND No: 3000-01-004 
100,996 
Study Drug Names:  Niraparib capsules, niraparib tablets 
Development Phase:  Phase 1 
Date of Original 
Protocol:  26 September 2017  
Date of Amendment 1:  05 February 2018  
Date of Amendment 2:  06 August 2018  
Date of Amendment 3:  29 January 2019  
Date of Amendment 4 : 
Date of Amendment 5:  18 June 2019 
22 December  2020 
Version of Protocol:  6.0 
 
The study will be conducted according to the protocol and in compliance with Good Clinical Practice 
(GCP), with the Declaration of Helsinki, and with other applicable regulatory requirements.  
Confidentiality Statement  
All information contained in this document is privileged and confidential to TESARO , a wholly 
owned subsidiary of Glaxo Smith Kline (GSK) . Any distributio n, copying, or disclosure is strictly 
prohibited without prior written approval by TESARO.  

Niraparib     
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 2 of 103 SPONSOR SIGNATURE PA GE 
 
Declaration of Spons or or Responsible Medical Officer  
 
Title: An Open -Label, Randomized -Sequence, Multicenter, Single -Crossover Study to 
Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation 
Compared to Niraparib Capsule Formulation in Patient s with Advanced Solid Tumors  
 
This study protocol was subjected to critical review and has been approved by the Sponsor. The 
information it contains is consistent with the current risk/benefit evaluation of the investigational 
products as well as with the moral, ethical, and scientific principles governing clinical research 
as set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice.  
 
___________________________________    _____________________  
Divya Gupta, MD, Senior Medical Director  Date 
on behalf of:  
Reginald Ewesuedo , MD  
Senior Medical Director  
TESARO , a GSK company  
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 3 of 103 INVESTIGATORâ€™S AGREE MENT 
 
Declaration of the Principal Investigator  
 
Title: An Open -Label, Randomized -Sequence, Multicenter, Single -Crossover Study to 
Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation 
Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors  
 
I have read this study protocol, including all appendices. By signing this protocol, I  agree to 
conduct the clinical study, following approval by an Independent Ethics Committee/Institutional 
Review Board, in accordance with the study protocol, the current International Council for 
Harmonisation Guideline for Good Clinical Practice, and applicable  regulatory requirements. I 
will ensure that all personnel involved in the study under my direction will be informed about the 
contents of this study protocol and will receive all necessary instructions for performing the 
study according to the study proto col. 
 
 
             
Printed Name of Investigator  
 
             
Institution  
 
             
Signature of Investigator  
 
       
Date 
 
Niraparib     
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 4 of 103 Table 1: Summary of Changes for Amendment 5 (Version 6.0)  
Header, cover page, and 
Table 1: Summary of 
Changes for Amendment 5 
(Version 6.0)  Header updated with new version 
number, cover page updated with 
new amendment number, version 
number, and date of approval. 
Table 1 created to include rationale 
for this version.  Updated document per best 
documentation practi ces 
Entire document  Added  Stage 3 FE Study.  
Editorial changes were made 
throughout the document and to 
align with the Sponsorâ€™s standards 
and processes.  To assess the effect  of a high-fat 
meal or a fasted state on 
niraparib PK following a single 
oral dose of niraparib 300 mg 
tablet formulation.  
Editorial changes were made for 
conformity, clarity, flow, and 
typographical error correction  
Section 1. Synopsis â€“ Studied 
period (years)  Added date last patient completed 
in the Stage 3 FE Study PK Phase  To provide an estimated date for 
last patient completion in 
Stage 3 FE Study PK phase  
Section 1. Synopsis â€“ 
Primary Objectives  
Section 5.1. Primary 
Objectives  New Stage 3 FE Study primary 
objective defined: to assess the 
effect of a high -fat meal on 
niraparib tablet PK  New primary objective for 
Stage 3 FE Study  
Section 1. Synopsis â€“ 
Secondary Objectives  
Section 5.2. Secondary 
Objectives  Included Stage 3 FE Study into the 
original secondary objective  New secondary objective for 
Stage 3 FE Study  
Section 1. Synopsis â€“ 
Rationale for Study  
Section 4.2. Rationale for 
Study Detailed rationale for Stage 3 FE 
Study New rationale for Stage 3 FE 
Study 
Section 1. Synopsis â€“  
Methodology: Overall Study 
Design 
Section 6.1. Overall Study 
Design Added a brief description  of Stage 
3 FE Study  New brief description of Stage 3 
FE Study 
Section 1. Synopsis â€“ 
Methodology: 
Pharmacokinetics (PK) Phase  
Section 6.1. Overall Study 
Design â€“ PK Phase  
Section 9.5. Administration  Described cohort -specific dietary 
instructions, requirem ents, PK 
parameters, and sampling intervals 
for Stage 3 FE Study PK Phase  New information pertinent to 
Stage 3 FE Study only  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 5 of 103 Table 1: Summary of Changes for Amendment 5 (Version 6.0)  (Continued)  
Section 1. Synopsis â€“ 
Methodology:  Extension 
Phase 
Section 6.1 Overall Study 
Design â€“ Extension Phase  Reduced window for Stage 3 FE 
Study Extension Phase enrollment.  
Addition of tablet formulation.  To reduce administrative 
burden. 
Patients may receive tablet 
formulation in the Stage 3 FE 
Study Extension Phase.  
Section 1. Synopsis â€“ Figure 
1: Study Design: 
Single-Crossover Study  
Section 6.1. Overall Study 
Design â€“ Figure 2: Study 
Design: Single Crossover 
Study Added Stage 3 FE Study  Details the study design for 
Stage 3 FE Study  
Section 1.  Synopsis â€“ 
Number of patients (planned)  
Section 6.2. Number of 
Patients Added Stage 3 FE Study  Provides estimate of patient 
numbers required for Stage 3 FE 
Study 
Section 1. Synopsis â€“ 
Inclusion and Exclusion 
Criteria for Stage 3 PK Phase 
and Extension Ph ase 
Section 7.1.2. Patient 
Inclusion Criteria (Stage 3 
only) 
Section 7.2.2. Patient 
Exclusion Criteria (Stage 3 
only) 
Section 7.3.1. Extension 
Study Patient Inclusion 
Criteria (Stage 3 only)  Added inclusion and exclusion 
criteria specific to Stage  3 FE 
Study PK and Extension Phase   Details the inclusion and 
exclusion criteria required for 
patient eligibility to enroll in 
Stage 3 FE Study PK and 
Extension Phase  
Section 1. Synopsis â€“ 
Duration of treatment  Added treatment duration for Stage 
3 FE Study  New information pertinent to 
Stage 3 FE Study only  
Section 1. Synopsis â€“ Criteria 
for evaluation: 
Pharmacokinetics  
Section 10. Pharmacokinetic 
Assessments  Added PK parameter t lag for 
Stage 3 FE Study  
 Per FDA guidance for industry: 
Food-Effect Bioavailabilit y and 
Fed Bioequivalence Studies  
Section 1. Synopsis â€“ Criteria 
for evaluation: Blood Sample 
Collection  
Section 10.1. Blood Sample 
Collection  Provided blood sample collection 
parameters for Stage 3 FE Study  New information pertinent to 
Stage 3 FE Study only 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 6 of 103 Table 1: Summary of Changes for Amendment 5 (Version 6.0)  (Continued)  
Section 1. Synopsis â€“ 
Analysis Populations  
Section 12.1. Analysis 
Populations  Added new analysis population for 
Stage 3 FE Study  New patient population to 
evaluate the PK parameters for 
Stage 3 FE Study PK Phase  
Section 1. Synopsis â€“ 
Statistical methods: Sample 
Size Consideration â€“ Stage 3 
Section 12.2. Sample Size 
Consideration  Added required sample size to 
characterize statistical calculations 
for Stage 3  FE Study PK Phase  Provides rationale for sample 
size and statistical calculations 
criteria for Stage 3 FE Study  
Section 1. Synopsis â€“ 
Statistical methods: Safety 
Analyses 
Section 12.3. Safety Analyses  Described safety analyses 
provisions for patients enr olled in 
Stage 3 FE Study PK and 
Extension Phases  Safety analyses expanded to  
include patients enrolled in 
Stage 3 FE Study PK and 
Extension Phases  
Section 1. Synopsis â€“ 
Statistical methods: Safety 
Analyses 
Section 11.2.1.4. Adverse 
Events of Special Int erest 
(AESI) Removed monitoring requirement 
for AESIs of pneumonitis and 
embryo-fetal toxicity  Pneumonitis and embryo -fetal 
toxicity will be monitored as an 
ADR and pregnancy outcome, 
respectively.  
Section 1. Synopsis â€“ 
Statistical methods: 
Pharmacokinetic Analyses  Added specific requirements 
related to Stage 3 FE Study  New information pertinent to 
Stage 3 FE Study only  
Section 4.2. Rationale for 
Study Included key results from Stage 2 
CSR New information available since 
last amendment (Amen dment 4) 
Section 6.1. Overall Study 
Design Briefly described of the Stage 3 FE 
Study cohort design  New information pertinent to 
Stage 3 FE Study only  
Section 6.1. Overall Study 
Design â€“ Extension Phase  Described patient eligibility criteria 
for inclusion  in Stage 3 FE Study 
Extension Phase (this study or an 
alternative study)  New information pertinent to 
Stage 3 FE Study only   
Section 6.1.1. Fasting and 
Study Drug Administration 
for the PK Phase  Described specific instructions for 
patients enrolled in St age 3 FE 
Study PK Phase  
Section 6.1.2. General Study 
Conduct 
Section 9.5. Administration  
Section 6.3.2. Randomization 
Scheme Briefly described the Stage 3 FE 
Study randomization scheme  New information pertinent to 
Stage 3 FE Study only  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 7 of 103 Table 1: Summary of Changes for Amendment 5 (Version 6.0)  (Continued)  
Section 6.6.1 Schedule of 
Events â€“ Table 7: Schedule of 
Events: Study Drug and PK 
Phase â€“ Stage 3, Table 8: 
Schedule of Events: 
Extension Phase (vital signs 
and weight row  and 
corresponding footnote 10)  New table added for Stage 3 FE 
Study PK Phase  New information pertinent to 
Stage 3 FE Study only.  
Increased vital signs monitoring 
from 1 week to 4 weeks to 
ensure they are appropriately 
monitored to address new PRES 
and hypertension guidelines.  
Section 7.4.1. 
Discontinuation from 
Pharmacokinetic Phase  Added that patient must fast for 
14 (10+4) hours for both fed and 
fasted conditions.  
Further detail on options for 
continuing to receive niraparib 
provided.  Clarity. 
 
 
New criteria pertinent to Stage 3 
FE Study only.  
Section 7.5. Restrictions 
During Study â€“ #6and #10 Added that patients must be able to 
fast for 14 (10+4)  hours for both 
PK dosing periods  
Added restriction #10.  Clarity 
 
Prohibits patients enrolled in 
Stage 3 from taking lipase 
inhibitors or cholesterol 
absorption inhibitors.  
Section 7.5.1. Lifestyle 
Considerations  Updated to detail potential 
photosensitivity associated with  
niraparib  New Sponsor guidelines due to 
updated niraparib safety 
information  
Section 8.1. Description of 
Study Drug â€“ Table 9: 
Investigational Product  Added Stage 3 FE Study  New information pertinent to 
Stage 3 FE Study only  
Section 11.1.6. Vital Signs  Included heart rate monitoring 
requirement  New Sponsor guidelines due to 
updated niraparib safety 
information  Section 11.2.8. Hypertension, 
Including Hypertensive Crisis  New safety monitoring 
requirements for hypertension, and 
hypertensive crisis added  
Section 6.4.2. Safety Criteria 
for Adjustment or Stopping 
Doses During Extension 
Phase â€“ Table 3: Niraparib 
Dose Reductions for 
Non-Hematologic Toxicities  
Section 11.2.9 â€“ Posterior 
Reversible Encephalopathy 
Syndrome  New safety monitoring 
requirements for PRES added  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 8 of 103 Table 1: Summary of Changes for A mendment 5 (Version 6.0)  (Continued)  
Section 11.2.10. Allergic 
Reaction New allergic reaction data added   
Section 11.1.10.6. Pregnancy 
Screen Revised language to indicate test 
should occur prior to PK period 1 
only Clarity 
Section 12.4. 
Pharmacokinetic Analysis Details specific PK analyses to be 
conducted for Stage 3 FE Study 
PK Phase  Clarifies additional requirement 
for Stage 3 FE Study PK Phase  
Appendix E â€“ Guidance on 
Composition of High -Fat 
Meal New appendix added to provide 
guidance on composition of a 
high-fat meal Provides supportive instruction 
for Stage 3 FE Study  
Abbreviations:  ADR=adverse drug reaction; AESI=adverse events of special interest; CSR=clinical study report; 
FDA=Food and Drug Administration; FE=food effect; PK=pharmacokinetic(s);  PRES=Posterior Reversible 
Encephalopathy Syndrome; t lag=time from administration of the dose to the first quantifiable concentration  
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRI6<1236,6 
1DPHRI6SRQVRU&RPSDQ\ 7(6$52D*6.FRPSDQ\
1DPHRI,QYHVWLJDWLRQDO3URGXFW 1LUDSDULE
1DPHRI$FWLYH,QJUHGLHQW 1LUDSDULE
7LWOHRI6WXG\ $Q2SHQ/DEHO5DQGRPL]HG6HTXHQFH0XOWLFHQWHU6LQJOH&URVVRY HU6WXG\WR
$VVHVVWKH5HODWLYH%LRDYDLODE LOLW\DQG%LRHTXLYDOHQFHRI1LUDS DULE7DEOHW)RUPXODWLRQ&RPSDUHGWR
1LUDSDULE&DSVXOH)RUPXODWLRQL Q3DWLHQWVZLWK$GYDQFHG6ROLG7 XPRUV
6WXG\FHQWHUV 1RUWK$PHULFD PXOWLFHQWHU 
6WXGLHGSHULRG\HDUV
(VWLPDWHGGDWHILUVWSDW LHQWHQUROOHG4 
(VWLPDWHGGDWHODVWSDWLHQWFRPSOHWHGLQWKH6WDJH3.
3KDVH4
(VWLPDWHGGDWHODVWSDWLHQWFRPSOHWHGLQWKH6WDJH3.
3KDVH4
(VWLPDWHGGDWHODVWSDWLHQWFRPSOHWHGLQWKH6WDJH3.
3KDVH43KDVHRIGHYHORSPHQW
3KDVH

2EMHFWLYHV 
3ULPDU\
x6WDJH7RREWDLQSUHOLPLQDU\ DVVHVVPHQWRIWKHUHODWLYH ELRDYDLODELOLW\%$RIPJ
QLUDSDULEDGPLQLVWHUHGDVDWDEO HWYHUVXVFDSVXOHIRUPXODWLRQD QGWRHVWLPDWHWKH
LQWUDVXEMHFWYDULDELOLW\RIQLUDSDULESKDUPDFRNLQHWLFV3.
x6WDJH7RHYDOXDWHLIWKHW DEOHWIRUPXODWLRQÃ®PJRIQL UDSDULELVELRHTXLYDOHQW
%(WRWKHFDSVXOHIRUPXODWLRQÃ®PJ
x6WDJH7RDVVHVVWKHHIIHFWRIDKLJK IDWPHDORQQLUDSDULE3.IROORZLQJDVLQJOHPJ
GRVHRIWKHWDEOHWIRUPXODWLRQ
6HFRQGDU\ 
x6WDJH6WDJHDQG6WDJH7RHYDOXDWHWKHVDIHW\RIVLQJOH GRVHQLUDSDULEZKHQ
DGPLQLVWHUHGDVDWDEOHWRUFDSVX OHIRUPXODWLRQLQSDWLHQWVZLW KDGYDQFHGVROLGWXPRUV
x([WHQVLRQ3KDVH7RHYDOXDWHW KHVDIHW\RIFRQWLQXRXVO\GRVHGQ LUDSDULELQSDWLHQWVZLWK
DGYDQFHGVROLGWXPRUV
5DWLRQDOHIRU6WXG\ 
7KLVVWXG\LVDQRSHQ ODEHO3KDVHVWXG\WRHYDOXDWHWKHUHODWLYH%$DQG%(RI QLUDSDULEDGPLQLVWHUHG
DVDWDEOHWIRUPXODWLRQFRPSDUHGWRWKHUHIHUHQFHFDSVXOHIRUPX ODWLRQPDQXIDFWXUHGE\WKHVDPH
SURFHVVDVFXUUHQWO\PDUNHWHGLQWKH8QLWHG6WDWHV 6SHFLILFDOO\D PJQLUDSDULEWDEOHWZLOOEHCCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 10 of 103 compared to 3 niraparib capsules (3Ã—1 00 mg). In addition, t his study will evaluate the effect of a 
high-fat meal on the PK of the niraparib 300 mg tablet formulation . The Extension Phase will enable 
patients enrolled in the study to continue to receive treatment with niraparib if they are tolerating it 
and, in the Investigatorâ€™s opinion, may receive benefit.  
Methodology:  
Overall Study Design  
This is a multicenter, open -label study in patients with advanced solid tumors. This is a 3 -stage, single 
cohort, randomized -sequence, single-crossover study to assess the relative BA and BE of niraparib 
tablet formulation relative to the capsule formulation . In addition, Stage 3 of the protocol is a single 
cohort, randomized -sequence, 2 -period, single dose, crossover study to assess effe ct of food on the PK 
of the niraparib tablet formulation.  
Pharmacokinetics (PK) Phase:  In Stages 1 and 2 , patients will be randomized 1:1 to receive tablet 
formulation followed by capsule formulation or capsule formulation followed by tablet formulation . In 
Stage 3, patients will be randomized 1:1 to receive tablet formulation in a fasted state followed by 
tablet formulation taken with a high -fat meal or tablet formulation  taken with a high -fat meal followed 
by tablet formulation taken in a fasted state.  
Stage 1:  Following an 8 -hour fast on Day  1 (see Section 6.1.1), patients will receive a single dose of 
the formulation (tablet [1Ã—300  mg] or capsul e [3Ã—100 mg]) followed by a 7 -day (+1 day) Washout/PK 
period followed by a dose of the alternate formulation also in a fasted state, followed by a 7 -day 
Washout/PK period. Patients receiving the tablet in the first treatment period will receive the capsule s 
in the second treatment period and vice versa ( see Section  6.1.1). Extensive PK sampling will be 
carried out after niraparib dosing (see Section 10.1).  
Stage 2:  Following an 8 -hour fast on Day  1 (see Section 6.1.1), patients will receive a single dose of 
the formulation (tablet [1Ã—300  mg] or capsule [3Ã—100  mg]) followed by a 14 -day (+/- 4 days) 
Washout/PK period, followed by a dose of the alternate for mulation also in a fasted state, followed by 
a 7-day Washout/PK period. Patients receiving the tablet in the first treatment period will receive the 
capsules in the second treatment period and vice versa ( see Section  6.1.1). Extensive PK sampling will 
be carried out after niraparib dosing (see Section 10.1 ).  
Stage 3: In period 1, patients will receive a single 300 mg niraparib tablet either following a 10 -hour 
fast (see Section 6.1.1) or directly following consumption of a high -fat meal (see Section 6.1.1), 
followed by a 14-day (+4 days) PK sampling and washout period. In period 2, patients will be crossed 
over to receive a single 300 mg niraparib tablet in a fasted state or with a high -fat meal, followed by a 
7-day PK sampling period. All patients will fast for a min imum of 4 hours postdose in both periods. 
Patients receiving the tablet in a fasted state in the first treatment period will receive the tablet with a 
high-fat meal in the second treatment period and vice versa.  
In the rare instance where a delay of the e ntire PK period 2 is needed for any reason beyond the 4-day 
window specified above , the site must contact the Sponsor's Medical Monitor to discuss the patient 
circumstances. The Sponsor will then decide if the patient can continue with PK period 2 with a delay.  
Similarly, should the laboratory results on D15 (the day of niraparib admin istration in PK Period 2) 
show changes in organ function such that the original inclusion criteria for laboratory values are no 
longer met, or in the event of a significant change of patientâ€™s clinical status as judged by the 
Investigator, the site must co nsult with the Sponsor to discuss the patient's continued participation in 
PK period 2. Note that sites need not wait for the pre -dose laboratory results to begin PK period 2, but 
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRIUDWKHUFRQVXOWWKH6SRQVRURQFHWKHUHVXOWVDUHDYDLODEOHDVQH HGHG3DWLHQWVZKRH[SHULHQFHHPHVLV
ZLWKLQKRXUVRIGRVLQJZLOOEHGLVFRQWLQXHGIURPWKH3.3KDVHDQGZLOOEHDO ORZHGWREHVFUHHQHG
IRUWKH([WHQVLRQ3KDVH 3DWLHQWVZKRPLVVFULWLFDO3.VDPSOHVZLOOEHGLVFRQWLQXHGIURP WKH3.
SKDVHWKRVHWKDWPHHWRWKHUFULWHU LDIRUFRQWLQXHGQLUDSDULEWKHUDS\ZLOOEHHOLJLEOHWREHVFUHH QHGIRU
WKH([WHQVLRQ3KDVH VHH6HFWLRQ
)RU6WDJH3.SDUDPHWHUVWKDWZLOOEH HVWLPDWHGLQFOXGHDUHDXQGHUWKHSODVPDFRQFHQWUDWLRQ WLPH
FXUYHIURPWLPHWRWKHWLPHRIW KHODVWTXDQWLILDEOHFRQFHQWU DWLRQ$8& WDUHDXQGHUWKHSODVPD
FRQFHQWUDWLRQ WLPHFXUYHIURPWLPHH[WUDSRODWHGWRLQILQLW\$8& Â’DSSDUHQWWRWDOERG\FOH DUDQFH
&/)PD[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ& PD[WLPHWRUHDFK& PD[WPD[WHUPLQDO
HOLPLQDWLRQKDOI OLIHWDSSDUHQWWHUPLQDOYROXPHRIG LVWULEXWLRQ9])DQG%$RIW DEOHW
IRUPXODWLRQUHODWLYHWRWKH FDSVXOHIRUPXODWLRQEDVHGRQ$8& W$8&Â’DQG&PD[5HODWLYH
ELRDYDLODELOLW\ZLOOEHDVVHVV HGEDVHGRQWKHUDWLRRIJHRPHWUL FOHDVWVTXDUHVPHDQVRIWKHWHVWWDEOHW
WRUHIHUHQFHFDSVXOH$GGLW LRQDOO\WKHSKDUPDFRNLQHWLFVRI ZLOO
EHGHWHUPLQHG6W DJHRQO\ 
)RU6WDJHWKHVDPH3.SDUDPHWHU VDVDERYHZLOOEHHVWLPDWHG 7RFRQFOXGHELRHTXLYDOHQFHWKH
FRQILGHQFHLQWHUYDO&,RIW KHUDWLRRIJHRPHWULFOHDVW VTXDUHVPHDQVRIWKHWHVWWDEOHWWRUHIHUHQFH
FDSVXOHSURGXFWVKRXOGEHZLWKLQ IRU$8& Â’$8&WDQG& PD[
)RU6WDJHWKHVDPH 3.SDUDPHWHUVDVDERYHZLOO EHHVWLPDWHG,QDGGLWLRQW ODJWKHWLPHIURP
DGPLQLVWUDWLRQRIWKHGRVHWRWKHILUVWTXDQWLILDEOHFRQFHQWUDW LRQZLOOEHGHWHUPLQHGDQGW PD[ZLOOEH
FRPSDUHGEHWZHH QWKHIHGDQGIDVWHGVWDWHV7KHUHODWLYH ELRDYDLODELOLW\ RIWKHPJQLUDSDULEWDEOHW
DGPLQLVWHUHGZLWKDKLJK IDWPHDOUHODWLYHWRIDVWHGGRVLQJZLOOEHEDVHGRQWKHUDWLRR IJHRPHWULFOHDVW 
VTXDUHVPHDQVRI$8& W$8&Â’DQG& PD[
$GGLWLRQDO3.SDU DPHWHUVPD\EHHVWLPDWHGHJU HVLGXDODUHDLIGHHPHGDSSURS ULDWH
([WHQVLRQ3KDVH :KHQSDWLHQWVFRPSOHWHWKH3. 3KDVHRIWKHVWXG\DWOHDVW GD\VIURPWKH
EHJLQQLQJRI3.SHULRGWKH\PD\EHHOLJLEOHWRSDUWLFLS DWHLQWKH([WHQVLRQ3KDVH VHH6HFWLRQ
,IWKHSDWLHQWKDVPHWWKHLQFO XVLRQFULWHULDDQGFRPSOHWHGWKH UHTXLUHGVFUHHQLQJDVVHVVPHQWVW KH
VWDUWLQJGRVHRIQLUDSDULELQWKH([ WHQVLRQ3KDVHZLOOEHEDVHGRQWKHSDWLHQWÂ¶VEDVHOLQHDFWXDOER G\
ZHLJKWRUSODWHOHWFRXQW3DWLHQWVZLWKDEDVHOLQHDFWXDOERG\ ZHLJKWRIÂ•NJDQGVFUHHQLQJSODWHOHW
FRXQWRIÂ•Â—/REWDLQHGDIWHUFRPSOHWLRQRI WKH3.3KDVHDVSDUWRI([WHQVLRQ3 KDVH
VFUHHQLQJZLOOWDNHRQHPJVWUHQJWKWDEOHWRUÃ®PJ WDEOHWVFDSVXOHVDWHDFKGRVH
DGPLQLVWUDWLRQRQFHDGD\>4' @3DWLHQWVZLWKDEDVHOLQHDFWX DOERG\ZHLJKWRINJRUVFUHHQLQJ
SODWHOHWFRXQWRIÂ—/ZLOOWDNHRQHPJVWUHQJWK WDEOHWRUÃ®PJ WDEOHWVFDSVXOHVDW
HDFKGRVHDGPLQLVWUDWLRQ4')RUSDWLHQWVZKRVHLQLWLDOVWDUW LQJGRVHLVPJ4'HVFDODWLRQWR
PJ4'LVSHUPLWWHGDIWHUF\FOHV RIWKHUDS\LIQRWUHDWPHQWLQ WHUUXSWLRQRUGLVFRQWLQXDWLRQZDV
UHTXLUHGGXULQJ WKHILUVWF\FOHVRI([WHQVLRQ3KDVHWKHUDS\DQGDIWHUDSSURYD OIURPWKH6SRQVRU
$GGLWLRQDOGRVHPRGLILFDWLRQVZLOOQRWEHEDVHGXSRQFKDQJHVLQ WKHSDWLHQWÂ¶VDFWXDOERG\ZHLJKW
GXULQJVWXG\SDUWLFLSDWLRQ,IODERUDWRU\YDOXHVDWWKHEHJLQQL QJRI([WHQVL RQ3KDVHDUHRXWVLGHRIWKH
UDQJHVSHFLILHGLQWKHLQFOXVLRQFULWHULDWKHSDWLHQWPD\FRQW LQXHWRSDUWLFLSDW HLQWKHVWXG\RQO\XSRQ
6SRQVRUDSSURYDODQGZLWKFRQVLGHUDW LRQIRUDQDSSURSULDWHO\UH GXFHGGRVH6KRXOGDSDWLHQWVWDUWWKH
([WHQVLRQ3KDVHDW PJFRQVLGHUDWLRQPD\EHJLYHQWRHVFDODWHWRPJDIWHU F\FOHVRIWKHUDS\CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 12 of 103 if no treatment interruption or discontinuation was required during the first 2 cycles of Extension Phase 
therapy and after approval from the Sponsor.  
Patients have up to 28 days (21 days for  Stage 3 only; up to 28 days may be acceptable following 
discussion between the Sponsor and Investigator ) after completion of the PK Phase to complete the 
screening assessments and the Extension Phase Screening Visit. A tumor assessment is to be 
performed prior to the first dose of the Extension Phase (pre -Extension Phase). The pre -Extension 
Phase tumor assessment need not be completed if the baseline tumor assessm ent was performed 
â‰¤56 days before the first dose of the Extension Phase.  
The Cycle 1/Day 1 Visit can occur on the same day as the Extension Phase Screening Visit, dependent 
upon availability of radiographic results obtained â‰¤56 days of the first planned do se in the Extension 
Phase. If the Extension Phase Screening Visit and the Cycle 1/Day 1 Visit occur on the same day, the 
clinical laboratory results will be reviewed by the study personnel prior to study drug administration to 
ensure eligibility. At the Cy cle 1/Day 1 Visit, patients will undergo safety assessments and will receive 
study drug supply for the duration of 1 cycle (300  mg or 200 mg tablets of niraparib for QD dosing or 
3Ã—100 mg or 2Ã—100 mg tablets/capsules of niraparib for QD dosing, depending o n availability). It is 
preferred that patients remain on the same formulation (tablet versus capsule) throughout the Extension 
Phase. Patients will return on the first day of every treatment cycle (28Â±7 days) to receive study drug 
and for safety assessment s. Visits will continue approximately every 4  weeks until treatment 
discontinuation. In line with the niraparib United States Package Insert (US PI), dose interruption (no 
longer than 28  days) will be allowed based on adverse events (AEs). In addition, dos e reductions to 
200 mg QD and subsequently to 100  mg QD will be allowed based on AEs (please refer to US PI). 
Any dose reductions differing from  this must be discussed with the medical monitor. Patients can 
continue in the Extension Phase until the patient  meets 1 of the withdrawal criteria  (Section 7.4). 
End of Treatment (EOT) and Safety Follow -up Visits: The EOT visit will occur within 7 days of 
the decision to discontinue study drug for any reason. Patients who do not participate in the Extension 
Phase will also have an EOT visit within 7 days of the decision to discontinue study. Should the first 
dose of a new anti -cancer therapy occur within 14 day s of the decision to discontinue study drug, all 
assessments required for the Safety Follow -up visit should occur at the EOT visit and this visit will be 
considered the Safety Follow -up visit. If the first dose of the new anti -cancer therapy occurs >14 day s 
of the decision to discontinue study, the Safety Follow -up visit will occur 30+7 days after the last dose 
of the study drug, or at the start of any new anti -cancer therapy, whichever occur first.    
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO9HUVLRQ 
&RQILGHQWLDO  3DJHRI)LJXUH 6WXG\'HVLJQ6LQJOH&URVVRYHU6WXG\

6WDJH






6WDJH
FRPSOHWHG







6WDJHFRPSOHWHG


$EEUHYLDWLRQV3. SKDUPDFRNLQHWLFV 
1XPEHURISDWLHQWVSODQQHG
6WDJH$SSUR[LPDWHO\6WDJ H$SSUR[LPDWHO\SDWLHQWV ZLOOEHHQUROOHGWRHQVXUH
HYDOXDEOHSDWLHQWVIRUWKH%(DQDO\VLV 6WDJH$SSUR[LPDWHO\SDWLHQWVZLOOEHHQUROOHGWR HQVXUH
HYDOXDEOHSDWLHQWVIRUWKH)(DQDO\VLV
0DLQ&ULWHULDIRU,QFOXVLRQ6WDJHDQGRQO\
3.3KDVH 
7REHFRQVLGHUHGHOLJLEOHWRSDU WLFLSDWHLQWKLVVWXG\DOORI WKHIROORZLQJUHTXLUHPHQWVPXVWEHPHW
3DWLHQWLVFDSDEOHRIXQGHUVWDQG LQJWKHZULWWHQLQIRUPHGFRQVHQ WSURYLGHVVLJQHGDQG
ZLWQHVVHGZULWWHQLQIRUPHGF RQVHQWDQGDJUHHVWRFRPSO\ZLWKS URWRFROUHTXLUHPHQWV
3DWLHQWKDVKLVWRORJLFDOO\RUF\WRORJLFDOO\FRQILUPHGGLDJQRVLV RIPHWDVWDWLFRUORFDOO\
DGYDQFHGVROLGWXPRUVWKDWKDYH IDLOHGWRUHVSRQGWRVWDQGDUGW KHUDS\KDVSURJUHVVHGGHVSLWH
14-day washout 
period, including 7-
day PK sample 
collection7-day PK sample 
collection
300 mg dose 
1:1 Randomization 
Niraparib
Dose 1: 
Tablet
Niraparib
Dose 1:
Capsule
14-day washout 
period, including 7-
day PK sample 
collection
Niraparib
Dose 2: 
Tablet
Niraparib
Dose 2:
Capsule
Option to qualify 
for treatment in 
Extension Phase 
Option to qualify 
for treatment in 
Extension Phase 
300 mg dose 
N=16 evaluable 
1:1 Randomization 
Niraparib
Dose 1: 
Fasted
Niraparib
Dose 1:
Fed
14-day washout 
period, including 7-
day PK sample 
collection
Niraparib
Dose 2: 
Fasted
Niraparib
Dose 2:
Fed
Option to qualify 
for treatment in 
Extension Phase 
Option to qualify 
for treatment in 
Extension Phase 14-day washout 
period, including 7-
day PK sample 
collection7-day PK sample 
collection7-day PK sample 
collection
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 14 of 103 standard therapy, or for which no standard therapy exists, and who may benefit from treatment 
with a poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor as assessed by the 
Investigat or. Patients with lymphoma are eligible. Patients with primary central nervous 
system (CNS) malignancy are eligible provided they do not have new or progressive signs or 
symptoms, and are not requiring steroid dose exceeding the equivalent of 10 mg of pred nisone 
daily. 
3. Patient is at least 18 years of age.  
4. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.  
5. Patient has adequate organ function as defined below (Note: complete blood count [CBC] 
should be obtained without tran sfusion or receipt of colony stimulating factors [CSFs],  
erythropoietin stimulating agents or platelet -stimulating agents within 2  weeks before first 
dose): 
a. Absolute neutrophil count â‰¥1,500/ÂµL  
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM)  
d. Serum creatinine â‰¤1.5Ã— the upper limit of normal (ULN) or a calculated creatinine 
clearance â‰¥60 mL/min using the Cockcroft -Gault equation.  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirubin.  
f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) â‰¤ 2.5Ã— ULN unless 
liver metastases are present, in which case, they must be â‰¤ 5Ã— ULN 
6. Patient has recovered to baseline or Grade  1 toxicity  from prior cancer therapy (a patient with 
Grade 2 neuropathy or Grade  2 alopecia or Grade 2 hypothyroidism on a stable dose of thyroid 
replacement are an exception to this criterion and may qualify for this study).  For patients with 
hematologic, renal or hepatic toxicity from prior therapy inclusion criterion #5 should be 
applied to determined eligibility.  
7. Patient is able to take oral medications.  
8. Female patient meets the following criteria:  
a. Patient (of childbearing potential) is not breastfeeding, has a n egative serum pregnancy test 
within 72  hours prior to taking study drug and agrees to abstain from activities that could 
result in pregnancy from Screening through 180  days after the last dose of study drug, or is 
of non-childbearing potential. Note: A uri ne pregnancy test may be performed if the serum 
pregnancy test is not available before dosing.  
b. Female patient of non -childbearing potential (other than medical reasons) is defined by the 
following:  
i. â‰¥45 years of age and has not had menses for >1  year. 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon Screening 
evaluation.  
iii. Had undergone a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oo phorectomy or tubal ligation must be confirmed in 
the medical records, otherwise the patient must be willing to use highly effective 
contraception ( see Appendix  C) throughout the study, starting with the Screening 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 15 of 103 Visit through 180  days after the last dose of study drug. Information must be 
captured appropriately within the siteâ€™s source documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
9. Male patient agrees to use an adequate method of contraception and not donate sperm starting 
with the first dose of study drug  through 90  days after the last dose of study drug.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.   
Main Criteria for Inclusion (Stage 3 only):  
PK Phase:  
To be considered eligible to participate in this study, all of the following requirements must be met:  
1. Patient is capable of understanding the written informed consent, provides signed and 
witnessed written informed consent, and agrees to comply with prot ocol requirements.  
2. Patient has histologically or cytologically confirmed diagnosis of metastatic or locally 
advanced solid tumors that have failed to respond to standard therapy, has progressed despite 
standard therapy, or for which no standard therapy exi sts, and who may benefit from treatment 
with a PARP inhibitor as assessed by the Investigator. Patients with lymphoma are eligible. 
Patients with CNS malignancy are eligible provided they do not have new or progressive signs 
or symptoms and are not requiri ng steroid dose exceeding the equivalent of 10 mg of 
prednisone daily.  
3. Patient is at least 18 years of age.  
4. Patient has an ECOG performance status of 0 to 2.  
5. Patient has adequate organ function as defined below (Note: CBC should be obtained without 
transfusion or receipt of CSFs in the 1 week before obtaining sample.):  
a. Absolute neutrophil count â‰¥1,000/ÂµL  
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM)  
d. Serum creatinine â‰¤1.5Ã— ULN or a calculated creatinine clearance â‰¥60 mL/min using the 
Cockcroft -Gault equation.  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirubin.  
f. AST and ALT â‰¤ 2.5Ã— ULN unless liver metastases are present, in which case, they must be 
â‰¤5Ã— ULN 
6. Patient has recovered to baseline or Grade  1 toxicity from prior cancer therapy (a patient with 
Grade 2 neuropathy or Grade  2 alopecia or Grade 2 hypothyroidism on a stable dose of thyroid 
replacement are an exception to this criterion and may qualify for this study). For patients with 
hematologic, renal, or hepatic toxicity resulting from prior cancer therapy should meet 
inclusion criterion # 5 for eligibility.  
7. Patient is able to swallow and retain oral medication.  
8. Female patient meets the following criteria:  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 16 of 103 a. Female patient (of childbearing potential) is not breastfeeding, has a negative serum 
pregnancy test within 72  hours prior to taking study drug, and agrees to abst ain from 
activities that could result in pregnancy from Screening through 180  days after the last 
dose of study drug, or is of nonchildbearing potential. Note: A urine pregnancy test may be 
performed if the serum pregnancy test is not available before dosi ng. 
b. Female patient of nonchildbearing potential (other than medical reasons) is defined by the 
following: 
i. â‰¥45 years of age and has not had menses for >1  year. 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon Screening 
evaluation.  
iii. Had undergone a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oophorectomy or tubal ligation must be confirmed in 
the medical records, otherwise the pa tient must be willing to use highly effective 
contraception (see Appendix  C) throughout the study, starting with the Screening 
Visit through 180  days after the last dose of study drug. Information must be 
captured appropriately within the siteâ€™s source documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
9. Male patient agrees to use an adequate method of contraception and not donate sperm starting 
with the first dose of study drug through 90  days after the last dose of study drug.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patien t. 
10. CNS inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must 
have one of the following:  
a. No evidence of brain metastases  
b. Untreated brain metastases not needing immediate local therapy  
c. Previously treated brain metastases not ne eding immediate local therapy  
d. Brain metastases previously treated with local therapy may either be stable since treatment 
or may have progressed since prior local CNS therapy  
e. Patients treated with CNS local therapy for newly identified lesions found on con trast 
brain MRI performed during screening for this study may be eligible to enroll if the 
following criteria are met:  
i. Time since whole brain radiation therapy (WBRT) is â‰¥21 days prior to first 
dose of study drug, time since stereotactic radiosurgery (SRS)  is â‰¥7 days prior 
to first dose of study drug, or time since surgical resection is â‰¥28 days.  
ii. Other sites of disease assessable by Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST v1.1) are present  
f. Relevant records of any CNS treatment must  be available to allow for classification of 
target and non -target lesions  
11. Patient is a ble to eat a high -fat meal. See Section 6.1.1.  
12. Patient is a ble to fast for a minimum of 10 hours before start of visit and for an additional 4 
hours after study visit.  See Section  6.1.1. 
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 17 of 103 Main Criteria for Exclusion (Stage 1 and 2 only):  
PK Phase:  
Patients will not be eligible for study entry if any of the following criteria are met:  
1. Patient has a known hypersensitivity to the components of niraparib or excipients ( see 
Appendix  B).  
2. Patient has a known diagnosis of immunodeficiency (Note: Patients with splenectomy are 
allowed)  
3. Patient has symptomatic uncontrolled brain or leptomeningeal metastases. To be considered 
â€œcontrolled,â€ the patient must have undergone treatment (eg, radiation or chemotherapy) at 
least 1 month prior to study entry. The patient must not have any new or progressive signs or 
symptoms related t o the central nervous system disease and must be taking â‰¤10  mg of 
prednisone or equivalent per day or no steroids.  
4. Patient underwent major surgery within 3  weeks of starting the study or patient has not 
recovered from any effects of any major surgery.  
5. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder; 
nonmalignant systemic disease; or active, uncontrolled infection. Examples include, but are not 
limited to, uncontrolled ventricular arrhythmia, recent (within 90  days) myocardial infarction, 
uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava 
syndrome, uncontrolled hypertension, active uncontrolled coagulopathy, bleeding disorder, or 
any psychiatric disorder that prohibits obtaining informed consent.  
6. Female patient is pregnant or is expecting to conceive children while receiving study drug or 
for up to 180 days after the last dose of study drug. Male patient is expecting to donate sperm 
or father children while receiving study drug or  for up to 90 days after the last dose of study 
drug. 
a. Female patient is breastfeeding or is expecting to breastfeed within 30 days of receiving 
final dose of study drug (females should not breastfeed or store breastmilk for use, during 
treatment and for 30  days after receiving the final dose of study drug).  
7. Patient has a known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia 
(AML). 
8. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
9. Patient is unable to refrain from any intake of grapefru it or grapefruit juice within 7 days of the 
first administration of niraparib until 2 days postdose (Does not apply for Extension Phase).  
10. Patient is currently taking any of the following P -glycoprotein inhibitors: amiodarone, 
azithromycin, captopril, carve dilol, clarithromycin, conivaptan, cyclosporine, diltiazem, 
dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, 
quercetin, quinidine, ranolazine, ticagrelor, and verapamil, unless the dose and regimen has 
been stable  for at least 14 days prior to first dose and will not change during PK periods 1 and 
2 (Does not apply for Extension Phase) . 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 18 of 103 11. Patient taking proton pump inhibitors, antacids, or histamine 2 blockers unless the dose and 
regimen is stable for at least 14 day s prior to first dose and will not change during PK periods 
1 and 2.  Patients must hold these therapies starting within 8  hours prior to study drug 
administration until 9 hours after study drug administration (Does not apply for Extension 
Phase). 
12. Patient has gastric, gastro -esophageal, or esophageal cancer; patient is unable to swallow orally 
administered medication; patient has gastrointestinal disorders or significant gastrointestinal 
resection likely to interfere with the absorption of niraparib.  
13. Patient has known active hepatic disease (known hepatic cirrhosis, hepatitis B surface 
antigen-positive status, or suspected active hepatitis C infection).  
14. Patient has a past or current history of chronic alcohol use (3  or more drinks per day for the 
30 days prior to the Screening Visit) or dependence or is unable to abstain from alcohol for the 
duration of the study.  
15. Patient has had a prior cytotoxic therapy or anticancer monoclonal antibodies (mAbs) within 
14 days prior to start of PK Phase. There is no require d washout for palliative radiation. For 
targeted small anti -cancer molecules (eg, tyrosine kinase inhibitors), the required washout is 5 
half-lives of the start of PK Phase. Certain hormonal agents are allowed and are listed in 
Appendix  D. For hormonal agents not listed  Appendix  D, the Site must consult with the 
Sponsor r egarding allowing patient on study. For patient taking hormonal agents, dose and 
regimen of hormonal agents should have been stable for at least 14 days prior to first dose and 
is not expected to change during PK periods 1 and 2.  
16. Patient has significant p leural effusion or ascites that is expected to require drainage during the 
PK Phase (Does not apply for Extension Phase) . 
Main Criteria for Exclusion (Stage 3 only):  
PK Phase:  
Patients will not be eligible for study entry if any of the following criteria are met:  
1. Patient has a known hypersensitivity to the components of niraparib or excipients ( see 
Appendix  B).  
2. Patient has a known diagnosis of immunodeficiency (Note: Patients with splenectomy are 
allowed)  
3. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
4. Patient underwent major surgery within 3 weeks of starting the study or patient has not 
recovered from any effects of any major surgery.  
5. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder; 
nonmalignant systemic disease , or active, uncontrolled infection. E xamples include, but are not 
limited to, uncontrolled ventricular arrhythmia, recent (within 90  days) myocardial infarction, 
uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava 
syndrome, uncontrolled hypertension, acti ve uncontrolled coagulopathy, bleeding disorder, or 
any psychiatric disorder that prohibits obtaining informed consent.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 19 of 103 6. Female patient is pregnant or is expecting to conceive children while receiving study drug or 
for up to 180 days after the last dose of study drug. Male patient is expecting to donate sperm 
or father children while receiving study drug or for up to 90 days after the last dose of study 
drug. 
a. Female patient is breastfeeding or is expecting to breastfeed within 30 days of receiving 
final dose  of study drug (females should not breastfeed or store breastmilk for use, during 
treatment and for 30 days after receiving the final dose of study drug).  
7. Patient has a known history of MDS or AML.  
8. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
9. Patient is unable to refrain from any intake of grapefruit or grapefruit juice within 7 days of the 
first administration of niraparib until 2 days postdose (Does not apply for participation in 
Extension Phase of this study).  
10. Patient is currently taking any of th e following P -glycoprotein inhibitors: amiodarone, 
azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, 
dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, 
quercetin, quinidine, r anolazine, ticagrelor, and verapamil, unless the dose and regimen has 
been stable for at least 14 days prior to first dose and will not change during PK periods 1 and 
2 (Does not apply for for participation in Extension Phase of this study ). 
11. Patient is taking a proton pump inhibitor, antacids, or H2 blocker within 48 of dose (Does not 
apply for participation in Extension Phase of this study).  
12. Patient has gastric, gastroesophageal or esophageal cancer; patient is unable to swallow orally 
administered medication; patient has gastrointestinal disorders or significant gastrointestinal 
resection likely to interfere with the absorption of niraparib.  
13. Patient has known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen 
positive statu s, or suspected active hepatitis C infection).  
14. Patient has a past or current history of chronic alcohol use (3  or more drinks per day for the 
30 days prior to the Screening Visit) or dependence or is unable to abstain from alcohol for the 
duration of the s tudy. 
15. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
16. Patient has significant pleural effusion or ascites that is expected to require drainage during the 
PK Phase (Does not apply for participation in Extension Phase of this study) . 
17. Patient is currently taking a lipase inhibitor or cholesterol absorption inhibitor, such as orlistat 
or ezetimibe, respectively .  (Does not apply for participation in Extension Phase of this study) . 
Main Criteria for Inclusion (Stage 1 and 2 only):  
Extension Phase:  
To be considered eligible to participate in the Extension Phase, all of the following requirements must 
be met: 
1. Patient has an ECOG performance status of 0 to 2.  
2. Patient has adequate organ function as defined below; these criteria must be confirmed within 
72 hours of dose 1 in Extension Phase (Note: CBC should be obtained without transfusion or 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 20 of 103 receipt of CSFs, erythropoietin stimulating agents or platelet stimulating factors within 
2 weeks before first dose) : 
a. Absolute neutrophil count â‰¥1,5 00/ÂµL 
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM) 
d. Serum creatinine â‰¤1.5Ã— the ULN or a calculated creatinine clearance â‰¥60  mL/min using 
the Cockcroft -Gault equation or 24 -hour urine creatinine clearance  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirubin.  
f. AST and ALT â‰¤ 2.5Ã— ULN unless liver metastases are present, in which case, they must be 
â‰¤5Ã— ULN 
Note:  If laboratory values at the beginning of Extension Phase are outside of the range 
specified above, the patient may continue to participate in the study only upon Sponsor 
approval and with consideration for an appropriately reduced dose.  
3. Female patient meets  the following criteria : 
a. Patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test 
within 72 hours prior to taking study drug and agrees to abstain from activities that could 
result in pregnancy from Screening through 18 0 days after the last dose of study drug, or is 
of non-childbearing potential. Note: A urine pregnancy test may be performed if the serum 
pregnancy test is not available before dosing.  
b. Female patient of non -childbearing potential (other than medical reason s) is defined by the 
following:  
i. â‰¥45 years of age and has not had menses for >1  year). 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon Screening 
evaluation.  
iii. Had a hys terectomy, bilateral oophorectomy, or tubal ligation. Documented 
hysterectomy, oophorectomy or tubal ligation must be confirmed in the medical 
records, otherwise the patient must be willing to use highly effective contraception 
(see Appendix  D) throughout the study, starting with the Screening Visit through 
180 days after the last dose of study drug. Information must be captured 
appropriately within the site â€™s source documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
4. Male patient agrees to use an adequate method of contraception and not donate sperm starting 
with the first dose of study drug through 90  days after the last dose of study drug.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
Main Criteria for Inclusion (Stage 3 only):  
Extension Phase:  
To be considered eligible to participate in the Extension Phase, all of the following requirements must 
be met: 
1. Patient has an ECOG performance status of 0 to 2.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 21 of 103 2. Patient has adequate organ function as defined below; these criteria must be confirmed within 
72 hours of dose 1 in the Extension Phase (should be obtained without transfusion or receipt of 
colony-stimulating factors in the 1 week before obtaining sample ): 
a. Absolute neutrophil count â‰¥1,000/ÂµL  
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM) 
d. Serum creatinine â‰¤1.5Ã— ULN or a calculated creatin ine clearance of â‰¥30 mL/min using the 
Cockcroft -Gault equation.  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirubin.  
f. AST and ALT â‰¤ 2.5Ã— ULN unless liver metastases are present, in which case, they must be 
â‰¤5Ã— ULN 
Note:  If laboratory values at the beginning of Extension Phase are outside of the range 
specified above, the patient may continue to participate in the study only upon Sponsor 
approval and with consideration for an appropriately reduced dose.  
3. Female patient meets the following criteria:  
a. Patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test 
within 72 hours prior to taking study drug, and agrees to abstain from activities that could 
result in pregnancy from Screening through 180  days after the last do se of study drug, or is 
of nonchildbearing potential. Note: A urine pregnancy test may be performed if the serum 
pregnancy test is not available before dosing.  
b. Female patient of nonchildbearing potential (other than medical reasons) is defined by the 
following: 
i. â‰¥45 years of age and has not had menses for >1  year). 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon Screening 
evaluation.  
iii. Had a hysterectomy, bilateral oopho rectomy, or tubal ligation. Documented 
hysterectomy, oophorectomy or tubal ligation must be confirmed in the medical 
records, otherwise the patient must be willing to use highly effective contraception 
(see Appendix  C) throughout the study, starting with the Screening Visit through 
180 days after the last dose of study drug. Information must be captured 
appropriately within the siteâ€™s source documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
4. Male patient agrees to use an adequate method of contraception and not donate sperm starting 
with the first dose of study drug through 90  days after the last dose of study drug.  
Note: Abstinence is acceptable if this is the established and preferred contraception method 
for the patient.  
Investigational product, dosage and mode of administration:  
Niraparib 300  mg QD (1Ã—300  mg tablet) orally  
Niraparib 200 mg QD (1Ã—200 mg tablet) orally (Stage 1 and 2 only)  
Niraparib 100 mg QD (1Ã—100 mg tablet) orally   
Reference product, dosage and mode of administration ( Stage 1 and 2 only ):  
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRI1LUDSDULEPJ4'Ã®PJFDSVXOHVRUDOO\
'XUDWLRQRIWUHDWPHQW
3.3KDVHDSSUR[LPDWHO\WRGD\VIRU6WDJHWR GD\VSHUSDWLHQWIRU6WDJHV DQGWR
GD\VIRU6WDJH RIWKHVWXG\H[FOXGLQJWKH6FUHHQLQJSHULRG
([WHQVLRQ3KDVH$SDWLHQWFDQFRQWLQXHLQWKH([WHQVLRQ3KDVH XQWLOWKHSDWLHQWPHHWVRQHRIWKH
ZLWKGUDZDOFULWHULD
5HIHUHQFHWKHUDS\GRVDJHDQGPRGHRIDGPLQLVWUDWLRQ 1RQH
&ULWHULDIRUHYDOXDWLRQ 
3KDUPDFRNLQHWLFV 
7KHSULPDU\3.SDUDPHWHUVIRUDQDO\VLVZLOOLQFOXGH $8&W$8&Â’DQG&PD[RIQLUDSDULE 6WDJH
DQGDQG $8&WDQG$8&Â’IRU6WDJH 
1LUDSDULEDQG 6WDJHRQO\3.SDU DPHWHUVWREHDVVHVVHGLQF OXGH
x$8&W
x$8&Â’
x&PD[
xWPD[
xW
x&/)QLUDSDULERQO\ 
x9])QLUDSDULERQO\ 
$GGLWLRQDO3.SDUDPHWHUIRU6WDJHRQO\ 
xWODJ
SDUDPHWHUV ZLOORQO\EHGHWHUPLQHGLQ6WDJHRIWKHVWXG\$GGLWLRQDO3. SDUDPHWHUVPD\EH
HVWLPDWHGLIGHHPHGDSSURSULDWH 7KH3.SDUDPHWHUVZLOOEHFDOF XODWHGIURPWKHSODVPDFRQFHQWUDWLRQ 
WLPHSURILOHV7KHQRQ FRPSDUWPHQWDODQDO\VLVZLOOEHSHUIRUPHGXVLQJ: LQ1RQOLQYHUVLRQRU
KLJKHU3RSXODWLRQ3.DQDO\VLVPD\EHSHUIRUPHGRQWKH3.3KDVH RIWKHVWXG\GDWDWRLQIRUPWKHGRVH
VHOHFWLRQIRUIXWXUHVWXGLHV 
%ORRG6DPSOH&ROOHFWLRQ 
'XULQJ6WDJHRIWKHVWXG\EORRGDSSUR[LPDWHO\P/SHUVDPS OHZLOOEHFROOHFWHGGXULQJWKHVWXG\
IRU3.DVVHVVPHQWVDWWKHIROORZLQJWLPHSRLQWVUHODWLYHWRQLU DSDULEGRVLQJ3KDVHSUHGRVH
PLQXWHVSULRUWRGRVLQJDQGDW DQGKRXUV
SRVWGRVH
)RU6WDJHDQG6WDJH 3.VDPSOHVZLOOEHGUDZQDWSUHGRVH PLQXWHVSULRUWRGRVLQJDQGDW
DQGKRXU VSRVWGRVH 
7KHIROORZLQJH[FXUVLRQV DUHSHUPLWWHGUHODWLYHWRWKHSURWRFRO VSHFLILHG3.VDPSOLQJWLPHV
'HYLDWLRQVRXWVLGHRIWKHVHWLPHZLQGRZVPXVWEHGRFXPHQWHG 
x3UHGRVHÂ”PLQXWHV CCI
CCI
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRIxWRKRXUVÂ“PLQXWHV 
xWRKRXUVÂ“PLQXWHV 
xKRXUVÂ“PLQXWHV 
xKRXUVÂ“PLQXWHV 
xKRXUVÂ“PLQXWHV 
xKRXUVÂ“PLQXWHV 
xDQGKRXUVÂ“PLQXWHV 
xKRXUV KRXUV 
7KHYROXPHRIEORRGVDPSOHVFROO HFWHGIRU3.DQDO\VLVLQWKH3. 3KDVHZRXOGEHDSSUR[LPDWHO\
P/%ORRGVDPSOHFROOHFWLRQSURFHVVLQJDQGVKLSSLQJGHWDLOVZ LOOEHRXWOLQHGLQDVHSDUDWH
ODERUDWRU\PDQXDO,QEULHIEO RRGZLOOEHFROOHFWHGLQWRSRWDV VLXPHWK\OHQHGLDPL QHWHWUDDFHWLFDFLG
.('7$WXEHVSURFHVVHGDQGSODVPDDQDO\]HGE\DYDOLGDWHGPHWKR GRIOLTXLGFKURPDWRJUDSK\
FRXSOHGWRWDQGHPPDVVVSHFWURP HWU\GHWHFWLRQPHWKRGI RUGHWHUPLQDWLRQRI DQDO\WHFRQFHQWUDWLR QV
6DPSOHVZLOOEHDQDO\]HGDQGUHSRUW HGIRUQLUDSDULEDQG FRQFHQ WUDWLRQVLQ6WDJH2QO\QLUDSDULE
FRQFHQWUDWLRQVZLOOEHUHSRUWHG IRUVDPSOHVFROOHFWHGGXULQJ 6WDJHDQG
6DIHW\
6DIHW\ZLOOEHDVVHVVHGEDVHGRQ$(VS K\VLFDOH[DPLQDWLRQVYLWDO VLJQVDQGFOLQLFDOODERUDWRU\
UHVXOWV
$QDO\VLV3RSXODWLRQV 
3.3RSXODWLRQ$OOSDWLHQWVZKRUHF HLYHDWOHDVWRQHGRVHRIQL UDSDULEDQGKDYHDWOHDVWRQHPHDVXUDEOH
QLUDSDULERUQLUDSDULE RU 6WDJHRQO\FRQFHQWUDWLRQ 

3.(YDOXDEOH3RSXODWLRQ $OOSDWLHQWVZKRFRPSOHWHDWOHD VWRQH3.3HULRGDQGKDYHVXIIL FLHQW
FRQFHQWUDWLRQGDWDWRDFFXUDWHO\ HVWLPDWH3.SDUDPHWHUVZLWKRXW VLJQLILFDQWQLUDSDULEFDUU\RYHU
EDVHOLQHFRQFHQWUDWLRQ !RI&PD[LQDWOHDVWRQH3HULRG 3DWLHQWVZLWKFDUU\RYHUZLOOEHH[FOXGHG
IURPWKHDQDO\VLVRI3HULRGEXW ZLOOEHLQFOXGHGLQWKHDQDO \VLVRISHULRGDVGDWDLVDYDLODEOH 

%$%((YDOXDEOH3RSXODWLRQ $OOSDWLHQWVZKRFRPSOHWHERWK3.3HULRGVDQGKDY HVXIILFLHQW3.
VDPSOHFROOHFWLRQWRDFFXUDWHO\HVWLPDWH3.SDUDPHWHUVZLWKRXW VLJQLILFDQWQLUDSDULEFDUU\RYHU
EDVHOLQHFRQFHQWUDWLRQ !RI& PD[LQERWK3.3HULRGV 3DWLHQWVZKRKDYHVLJQLILFDQWQLUDSDULE
FDUU\RYHULQ3HULRGZLOOEHFRPSOHWHO\H[FO XGHGIURPWKH%$%((YDOXDEOH3RSXODWLRQ 

)RRG(IIHFW)((YDOXDEOH3RSXODWLRQ$OOSDWLHQWVZKRFRPSOHW HERWK3.3HULRGVDQGKDYHVXIILFLHQW
3.VDPSOHFROOHFWLRQWRDFFXUDWHO\HVWLPDWH3.SDUDPHWHUVLQER WKSHULRGV3DWLHQWVPHHWLQJ
QRQHYDOXDELOLW\FU LWHULDSHUSURWRFRORUKDYLQJVLJQLILFDQWQLUDSDULEFDUU\RYHU EDVHOLQHFRQFHQWUDWLRQ
!RI& PD[ZLOOEHFRPSOHWHO\H[FOXGHGIURPWKH)(3RSXODWLRQ 

6DIHW\3RSXODWLRQ$OOSDWLHQWVZKRUHFHLYHGUXJ 


CCI
CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 24 of 103 Statistical methods:  
Sample Size Consideration  
Stage 1 
No formal sample size calculation was performed for Stage 1. Approximately 24 patients will be 
enrolled in Stage 1. This sample size is considered adequate for preliminary assessment of the relative 
bioavailability of the tablet compared to the cap sules and for estimating the intra -subject coefficient of 
variation, after accounting for patient drop -outs and potential carryover.  
Stage 2 
Based on estimates from Stage 1, 100 BA/BE evaluable patients are required in Stage 2.   With 100 
evaluable patients , assuming the intra -subject coefficient of variation (CV) is 25% and  the true ratio of 
means is 0.89, there is at least 90% power to demonstrate the bioequivalence (bioequivalence range: 
0.800 to 1.250; alpha=0.05).  Power calculations were also performed  under alternative assumptions 
for the CV and mean ratio.   Assuming the CV is 30% and the true ratio of means is 0.89, with 100 
evaluable patients, there is 82% power to demonstrate bioequivalence.  Assuming the true ratio is 0.90, 
the power is 96% and 88% assuming CVs of 25% and 30%, respectively.  
The final analysis of bioequivalence will be based on Stage 2 BA/BE evaluable patients only, with a 
target sample size of 100 evaluable patients . Patients may be identified as non -evaluable due to issues 
arising during the study conduct, such as:  
â€¢ emesis within 9 hours of dosing,  
â€¢ dosing errors,  
â€¢ patient did not fast prior to dosing,  
â€¢ missing critical PK sample on Day 8,  
â€¢ failure to complete both PK periods, and  
â€¢ significant changes to the patient â€™s medical status th at would potentially affect the PK profile 
as determined by the Sponsor in consultation with the Investigator prior to PK data analysis.  
In this patient population, approximately 170 total patients are targeted for enrollment, assuming a 35% 
non-evaluability rate during the study conduct, and an additional 10% non -evaluability rate during PK 
analysis. The non-evaluability rate arising during the study conduct will be continuously monitored by 
the Sponsor  and the total number of enrolled patients  may be adjusted accordingly with the aim to 
target the resulting sample size of 100 BA/BE evaluable patients.   
Stage 3 
Assuming the true ratio of means is 1 and the intra -subject CV is 20% for AUC0-t and AUC0-âˆž, with 16 
evaluable patients, there is approximately 83%  probability the 90% CI of the ratio of geometric means 
will be within 0.800 and 1.250.  Based on the results of a FE study conducted using the capsule 
formulation, an effect of a high -fat meal on C max is possible. The sample size of 16 patients is deemed 
adequate to characterize this effect. AUC0-t and AUC 0-âˆž will be the primary parameters for analysis.   
The primary analysis will be based on the FE Evaluable Population as it is the most conservative 
approach, which maximizes the benefits of the crossover de sign, where each patient serves as their 
own control. Results for the PK Evaluable Population will also be summarized and reported for this 
study. 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 25 of 103 Patients may be identified as non -evaluable due to issues arising during the study conduct, such as:  
â€¢ dosing errors,  
â€¢ patient did not follow dietary requirements prior to dose and postdose,  
â€¢ failure to complete both PK periods, and  
â€¢ significant changes to the patient â€™s medical status that would potentially affect the PK profile 
as determined by the Sponsor in consultation with the Investigator prior to PK data analysis.  
Patients who experience emesis within 10 hours of dosing or miss sufficient samples to render 
calculation of AUC unreliable will be discontinued from the PK phase. To account for non -evaluable 
patients, approximately 20 total patients are targeted for enrollment.  The non-evaluability rate arising 
during the study conduct will be continuously monitored by the Sponsor  and the total number of 
enrolled patients  may be adjusted accordingly with th e aim to target the resulting sample size of 16  
evaluable patients.   
Safety Analyses  
Data from the Stage 1 PK Phase, Stage 2 PK Phase, Stage 3 PK Phase and Extension Phase will be 
summarized separately. Summaries will be performed by formulation, fed/fasted state, and dosing 
period as applicable.  
Demographic characteristics will be summarized descriptively and will include age, sex, race, height, 
and weight.  
Protocol deviations will be listed by patient.  
All analysis for safety endpoints will be performed in a descriptive manner. Continuous variables will 
be summarized using descriptive statistics (number of patients, mean, standard deviation [SD], 
minimum, median, and maximum). Categorical variables will be summarized using counts of patients 
and percentag es. 
All AEs will be listed. The number and percent of patients who experience a TEAE will be 
summarized by timing/treatment for each system organ class and preferred term. AEs will also be 
tabulated accordingly by intensity and causality.  
Serious treatmen t emergent adverse events ( TEAEs) and TEAEs resulting in study discontinuation  will 
be listed separately.  
All AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities. 
Safety will be assessed through adverse event ass essment, physical examination, vital sign 
measurements, clinical laboratory tests, and monitoring of concomitant medications.  
AEs are required to be captured through 30 days after cessation of study drug; serious adverse events 
(SAEs) are required to be ca ptured through 90 days after cessation of study drug (or to a minimum of 
30 days post -treatment if the patient starts alternative anticancer therapy); and any pregnancies that 
occur within 180 days post -treatment are to be captured. Study drug -related SAEs  and adverse events 
of special interest (AESIs)  (Section 11.2.1.4 )  will continue to be monitored until study closeout 
(unless death or loss to follo w-up occurs first). All AEs and SAEs experienced by a patient, regardless 
of the suspected causality, will be monitored until the AE or SAE has resolved, until any abnormal 
laboratory values have returned to baseline or normalized, until there is a satisfa ctory explanation for 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 26 of 103 the change(s) observed, until the patient is lost to follow -up or withdraws consent, or until the patient 
has died. 
The AESIs for this study are MDS, AML , and secondary cancer (new malignancies other than 
MDS/AML). AESIs must be repor ted to the Sponsor as soon as the Investigator becomes aware of 
them or within 24 hours.  
Individual data listings of laboratory test results will be presented. Flags will be attached to values 
outside of the laboratory's reference limits along with the Inv estigator's assessment. Clinically 
significant laboratory test abnormalities that were considered AEs by the Investigator will be presented 
in the AE listing.  
In addition, for the Extension Phase, clinical laboratory tests (observed values and changes from  
baseline) will be summarized descriptively in tabular format. Shift tables will be presented for select 
laboratory parameters (chemistry and hematology).  
Individual data listings of vital signs (observed and change from Baseline) will be presented for eac h 
patient. Individual clinically significant vital sign findings that were considered AEs by the 
Investigator will be presented in the AE listing.  
All clinically relevant abnormal physical examination findings will be listed.  
Pharmacokinetic Analysis  
Individual patient PK parameter values will be derived by non -compartmental methods using Phoenix 
WinNonlin, version 5.1 or higher. Actual time will be used for parameter calculation. The analysis of 
Stage 1, Stage 2, and Stage 3 will be conducted separate ly.  
During the pharmacokinetic analysis, the following rules will apply:  
â€¢ Predose sample >5% of C max: profile will be excluded from PK concentration and PK parameters 
summary and inferential statistics  
â€¢ Rsq,adj <0.800: AUC 0-âˆž, Î»z, CL/F, Vz/F, and t 1/2 will be excluded from descriptive and  
inferential statistics  
â€¢ AUC0-t /AUC 0-âˆž, <0.800: AUC 0-âˆž and parameters  derived from it will be excluded from 
descriptive and inferential statistics  
Planned sampling times will be used to generate the mean concentratio n-time profiles. Individual and 
mean plasma concentrations over time will be plotted by formulation  in Stage 1 and 2 and by 
fed/fasted state in Stage 3 . Plasma concentrations and PK parameters will be summarized in terms of 
the number of patients, arithmet ic mean, median, SD, coefficient of variation (CV), geometric mean, 
geometric CV, minimum and maximum by formulation in Stage 1 and 2 and by fed/fasted state in 
Stage 3, as appropriate. In Stage 3, differences in t max between the fed and fasted state will be assessed 
and summarized based on the FE Evaluable Population. Details will be provided in the 
Pharmacokinetic Analysis Plan.  
The pharmacokinetic profiles and parameters will be summarized across the PK, PK Evaluable, 
BA/BE Evaluable, and FE Evaluable populations, as appropriate. Details will be provided in the 
Pharmacokinetic Analysis Plan.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 27 of 103 To assess relative bioavailability/bioequivalence, an analysis of variance model (ANOVA) will be used 
on logarithmically transformed AUC 0-t, AUC0-âˆž, and Cmax accounting for the following sources of 
variation: sequence, subjects nested in sequences, period and treatment. The point estimate and 90% CI 
for the ratios of the geometric means of the test treatment (tablet) compared to the reference treatment 
(capsule) will be obtained. Bioequivalence will be claimed if the 90% CI for the ratio of geometric 
means is between 0.800 and 1.250 for AUC 0-âˆž, AUC0-t and Cmax. To assess the effect of food in Stage 
3, the ratio of geometric means for  AUC0-t, AUC0-âˆž, and C max of the test treatment (high -fat meal) 
compared to the reference treatment (fasted state) and corresponding 90% CI will be obtained for 
AUC0-t,, AUC0-âˆž, and C max. 
A population PK analysis may be performed on the PK data from the PK Phase of the study and will be 
reported separately from the study.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 28 of 103 2. TABLE OF CONTENTS, L IST OF TABLES, AND L IST OF 
FIGURES  
SPONSOR SIGNATURE PA GE ................................ ................................ ................................ ....2 
INVESTIGATORâ€™S AGREE MENT ................................ ................................ ............................... 3 
1. SYNOPSIS  ................................ ................................ ................................ ................... 9 
2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES  ...............28 
LIST OF TABLES  ................................ ................................ ................................ ......................... 33 
LIST OF FIGURES  ................................ ................................ ................................ ....................... 33 
3. LIST OF ABBREVI ATIONS AND DEFINITIO NS OF TERMS ............................. 34 
4. INTRODUCTION  ................................ ................................ ................................ ......37 
4.1. Background  ................................ ................................ ................................ ................. 37 
4.1.1.  Niraparib Nonclinical Studies  ................................ ................................ ..................... 37 
4.1.2.  Niraparib Clinical Studies  ................................ ................................ ........................... 37 
4.1.3.  Baseline Platelet Count and Weight as Predictors of Thrombocytopenia in 
Patients Trea ted with Niraparib  ................................ ................................ .................. 38 
4.2. Rationale for Study  ................................ ................................ ................................ .....39 
5. STUDY OBJECTIVES AND  PURPOSE  ................................ ................................ ..40 
5.1. Primary Objective  ................................ ................................ ................................ .......40 
5.2. Secondary Objectives  ................................ ................................ ................................ .40 
5.3. Exploratory Objectives  ................................ ................................ ............................... 40 
6. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 41 
6.1. Overall Study Design  ................................ ................................ ................................ ..41 
6.1.1.  Fasting and Study Drug Administration for the PK Phase  ................................ .........44 
6.1.2.  General Study Conduct  ................................ ................................ ............................... 45 
6.2. Number of Patients  ................................ ................................ ................................ .....46 
6.3. Treatment Assignment  ................................ ................................ ................................ 46 
6.3.1.  Patient Identification  ................................ ................................ ................................ ...46 
6.3.2.  Randomization Scheme  ................................ ................................ .............................. 46 
6.4. Dose Adjustment Criteria  ................................ ................................ ........................... 47 
6.4.1.  Safety Criteria for Stopping Doses During PK Phase  ................................ ................ 47 
6.4.2.  Safety Criteria for Adjustment or Stopping Doses During Extension Phase  .............47 
6.5. Criteria for Study Termination  ................................ ................................ ................... 49 
6.6. Study Conduct  ................................ ................................ ................................ ............49 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 29 of 103 6.6.1.  Schedule of Events  ................................ ................................ ................................ .....49 
7. SELECTION AND WITHDR AWAL OF PATIENTS  ................................ ..............59 
7.1. Patient Inclusion Criteria  ................................ ................................ ............................ 59 
7.1.1.  Patient Inclusion Criteria (Stages 1 and 2)  ................................ ................................ .59 
7.1.2.  Patient Inclusion Criteria (Stage 3 only)  ................................ ................................ ....60 
7.2. Patient Exclusion Criteria  ................................ ................................ ........................... 62 
7.2.1.  Patient Exclusion Criteria (Stages 1 and 2)  ................................ ................................ 62 
7.2.2.  Patient Exclusion Criteria (Stage 3 only)  ................................ ................................ ...64 
7.3. Extension Study Patient Inclusion Criteria (Stage 1 and 2)  ................................ .......65 
7.3.1.  Extension Stu dy Patient Inclusion Criteria (Stage 3 only)  ................................ .........66 
7.4. Patient Withdrawal Criteria  ................................ ................................ ........................ 67 
7.4.1.  Discontinuation from Pharmacokinetic Phase  ................................ ............................ 67 
7.4.2.  Discontinuation from Treatment During Extension Phase  ................................ .........68 
7.4.3.  Discontinuation from the Study  ................................ ................................ .................. 69 
7.4.4.  Replacement of Patients  ................................ ................................ ............................. 69 
7.5. Restrictions During Study ................................ ................................ ........................... 69 
7.5.1.  Lifestyle Considerations  ................................ ................................ ............................. 70 
8. TREATMENT OF PATIENT S ................................ ................................ .................. 71 
8.1. Description of Study Drug  ................................ ................................ .......................... 71 
8.2. Concomitant Medications  ................................ ................................ ........................... 71 
8.2.1.  Permitted Concomitant Medications  ................................ ................................ ..........71 
8.2.2.  Concomitant Medications Taken with Caution  ................................ .......................... 72 
8.3. Contraception  ................................ ................................ ................................ ..............72 
8.4. Treatment Compliance  ................................ ................................ ................................ 72 
9. STUDY DRUG MATERIALS  AND MANAGEMENT  ................................ ...........73 
9.1. Study Drug  ................................ ................................ ................................ .................. 73 
9.2. Study Drug Packaging and Labeling  ................................ ................................ ..........73 
9.3. Study Drug Storage  ................................ ................................ ................................ .....73 
9.4. Study Drug Administration ................................ ................................ ......................... 73 
9.5. Administration  ................................ ................................ ................................ ............73 
9.6. Study Dru g Accountability  ................................ ................................ ......................... 74 
9.7. Study Drug Handling and Disposal  ................................ ................................ ............74 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 30 of 103 10. PHARMACOKINETIC ASSE SSMENTS  ................................ ................................ .75 
10.1.  Blood Sample Collection  ................................ ................................ ............................ 75 
10.2.  Sample Analysis  ................................ ................................ ................................ .........76 
11. ASSESSMENT OF SAFETY  ................................ ................................ ..................... 77 
11.1.  Safety Parameters  ................................ ................................ ................................ .......77 
11.1.1.  Demographics and Baseline Characteristics  ................................ ............................... 77 
11.1.2.  Patient Eligibility  ................................ ................................ ................................ ........77 
11.1.3.  Patient Demography  ................................ ................................ ................................ ...77 
11.1.4.  Disease History  ................................ ................................ ................................ ...........77 
11.1.5.  Medical and Surgical History  ................................ ................................ ..................... 77 
11.1.6.  Vital Signs  ................................ ................................ ................................ .................. 77 
11.1.7.  Physical Examination  ................................ ................................ ................................ .78 
11.1.8.  Concomitant Medications and Procedures  ................................ ................................ .78 
11.1.9.  Electrocardiogram  ................................ ................................ ................................ .......78 
11.1.10.  Laboratory Assessments  ................................ ................................ ............................. 78 
11.1.10.1.  Hematology  ................................ ................................ ................................ ................. 78 
11.1.10.2.  Chemistry ................................ ................................ ................................ .................... 78 
11.1.10.3.  Urinalysis  ................................ ................................ ................................ .................... 79 
11.1.10.4.  Virus Serology  ................................ ................................ ................................ ............79 
11.1.10.5.  Drug Screen  ................................ ................................ ................................ ................ 79 
11.1.10.6.  Pregnancy Screen  ................................ ................................ ................................ ........79 
11.1.10.7.  Eastern Cooperative Oncology Group Performance Status  ................................ ........79 
11.2.  Adverse Events and Special Situations  ................................ ................................ .......80 
11.2.1.  Definitions  ................................ ................................ ................................ .................. 80 
11.2.1.1.  Adverse Event (AE) ................................ ................................ ................................ ....80 
11.2.1.2.  Serious Adverse Event (SAE)  ................................ ................................ .................... 80 
11.2.1.3.  Treatment -Emergent Adverse Event (TEAE)  ................................ ............................ 81 
11.2.1.4.  Adverse Events of Special Interest (AESI)  ................................ ................................ 81 
11.2.1.5.  Special Situation: Abuse, Misuse, Medication Errors, Overdose, and 
Accidental or Occupational Exposure  ................................ ................................ ........81 
11.2.2.  Assessment of Adverse Events  ................................ ................................ ................... 82 
11.2.2.1.  Severity Assessment  ................................ ................................ ................................ ...82 
11.2.2.2.  Relationship to Study Intervention  ................................ ................................ .............82 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 31 of 103 11.2.2.3.  Expectedness  ................................ ................................ ................................ ...............82 
11.2.3.  Collection and Recording of Adverse Events  ................................ ............................. 82 
11.2.4.  Follow-Up of Adverse Events  ................................ ................................ .................... 83 
11.2.5.  Reporting  ................................ ................................ ................................ .................... 83 
11.2.6.  Submission and Distribution of Serious Adverse Event Reports  ............................... 84 
11.2.7.  Adverse Events of Special Interest  ................................ ................................ .............84 
11.2.8.  Hypertension, Including Hypertensive Crisi s ................................ ............................. 85 
11.2.9.  Posterior Reversible Encephalopathy Syndrome  ................................ ........................ 85 
11.2.10.  Allergic Reaction  ................................ ................................ ................................ ........85 
11.2.11. Pregnancy  ................................ ................................ ................................ ................... 85 
11.2.12.  Special Situations  ................................ ................................ ................................ ........86 
12. STATISTICS  ................................ ................................ ................................ ..............87 
12.1.  Analysis Pop ulations ................................ ................................ ................................ ..87 
12.2.  Sample Size Consideration  ................................ ................................ ......................... 87 
12.3.  Safety Analyses  ................................ ................................ ................................ ..........89 
12.4.  Pharmacokinetic Analysis  ................................ ................................ .......................... 90 
13. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS ................................ .........92 
13.1.  Study Monitoring  ................................ ................................ ................................ ........92 
13.2.  Audits and Inspections  ................................ ................................ ................................ 92 
13.3.  Institutional Review Board  ................................ ................................ ......................... 93 
14. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ .........94 
15. ETHICS ................................ ................................ ................................ ...................... 95 
15.1.  Ethics Review  ................................ ................................ ................................ .............95 
15.2.  Ethical Conduct of the Study  ................................ ................................ ...................... 95 
15.3.  Written Informed Consent  ................................ ................................ .......................... 95 
16. DATA HANDLING AND RE CORDKEEPING  ................................ ....................... 96 
16.1.  Inspection of Records  ................................ ................................ ................................ .96 
16.2.  Retention of Records  ................................ ................................ ................................ ..96 
17. PUBLICATION POLICY  ................................ ................................ .......................... 97 
18. LIST OF REFERENCES  ................................ ................................ ............................ 98 
APPENDIX  A. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE STATUS  ................................ ................................ ....................... 99 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 32 of 103 APPENDIX  B. COMPONENTS AND EXCIP IENTS OF NIRAPARIB C APSULES 
AND TABLETS  ................................ ................................ ................................ .......100 
APPENDIX  C. CONTRACEPTION GUIDEL INES ................................ ............................... 101 
APPENDIX  D. PERMITTED HORMONAL T HERAPIES  ................................ .................... 102 
APPENDIX  E. GUIDANCE ON COMPOSIT ION OF HIGH -AT MEAL  .............................. 103 
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 33 of 103 LIST OF TABLES  
Table 1: Summary of Changes  for Amendment 5 (Version 6.0)  ................................ ................ 4 
Table 2:  Abbreviations and Specialist Terms  ................................ ................................ ...........34 
Table 3: Niraparib Dose Reductions for Non -Hematologic  Toxicities  ................................ .....47 
Table 4: Management of Hematologic Toxicities  ................................ ................................ ....48 
Table 5: Schedule of Events: Study Drug and PK Phase â€“ Stage 1 (COMPLETED)  ..............50 
Table 6: Schedule of Events: Study Drug and PK Phase â€“ Stage 2  (COMPLETED)  .............52 
Table 7: Schedule of Events: Study Drug and PK Phase â€“ Stage 3 ................................ ..........54 
Table 8: Schedule of Events: Extension Phase  ................................ ................................ .........57 
Table 9:  Investigational Product  ................................ ................................ ............................... 71 
Table 10: Timing of Contraception and Sperm Donation  ................................ .......................... 72 
 
LIST OF FIGURES  
Figure 1: Study Design: Single -Crossover Study  ................................ ................................ ......13 
Figure 2:  Study Design: Single -Crossover Study  ................................ ................................ ......44 
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 34 of 103 3. LIST OF ABBREV IATIONS AND DEFINITI ONS OF TERMS  
Table 2: Abbreviations and Specialist Terms  
Abbreviation or Specialist Term  Explanation  
ADP Adenosine diphosphate  
AE Adverse event  
AESI Adverse Event of Special Interest  
ALT Alanine aminotransferase  
AML Acute myeloid leukemia  
ANOVA Analysis of covariance  
AST Aspartate aminotransferase  
AUC Area under the plasma concentration -time curve  
AUC0-âˆž Area under the plasma concentration -time curve from time 0 
extrapolated to infinity  
AUC0-t Area under the plasma concentration -time curve from time 0 
to the time of the last quantifiable concentration  
BA Bioavailability  
BE Bioequivalence  
BP Blood pressure  
BRCA Breast cancer  
CBC Complete blood count  
CI Confidence interval  
CIOMS Council for International Organizations of Medical Sciences  
CL/F Apparent total body clearance  
Cmax Maximum observed plasma concentration  
CNS Central nervous system  
CRF Case report form  
CSF Colony stimulating factor  
CTCAE Common Terminology Criteria for Adverse Events  
CV Coefficient of variation  
CYP Cytochrome P450 
ECG Electrocardiogram  
ECOG Eastern Cooperative Oncology Group  
eCRF Electronic case report form  
EOT End of Treatment  
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRI7DEOH$EEUHYLDWLRQVDQG6SHFLDOLVW 7HUPV&RQWLQXHG 
$EEUHYLDWLRQRU6SHFLDOLVW7HUP ([SODQDWLRQ
)( )RRGHIIHFW
J%5&$PXW *HUPOLQH %5&$PXWDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
+5 +D]DUGUDWLR
+5' +RPRORJRXVUHFRPELQDWLRQGHILFLHQW
,% ,QYHVWLJDWRUÂ¶V%URFKXUH
,& 0HGLDQLQKLELWRU\FRQFHQWUDWLRQ
,&) ,QIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQL]DWLRQ
,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG
,9 ,QWUDYHQRXVO\
.('7$ 3RWDVVLXPHWK\OHQHGLDP LQHWHWUDDFHWLFDFLG
/&0606 /LTXLGFKURPDWRJUDSK\FRXSOHGWRWDQGHPPDVV
VSHFWURPHWU\
P$E 0RQRFORQDODQWLERG\
0'6 0\HORG\VSODVWLFV\QGURPHV
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
1&, 1DWLRQDO&DQFHU,QVWLWXWH
1,+ 1DWLRQDO,QVWLWXWHRI+HDOWK
3$53 3RO\$'3ULERVHSRO\PHUDVH
3)6 3URJUHVVLRQIUHHVXUYLYDO
3JS 3JO\FRSURWHLQ
3. 3KDUPDFRNLQHWLFV
32 2UDOO\
4' 2QFHDGD\
47F &RUUHFWHG47LQWHUYDO
5(&,67Y 5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUVYHUVLRQ
6$( 6HULRXVDGYHUVHHYHQWCCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 36 of 103 Table 2: Abbreviations and Specialist Terms  (Continued)  
Abbreviation or Specialist Term  Explanation  
SD Standard deviation  
SUSAR Serious Unexpected Serious Adverse Reaction  
t1/2 Terminal elimination half -life 
TEAE Treatment -emergent adverse event  
tmax Time to reach Cmax 
tlag Time from administration of the dose to the first quantifiable 
concentration  
ULN Upper limit of normal  
US PI United States Package Insert  
Vz/F Apparent terminal volume of distribution  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 37 of 103 4. INTRODUCTION  
4.1. Background  
Niraparib  is an orally available, potent, highly selective poly (adenosine diphosphate 
[ADP])-ribose polymerase (PARP) -1 and -2 inhibitor. Niraparib cocrystallized with the human 
PARP-1 catalytic domain and was shown to inhibit PARP -1 and PARP -2 activity in vitro with a 
median inhibitory concentration (IC 50) of 3.8 and 2.1  nM, respectively.  
Niraparib was approved by the Food and Drug Administration in March 2017 and is indicated 
for the maintenance treatment of adult patients with re current epithelial ovarian, fallopian tube, 
or primary peritoneal cancer who are in a complete or partial response to platinum -based 
chemotherapy.  
4.1.1. Niraparib Nonclinical Studies  
The niraparib nonclinical studies are described in detail in the Investigatorâ€™s  Brochure (IB).  
4.1.2. Niraparib Clinical Studies  
In 2008, a Phase 1 study was initiated in an all solid tumors population to investigate the safety 
and tolerability of niraparib. Eight (40% [95% CI 19 -64]) of 20 BRCA1 or BRCA2 mutation 
carriers with ovarian canc er had Response Evaluation Criteria in Solid Tumors  (RECIST) partial 
responses, as did two (50% [7 -93]) of four mutation carriers with breast cancer. Antitumor 
activity was also reported in sporadic high -grade serous ovarian cancer, non -small-cell lung 
cancer, and prostate cancer  (Sandhu, 2013).   
Clinical studies have shown that PARP inhibitors are active in recurrent ovarian cancer, breast 
cancer, and prostate cancer (Sandhu, 2013; Fong, 2009; Audeh, 2010; Gelmon, 2011; Kummar, 
2012; Ledermann , 2012; Ledermann, 2014). PARP inhibition appears to be most active in 
patients with g BRCA mutations  and in patients who are sensitive to platinum -containing therapy. 
However, clinical benefit has also been observed in g BRCA wild-type patients  (Sandhu, 2013; 
Gelmon, 2011; Kummar, 2012; Ledermann , 2012; Ledermann , 2014).  In the registrational 
ENGOT-OV16/NOVA trial, maintenance treatment of patients with recurrent high-grade serous 
ovarian cancer showed that the PARP -1/2 inhibitor niraparib significantly improved 
progression -free survival (PFS) in g BRCAmut patients (21  months for niraparib vs. 5.5  months 
for control). Furthermore, in the non-BRCAmut population, significant improvement in PFS was 
also observed (9.3 months for niraparib vs. 3.9 months for placebo, hazard ratio [ HR]=0.45, 
p < 0.0001). (Sandhu, 2013; Mirza, 2016) Niraparib has been recently approved in the US for the 
maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer  (Guan, 2017). The niraparib clinical studies are described in detail in the IB.  
The safety, tolerability,  and PK of niraparib has been evalu ated in a series of clinical studies 
including single-and multiple-dose PK, absorption, metabolism  and elimination, and a Phase 3  
study (ENGOT-OV16/NOVA) , (Mirza, 2016) comprising the QT/QTc and food effect substudy , 
using the capsule formulation . No clinically significant food effect was observed  with the 
capsule formulation , with no change in niraparib AUC0-t and AUC 0-âˆž following a high-fat meal, 
and a 20% reduction in C max when compared to fasted state administration .  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 38 of 103 Orally-administered niraparib was absorbed with a median time to reach maximum observed 
plasma concentration (t max) of approximately 2 to 4  hours, highly tissue-distributed, and slowly 
metabolized and eliminated. The oral BA of niraparib with the capsule formulation is high 
(absolute BA of the capsule formulation  of approximately 73%). Details of the clinical 
pharmacology of niraparib are described in the n iraparib label and IB.  
4.1.3. Baseline Platelet Count and Weight as Predictors of Thrombocytopenia  in 
Patients Treated with Niraparib  
An analysis was conducted using the data collected in ENGOT -OV16/NOVA and the initial 
Phase 1 study, PN001. This analysis determi ned that only baseline platelets had an impact on 
platelet nadir; lower baseline platelets (<180,000 /Î¼L) were associated with an increased 
frequency of thrombocytopenia Grade â‰¥1 (76%) or Grade â‰¥ 3 (45%) compared to patients with 
higher baseline platelet c ounts. Further, an exploratory analysis of clinical data versus baseline 
body weight from ENGOT -OV16/NOVA was conducted. For this analysis, the weight categories 
were based on quartiles with the lowest quartile (patients with a body weight less than 58 kg at 
baseline) compared to the highest quartile (patients with a body weight greater than or equal to 
77 kg at baseline). While TEAEs occurred in most patients regardless of body weight, Grade â‰¥3 
TEAEs, SAEs, and TEAEs leading to dose modification or treatme nt discontinuation occurred 
more commonly in the weight <58 kg cohort than in the â‰¥77 kg cohort. In the cohort of patients 
with a body weight <58 kg, approximately 80% of patients had a dose reduction compared to 
59% of patients with a weight greater than or equal to 77 kg. Treatment discontinuations were 
increased in the subjects with lower body weight (24%) compared to patients in the highest 
quartile (10%).  
The potential relationship between body weight and TEAEs was further explored in an analysis 
to evaluate the correlation of Grade 3 or 4 thrombocytopenia and baseline body weight. The 
lowest platelet count in the first 30 days was plotted versus baseline b ody weight to determine if 
low body weight identified a subgroup of patients with higher levels of thrombocytopenia during 
Cycle 1. In the first 30 days of treatment, a baseline body weight >77 kg is associated with a 
lower incidence of Grade 3 or 4 thromb ocytopenia (14%) relative to the group with body 
weight<58 kg (43%).  
Finally, a classification tree approach was used to refine the best cut -off points for predicting the 
likelihood of a patient developing Grade â‰¥3 thrombocytopenia within 30 days after the  first dose 
of niraparib. The results of the model show that the subgroup of patients with a baseline body 
weight <77 kg or baseline platelet count <150,000/Î¼L had a Grade 3/4 thrombocytopenia rate in 
the first 30 days of 35.4% compared to 11.5% in the gro up of patients with a body weight >77 kg 
and a platelet count >150,000/Î¼L. Further, the average daily dose was 258 mg through the first 
two cycles for patients with a body weight >77 kg and platelet count >150,000/Î¼L, and was only 
206 mg for patients with body weight < 77 kg or platelet count <150,000/Î¼L. Thus, the actual 
delivered dose approximated a starting dose of 200 mg despite the intended delivery of a starting 
dose of 300 mg . Therefore , in the present study in the Extension Phase , patients whose baseline 
weight is <77 kg or baseline platelet count is <150,000/Î¼L  will be treated at the 200 mg starting 
dose of niraparib . 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 39 of 103 4.2. Rationale for Study  
The approved niraparib drug product is an immediate release hard gelatin capsule dosage form 
that contains 100  mg of niraparib per capsule. The labelled starting dose for niraparib is 300 mg. 
Facilitating this dose requires the administration of three 100 mg capsules.  
It is the Sponsor â€™s intent to introduce a tablet dosage form that provides the 100 mg, 200 mg an d 
300 mg dose in single dose strength tablets to reduce the pill burden on the patients.  
To this end, the Sponsor  has developed a tablet dosage form with the specific intent to provide 
comparable performance to the approved capsule dosage form. The formula tion and 
manufacturing process of the tablet were selected to produce a tablet with comparable in -vitro 
performance to the capsule.  
This study is an open label Phase 1 study to evaluate the relative BA and BE of niraparib 
administered as a tablet formulat ion compared to the reference capsule formulation 
manufactured by the same process as currently marketed in the United States. Specifically, a 300 
mg niraparib tablet will be compared to 3 niraparib capsules (3Ã—100 mg).  
Following the PK analysis from the Stage 1 (relative BA), the tablet and capsule formulation  
were found to have similar bioavailability with the 90% confidence interval (CI) for the least 
squares geometric mean ratios of the tablet/capsule C max, AUC 0-t , and AUC 0-âˆž falling entirely 
within 0.800 to 1.250. The inter -subject variability of the tablet formulations â€™ PK parameter 
estimates appears to be lower than the capsule formulation.  
Niraparib PK in Stage 2 of this study was found to be consistent with the values reported in 
Stage 1 and othe r studies where niraparib PK was assessed. BE was established between the 
niraparib tablet (1Ã—300  mg) and capsule (3Ã—100  mg) formulations. The 90% CIs of the least 
squares geometric mean ratios  for tablet compared to capsules fell within the limits of 0.800 and 
1.250 for all 3 primary niraparib PK parameters (C max, AUC 0-t, and AUC 0-âˆž). Intrasubject 
variability was low, ranging from 18.1% to 23.7% for the key PK parameters.  
In addition, t his study will evaluate the effect of a high-fat meal on the PK of the niraparib 300  
mg tablet formulation  (Stage 3). The Extension Phase of this study  will enable patients to 
continue to receive treatment with niraparib if they are tolerating it and, in the Investigatorâ€™s 
opinion, may receive clinical benefit. 
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO   3DJHRI678'<2%-( &7,9(6$1'385326( 
3ULPDU\2EMHFWLYH 
7KHSULPDU\REMHFWLYHRIWKLVVWXG\ IRUHDFK6WDJHLV 
x6WDJH7RREWDLQSUHOLPLQDU\DVVHVVPHQWRIWKHUHODWLYHELRDY DLODELOLW\RIPJ
QLUDSDULEDGPLQLVWHUHGDV DWDEOHWYHUVXVFDSVXOHIRUPXODWLRQD QGWRHVWLPDWHWKH 
LQWUDVXEMHFWYDULDELOLW\RIQLUDSDULE3. 
x6WDJH7RHYDOXDWHLIWKHWDEOHWIRUPXODWLRQ Ã®PJRIQLUDSDULELV
ELRHTXLYDOHQW%(WRWKHFDSVXOHIRUPXODWLRQ Ã®PJ
x6WDJH7RDVVHVVW KHHIIHFWRIDKLJK IDWPHDORQQLUDSDULE 3.IROORZLQJDVLQJOH
PJGRVHRI WKHWDEOHWIRUPXODWLRQ 
6HFRQGDU\2EMHFWLYHV 
7KHVHFRQGDU\REMHFWLYHRIWKLVVWXG\LV 
x6WDJH6WDJHDQG6WDJH 7RHYDOXDWHWKHVDIHW\ RIVLQJOHGRVHQLUDSDULEZKHQ
DGPLQLVWHUHGDVDWDEOH WRUFDSVXOHIRUPXODWLRQLQS DWLHQWVZLWKDGYDQFHGVROLGWXPRUV 
x([WHQVLRQ3KDVH7RHYDOXDWHWKH VDIHW\RIFRQWLQXRXVO\GRVHGQLUDSDULELQSDWLHQWV
ZLWKDGYDQFHGVROLGWXPRUV 
([SORUDWRU\2EMHFWLYHV 
CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 41 of 103 6. INVESTIGATIONAL PLAN  
6.1. Overall Study Design  
This is a multicenter, open label study in patients with advanced solid tumors. This is a 3-stage, 
randomized -sequence, single -crossover study to assess the relative BA and BE of niraparib tablet 
formulation relative to the capsule formulation. In addition , Stage 3 of the protocol is a single 
cohort, randomized -sequence, 2 period, single dose, crossover study to assess effect of food on 
the PK of the niraparib tablet  formulation . 
Pharmacokinetics (PK) Phase : In Stages 1 and 2  patients will be randomized 1:1 to receive 
tablet formulation followed by capsule formulation or capsule formulation followed by tablet 
formulation. In Stage 3, patients will be randomized 1:1 to receive tablet formulation in a fasted 
state followed by tabl et formulation taken with a high -fat meal, or tablet formulation taken with a 
high-fat meal followed by tablet formulation taken in a fasted state.  
Stage 1: Following an 8 -hour fast on Day  1 (see Section  6.1.1), patients will receive a single dose 
of the formulation (tablet [1 Ã—300 mg] or capsule [3 Ã—100 mg]) followed by a 7 -day (+1 day) 
Washout/PK period followed by a dose of the alternate formulation a lso in a fasted state, 
followed by a 7 -day Washout/PK period. Patients receiving the tablet in the first treatment period 
will receive the capsules in the second treatment period and vice versa ( Figure 2). Extensive PK 
sampling will be carried out after niraparib dosing (see Section 10.1).  
Stage 2: Following an 8 -hour fast on Day  1 (see Section  6.1.1), patients will rec eive a single dose 
of the formulation (tablet [1 Ã—300 mg] or capsule [3 Ã— 100 mg]) followed by a 14 -day (+/- 4 days) 
Washout/PK period followed by a dose of the alternate formulation also in a fasted state, 
followed by a 7 -day Washout/PK period. Patients rec eiving the tablet in the first treatment period 
will receive the capsules in the second treatment period and vice versa ( Figure 2). Extensive PK 
sampling will be carried out after niraparib dosing (see S ection 10.1).  
Stage 3: In period 1, patients will receive a single 300 mg niraparib tablet either following a 
10-hour fast (see Section 6.1.1) or directly foll owing consumption of a high -fat meal (see 
Section 6.1.1), followed by a 14 -day (+4 days) PK sampling and washout period. In period 2, 
patients will b e crossed over to receive a single 300 mg niraparib tablet in a fasted state or with a 
high-fat meal, followed by a 7 -day PK sampling period. All patients will fast for a minimum of 4  
hours postdose in both periods. Patients receiving the tablet in a fasted state in the first treatment 
period will receive the tablet with a high -fat meal in the second treatment period and vice versa .  
In the rare instance where a delay of the entire PK period 2 is needed for any reason beyond the 
4-day window specified above the site must contact the sponsor's medical monitor to discuss the 
patient circumstances, the Sponsor will decide if the patient can continue with PK period 2 with 
a delay. Similarly,  should the laboratory results on D15 in Stage 2 (the day of niraparib 
administration in PK Period 2) show changes in organ function such that the original inclusion 
criteria for laboratory values are no longer met, or in the event of a significant change of 
patientâ€™s clinical status as judged by the Inv estigator, the site must consult with the Sponsor to 
discuss the patient's continued participation in PK period 2. Note that sites need not wait for the 
pre-dose laboratory results to begin PK period 2, but rather consult the Sponsor once the results 
are available as needed.   
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 42 of 103 In Stage 1 and 2, p atients who experience emesis within 9 hours of dosing or who miss a critical 
PK sample (such as the last PK sample on Day 8 in each Period  [Stage 3]) will be discontinued 
from the PK phase and will be allowed to be screened for the Extension Phase  (see Section  6.1).  
In Stage 3, patients  who experience emesis within 10 hours of dosing or miss sufficient samples 
to render calculation of AUC unreliable will be discontinued from the PK phase . Patients may 
also be identified and discontinued from the PK phase as non-evaluable due to issues arising 
during the study conduct ( Section 7.4.1). Patients who are discontinued from the PK phase  and 
meet other criteria for continued niraparib therapy will be eligible to be screened for th e 
Extension Phase (see Section  6.1). 
The PK parameters that will be estimated include area under the plasma concentration -time 
curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC 0-t), area under 
the plasma concentration -time curve from time 0 extrapolated to infinity (AUC 0-âˆž), apparent total 
body clearance (CL/F), C max, tmax, terminal elimination half -life (t1/2), apparent ter minal volume 
of distribution (Vz/F), and bioavailability/bioequivalence of the tablet formulation relative to the 
capsule formulation.  
For Stage 2, the same PK parameters as above will be estimated. To conclude bioequivalence, 
the 90% CI of the ratio of ge ometric least -squares means of the test (tablet) to reference (capsule) 
product should be within 0.800 - 1.250 for AUC 0-âˆž AUC0-t and Cmax. 
For Stage 3, the same PK parameters as above will be estimated. In addition, t lag, the time from 
administration of th e dose to the first quantifiable concentration, will be determined, and t max will 
be compared between the fed and fasted states. The relative bioavailability  of the 300 mg 
niraparib tablet administered with a high -fat meal relative to fasted dosing will be  based on the 
ratio of geometric least -squares means of AUC 0-t, AUC 0-âˆž, and C max.  
Additional PK parameters may be estimated (e.g., residual area)  if deemed appropriate.  
Extension Phase:  When patients complete the PK Phase of the study (at least 7 days fr om 
niraparib, dose 2 ), the Sponsor will work with the Investigator to determine if the patient would 
benefit from continued access to niraparib therapy. Eligibility to participate in the Extension 
Phase will be at the discretion of the Investigator  and Sponsor and will follow review of the 
studyâ€™s Extension Phase â€™s respective  inclusion criteria and completion of the required screening 
assessments. Continued treatment in the study will be based on documented evidence of clinical 
benefit determined by local standard of care  disease assessment frequency.   
The starting dose of niraparib in the Extension Phase will be based on the patientâ€™s baseline 
actual body weight or platelet count. Patients with a baseline actual body weight of â‰¥77 kg and 
screening platelet count of â‰¥150,000/ÂµL (obtained after completion of the PK phase, as part of 
Extension Phase screening) will take one 300 mg strength tablet or 3 x 100 mg tablets/capsules at 
each dose administration (QD). Patients with a baseline actual body weight of <77 kg or 
screening platelet count of <150,000/ÂµL will take one 200 mg strength tablet or 2 x 100 mg 
tablets/capsules at each dose administration (QD). For patients w hose initial starting dose is 200 
mg QD, escalation to 300 mg QD is permitted after 2 cycles of therapy if no treatment 
interruption or discontinuation was required during the first 2 cycles of Extension Phase therapy 
and after approval from the Sponsor. A dditional dose modifications will not be based upon 
changes in the patientâ€™s actual body weight during study participation. If laboratory values at the 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 43 of 103 beginning of Extension Phase are outside of the range specified in the inclusion criteria, the 
patient may continue to participate in the study only upon Sponsor approval and with 
consideration for an appropriately reduced dose. Should a patient start Extension Phase at 100 
mg, consideration may be given to escalate to 200 mg after 2 cycles  of therapy if no treatment 
interruption or discontinuation was required during the first 2 cycles of Extension Phase therapy 
and after approval from the Sponsor.  
Patients have up to 28 days (21 days for S tage 3 only; up to 28 days may be acceptable following 
discussion bet ween the Sponsor and Investigator) after completion of the PK Phase to complete 
the screening assessments and the Screening Visit.  
A tumor assessment is to be performed prior to the first dose of the Extension (pre -Extension 
Phase). The pre -Extension Phas e tumor assessment need not be completed if the baseline tumor 
assessment was performed â‰¤56 days before the first dose of the Extension Phase.  
The Cycle 1/Day 1 Visit can occur on the same day as the Extension Phase Screening Visit, 
dependent upon availabi lity of radiographic results obtained â‰¤ 56 days of the first planned dose 
in the Extension Phase. If the Extension Phase Screening Visit and the Cycle 1/Day 1 Visit occur 
on the same day, the clinical laboratory results will be reviewed by the study person nel prior to 
study drug administration to ensure eligibility. At the Cycle 1/Day 1 Visit, patients will undergo 
safety assessments and will receive study drug supply for the duration of 1 cycle (300  mg or 200 
mg tablets of niraparib for QD dosing or 3 x 10 0 mg or 2 x 100 mg tablets/capsules of niraparib 
for QD dosing, depending upon availability). It is preferred that patients remain on the same 
formulation (tablet versus capsule) throughout the Extension  Phase. Patients will return on the 
first day of ever y treatment cycle (28 Â± 7 days) to receive study drug and for safety assessments. 
Visits will continue approximately every 4  weeks until treatment discontinuation. In line with the 
niraparib US PI, dose interruption (no longer than 28  days) will be allowed  based on adverse 
events (AEs). In addition, dose reductions to 200  mg QD and subsequently to 100  mg QD will be 
allowed based on AEs (please refer to US PI). Any dose reductions differing from this must be 
discussed with the medical monitor. Patients can c ontinue in the Extension Phase until the 
patient meets 1  of the withdrawal criteria.  
EOT and Safety Follow -up Visits:  
The EOT visit will occur within 7 days of the decision to discontinue study treatment for any 
reason. Patient s who do not participate in the Extension Phase will also have an EOT visit within 
7 days of the decision to discontinue study. Should the first dose of a new anti -cancer therapy 
occur within 14 days of the decision to discontinue study treatment, all asses sments required for 
the Safety Follow -up visit should occur at the EOT visit and this visit will be considered the 
Safety Follow -up visit. If the first dose of the new anti -cancer therapy occurs >14 days of the 
decision to discontinue study, the Safety Fol low-up visit will occur 30+7 days after the last dose 
of the study drug, or at the start of any new anti -cancer therapy, whichever occur first.    
1LUDSDULE   
&OLQLFDO6WXG\3URWRFRO9HUVLRQ 
&RQILGHQWLDO  3DJHRI)LJXUH 6WXG\'HVLJQ6LQJOH&URVVRYHU6WXG\
6WDJH





6WDJHFRPSOHWHG








6WDJHFRPSOHWHG

$EEUHYLDWLRQV3. SKDUPDFRNLQHWLFV
)DVWLQJDQG6WXG\'UXJ$GPLQLVWUDWLRQIRUWKH3.3KDVH
,Q6WDJHDQGGXULQJWKH 3.3KDVHRIWKHVWXG\SDWLHQWVVK RXOGFRPHWRWKHFOLQLFRQWKH
PRUQLQJRI'D\RIWKH6WXG\'UXJ DQG:DVKRXW3.SHULRGDQGVX EVHTXHQW6WXG\'UXJDQG3.
SHULRGIROORZLQJDQKRXURYHUQLJKWIDVW'XULQJWKHRYHUQLJKW IDVWSDWLHQWVDUHSHUPLWWHGWR
FRQVXPHZDWHUEXWQRRWKH UEHYHUDJHVXSWRKRXUVSULRUWRG RVLQJRIWKHVWXG\GUXJ3DWLHQWV
PD\WDNHWKHLUURXWLQHPHGLFDWLRQVZLWKVLSVRIZDWHU,IWKHS DWLHQWSUHVHQWVWRWKHFOLQLFDQGLV
GHWHUPLQHGQRWWREHLQDIDVWL QJVWDWHDVPDQGDWHGE\WKHSURW RFROWKHGRVLQJQHHGVWREH
UHVFKHGXOHG
7-day PK sample 
collection
7-day PK sample 
collection14-day washout 
period, including 
7-day PK sample 
collection
300 mg dose 
1:1 Randomization 
Niraparib
Dose 1: 
Tablet
Niraparib
Dose 1:
Capsule
14-day washout 
period, including 
7-day PK sample 
collection
Niraparib
Dose 2: 
Tablet
Niraparib
Dose 2:
Capsule
Option to qualify 
for treatment in 
Extension Phase 
Option to qualify 
for treatment in 
Extension Phase 
300 mg dose 
N=16 evaluable 
1:1 Randomization 
Niraparib
Dose 1: 
Fasted
Niraparib
Dose 1:
Fed
14-day washout 
period, including 7-
day PK sample 
collection
Niraparib
Dose 2: 
Fasted
Niraparib
Dose 2:
Fed
Option to qualify 
for treatment in 
Extension Phase 
Option to qualify 
for treatment in 
Extension Phase 14-day washout 
period, including 
7-day PK sample 
collection7-day PK sample 
collection
7-day PK sample 
collection
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0  
Confidential   Page 45 of 103 Patients will receive a single dose of the study drug with approximately 250  ml of water on 
Day 1 of the Study Drug and Washout/PK period and subsequent Study Drug and PK period. 
Patients may take sips of water after the single dose and resume their regular diet 4  hours 
thereafter.  
In Stage 3, all patients should arrive at the clinic following an overnight fast for a minimum of  
10 hours. For patients taking niraparib with a high -fat meal, the  meal (see Appendix  E) should 
start 30 minutes before administration of niraparib. Patients should eat this meal in 30 minutes or 
less, and ever y effort should be made for the patient to complete the entire meal .. The dose of 
niraparib should be taken within 5 minutes of finishing the meal, with 240 mL (8 fluid ounces) of 
water. Patients taking the drug product in a fasted state should also take it with 240 mL of water. 
Additional water is allowed except for 1 hour before and 1 hour after drug administration. No 
food is allowed for at least 4 hours postdose in both treatment periods . 
6.1.2. General Study Conduct  
This study will consist of a Screenin g Period (Day -21 to Day -1), a PK Phase (Study Drug and 
Washout/PK period 1 and Study Drug and PK period 2), an EOT visit, and a Safety Follow -up 
Visit. When patients complete the PK Phase of the study  (at least 7 days from the beginning of 
PK period 2) , they may be eligible to participate in the Extension  Phase prior to EOT and Safety 
Follow-up Visits, following review of the Extension Phase inclusion criteria and completion of 
the required screening assessments.  See Section 6.1. 
Following informed consent, all patients will undergo screening procedures within 21  days prior 
to the first dose of study drug to determine eligibility for study entry. Screening procedures 
include medical, surgical, cancer, and medication history; complete physical examination, 
including vital signs, height, and weight; Eastern Cooperative Oncology Group (ECOG) 
performance status; clinical laboratory assessments (complet e blood count [CBC], chemistry, 
and urinalysis); pregnancy test for women of childbearing potential; baseline tumor assessment 
and electrocardiogram (ECG).  
Once randomized to either capsule to tablet crossover or tablet to capsule crossover, patients will 
receive a single dose of the formulation (tablet or capsule) in a fasted state  (Stage 1 and Stage 2) . 
Stage 1:  Following an 8-hour fast on Day 1  (see Section  6.1.1), patients will receive a single 
dose of the formulation (tablet [1 Ã— 300 mg] or capsule [3 Ã— 100 mg]) followed by a 7 -day (+ 1 
day) Washout/PK period followed by a dose of the alternate formulation also in a fasted state, 
followed by a 7 -day Washout/PK period. Patients receiving the tablet in the first treatment period 
will receive the capsules in the second treatment period and vice versa ( Figure 2). Extensive PK 
sampling will be carried out after niraparib dosing (see S ection 10.1). Blood will be collected 
during the study for PK assessments at the following time points relative to niraparib dosing: 
predose (30  minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 , 12, 24, 48, 72, 96, 120, and 
168 hours postdose.   
Stage 2: Following an 8 -hour fast on Day  1 (see Section  6.1.1), patients will receive a single dose 
of the formulation (tablet [1 Ã— 300 mg] or capsule [3 Ã— 100 mg]) followed by a 14 -day (+/- 4 days) 
Washout/PK period followed by a dose of the alternate formulation also in a fasted state, 
followed by a 7 -day Washout/PK period. Patients receiving the ta blet in the first treatment period 
will receive the capsules in the second treatment period and vice versa ( Figure 2). Extensive PK 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0  
Confidential   Page 46 of 103 sampling will be car ried out after niraparib dosing (see S ection 10.1). Blood will be collected 
during the study for PK assessments at the following time points relative to niraparib dosing: 
predose (30  minutes prior to dosing) and at 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, 96,120, and 
168 hours postdose . 
Stage 3: In period 1, patients will receive a single 300 mg niraparib tablet either following a 10-
hour fast or directly following consumption of a high -fat meal followed by a 14 -day (+4 days) 
PK sampling and washout period. In period 2, patients will be crossed over to r eceive a single 
300 mg niraparib tablet in a fasted state or with a high -fat meal, followed by a 7 -day PK 
sampling period. All patients will fast for a minimum of 4 hours postdose in both periods. 
Patients receiving the tablet in a fasted state in the firs t treatment period will receive the tablet 
with a high -fat meal in the second treatment period and vice versa. Extensive PK sampling will 
be carried out after niraparib dosing (see Section 10.1). Blood will be collected during the study 
for PK assessments at the following time points relative to niraparib dosing: predose (30  minutes 
prior to dosing) and at 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose.  
Safety assessments conducted throughout the study include symptom -directed physical 
examination, vital signs, ECOG performance status, clinical laboratory assessments (CBC, 
chemistry, and urinalysis) (Section  6.6.1). Laboratory results from D8 (start of PK Period 2) 
should be reviewed by the site personnel, and significant changes in renal or hepatic function 
compared t o baseline should be discussed with the sponsor.  
6.2. Number of Patients  
Approximately 24 patients will be enrolled in Stage 1, and approximately  170 will be enrolled in 
Stage 2 to ensure 100 evaluable patients for BE analysis . Approximately 20 patients will be  
enrolled in Stage 3 to ensure 16 evaluable patients for the FE analysis.  
6.3. Treatment Assignment  
6.3.1. Patient Identification  
All patients who enter into the screening period of the study (defined as the point at which the 
patient signs the Informed Consent Form [ ICF]) will receive a unique patient identification 
number. This number will be used to identify the patient throughout the study and must be used 
on all study documentation related to that patient. A patient will be considered enrolled when the 
patient has  been consented, screened, and all eligibility criteria have been confirmed in the 
electronic case report form (eCRF). The patient identification number must remain constant 
throughout the entire study, and it must not be changed at the time of enrollment.  
6.3.2. Randomization Scheme  
Randomization will occur centrally using an interactive voice response system/integrated web 
response system. In Stage 1 and Stage 2, subjects will be assigned randomly in a 1:1 ratio to a 
dosing sequence: capsule formulation followed by tablet formulation , or vice versa.  In Stage 3, 
subjects will be assigned randomly in a 1:1 ratio to a dosing sequence: dosing after receiving a 
high-fat meal (fed) followed by dosing after fasting, or vice versa.  The period between 
randomizatio n and Cycle  1/Day 1 should be no longer than 5 calendar days.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0  
Confidential   Page 47 of 103 6.4. Dose Adjustment Criteria  
6.4.1. Safety Criteria for Stopping Doses During PK Phase  
During the PK Phase, patients must be discontinued for any treatment -related nonhematologic 
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 
(NCI-CTCAE v.4.03) Grade  3 or 4 AE or serious adverse event (SAE) that the Investigator 
considers to be related to the administration of niraparib and, in case this resulted in incomplete 
PK collection. Patients may be permitted to enter the Extension Phase at an appropriately 
reduced dose.  
6.4.2. Safety Criteria for Adjustment or Stopping Doses During Extension Phase  
During the Extension Phase, dose interruption and/or reduction may be implemented at any  time 
for any grade toxicity considered intolerable by the patient and per the US label. In addition, 
protocol-defined criteria for dose modification are discussed below.  
Treatment must be interrupted for any treatment -related nonhematologic NCI -CTCAE v.4. 03 
Grade 3 or 4 AE or SAE that the Investigator considers to be related to niraparib administration. 
If the toxicity is resolved to baseline or â‰¤Grade 1 within 28  days, the patient may restart 
treatment with niraparib but with an appropriate dose reduction  unless prophylaxis is considered 
feasible (Table 3). If the event recurs at a similar or worse grade, treatment should be interrupted 
again, and upon resolution, a further dose reduction must be made. If upon rechallenging  with 
niraparib at the lowest allowable dose, any NCI -CTCAE Grade  3 or 4 AEs, which the 
Investigator considers to be related to niraparib recur, the patient must be discontinued. At th e 
Investigatorâ€™s discretion, following dose interruption (no longer than 28  days), patients may be 
considered for dose reductions, provided that they have not already undergone the maximum 
number of 2  dose reductions allowed (no more than 2  dose reductions  will be permitted). Any 
dose reductions deviating from this guidance must be discussed with the medical monitor.  
Table 3: Niraparib Dose Reductions for Non -Hematologic  Toxicities  
Event Dose1 
Initial dose  300 mg QD 
First dose reduction for treatment -related NCI -CTCAE 
v.4.03 Grade 3 or 4 AE or SAE where prophylaxis is not 
considered feasible  200 mg QD 
Second dose reduction for NCI -CTCAE v.4.03 Grade 3 or 4 
AE or SAE where prophylaxis is not considered feasible  100 mg QD 
Continued treatment -related CTCAE Grade 3 or 4 AE or 
SAE â‰¥28 days Discontinue study medication  
Posterior Reversible Encephalopathy Syndrome (PRES) 
(see Section  11.2.9) Discontinue niraparib and treat specific 
symptoms including hypertension.  
Abbreviations: AE =adverse event; CTCAE =Common Terminology Criteria for Adverse Events; 
NCI-CTCAE=National Cancer Institute CTCAE; QD=once daily; PRES=Posterior Reversible Encephalopathy 
Syndrome; SAE=serious adverse event . 
1 Dose not to be decreased below 100  mg daily.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0  
Confidential   Page 48 of 103 Management of hematolo gic toxicities  (Guan, 2017) is described in Table 4. For Grade 3 or 4 
neutropenia, thrombocytopenia, or anemia, treatment with niraparib must be interrupted with 
weekly blood counts monitored until recovery to â‰¤Grade 1. Niraparib should be resumed with a 
dose level reduction at that time. Cytokines (granul ocyte colony stimulating factor [CSF]) may 
be administered as clinically indicated to manage febrile neutropenia according to local standard 
of care.  
For major surgery, up to 28  days of drug interruption is allowed.  
Thrombocytopenia is an expected event a ssociated with the use of niraparib and is described in 
the IB. Thrombocytopenia associated with the use of niraparib resolved upon treatment 
interruption and/or dose reduction. The occurrence of thrombocytopenia during Cycle  1 requires 
additional patient monitoring in order to identify hematologic changes early and prevent higher 
grade thrombocytopenic events. A weekly monitoring of CBC during the first month is 
mandatory.  
If a patient completes the first cycle with no incidence of hematologic toxicity req uiring dose 
interruption or modification, then CBC monitoring will proceed according to protocol every 
4 weeks, thereafter. If dose interruption or modification is required at any point on study, weekly 
CBC will be required for another 4  weeks after the AE  has been resolved, to ensure safety of the 
new dose, after which monitoring every 4  weeks may resume.  
It is strongly recommended to refer the patient to the hematologist for further evaluation if (1) 
transfusions are required on more than 2 occasions in t he absence of non -treatment related causes 
or (2) the treatment -related hematologic toxicities have not recovered to allow retreatment with 
niraparib after 4 weeks. If a diagnosis of myelodysplastic syndromes (MDS)/acute myeloid 
leukemia (AML) is confirmed  by a hematologist, the patient must permanently discontinue study 
drug. 
Table 4: Management of Hematologic Toxicities  
Platelet count <  100,000/Î¼L  First occurrence:  
â€¢ Withhold study medication for a maximum of 28  days and 
monitor blood counts weekly until platelet counts return to 
â‰¥100,000/Î¼L.  
â€¢ Resume study medication at same or reduced dose per Table 3. 
â€¢ If platelet co unt is <75,000/Î¼L, resume at a reduced dose.  
Second occurrence:  
â€¢ Withhold study medication for a maximum of 28  days and 
monitor blood counts weekly until platelet counts return to 
â‰¥100,000/Î¼L.  
â€¢ Resume study medication at a reduced dose per Table 3. 
â€¢ Discontinue study medication if platelet count has not returned 
to acceptable levels within 28 days of the dose interruption 
period, or if the  patient has already undergone dose reduction 
to 100 mg once daily.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0  
Confidential   Page 49 of 103 Table 4: Management of Hematologic Toxicities (Continued)  
Neutrophil <  1,000/ÂµL or 
hemoglobin <  8 g/dL â€¢ Withhold study medication for a maximum of 28  days and 
monitor blood counts weekly until neutrophil counts return to 
â‰¥1,500/Î¼L or hemoglobin returns to â‰¥9  g/dL. 
â€¢ Resume study medication at a reduced dose per  Table 3. 
â€¢ Discontinue study medication if neutrophils and/or hemoglobin 
have not returned to acceptable levels within 28  days of the 
dose interruption period, or if the patient has already undergone 
dose reduction to 100  mg once daily.a 
Hematologic advers e 
reaction requiring 
transfusion  â€¢ For patients with platelet count â‰¤10,000/Î¼L, platelet transfusion 
should be considered. If there are other risk factors such as 
co-administration of anticoagulation or antiplatelet drugs, 
consider interrupting these drugs a nd/or transfusion at a higher 
platelet count.  
â€¢ RBC transfusion is at the discretion of the Investigator  
â€¢ Resume study medication at a reduced dose.  
Confirmed MDS/AML  â€¢ Permanently discontinue treatment.  
Abbreviations: AML=acute myeloid leukemia; CBC=complete blood count; Hb =hemoglobin ; 
MDS=myelodysplastic syndrome ; RBC=red blood cell .  
a If MDS/AML is confirmed, niraparib will be discontinued.  
6.5. Criteria for Study Termination  
The Sponsor may terminate this study at any time. The Sponsor will notify the Investigators 
when the study is to be placed on hold, completed, or terminated.  
6.6. Study Conduct  
6.6.1. Schedule of Events  
The schedule of events for the study is provided in Table 5: for Stage 1, Table 6 for Stage 2, 
Table 7: for Stage 3, and Table 8 for the Extension Phase .  
Niraparib          
Clinical Study Protocol 3000 -01-004 Version 6.0    
Confidential        Page 50 of 103 Table 5: Schedule of Events: Study Drug and PK Phase â€“ Stage 1 (COMPLETED)  
Cycle/Visit  Screening  Study Drug and Washout/PK 
Period 1 Study Drug and Washout/PK 
Period 2    EOT Safety Follow -up 
Day of Procedure  -21 to -1 1 2 3 4 5 6 81 9 10 11 12 13 15 +7 days of 
the decision 
to 
discontinue 
treatment for 
any reason2 30 + 7 days post - 
treatment2 
 
Informed consent  X                
Inclusion/ exclusion criteria review  X                
Randomization  X3                
Demographics  X                
Medical, surgical, cancer, and 
medication  history X                
Laboratory assessments:                  
CBC4 X X5      X5       X X 
Chemistry6 X X5      X5       X X 
Pregnancy test  X               X 
Urinalysis  X               X 
ECG X               X 
Complete physical examination  X               X 
Symptom -directed physical examination   X5      X5         
Vital signs and weight  X X5      X5        X 
Height X                
ECOG performance status  X X5      X5       X X 
Tumor assessment  X7                
Niraparib study drug  
administration   X      X         
Niraparib          
Clinical Study Protocol 3000 -01-004 Version 6.0    
Confidential        Page 51 of 103 Cycle/Visit  Screening  Study Drug and Washout/PK 
Period 1 Study Drug and Washout/PK 
Period 2    EOT Safety Follow -up 
Day of Procedure  -21 to -1 1 2 3 4 5 6 81 9 10 11 12 13 15 +7 days of 
the decision 
to 
discontinue 
treatment for 
any reason2 30 + 7 days post - 
treatment2 
 
Pharmacokinetic sample collection   X X X X X X X8 X X X X X X   
Concomitant medications and 
procedures  X  Recorded from informed consent through EOT  
Adverse event monitoring9 X  Recorded from informed consent through 30 days post -treatment  
Abbreviations: AE =adverse event; AESI =adverse events of special interest; CBC =complete blood count; CT =computed tomography; ECG =electrocardiogram; 
ECOG=Eastern Cooperative Oncology Group; EOT =end of treatment; MRI =magnetic resonance imaging; PK =pharmacokinetics; SAE =serious adverse event.  
1 Study Drug and PK Period may be  delayed up to 1 day if necessary for scheduling purposes.  
2 Patients who do not participate in the Extension Phase of the study will proceed to the EOT  visit followed by the Safety Follow -up Visit. Patients participating 
in the Extension Phase will proceed into screening for the Extension Phase directly after completing the Study drug and PK pe riod.  
3 Patients to be randomized within 5  calendar days of first dose.  
4 CBC to include: Hemoglobin, Platelet count, Mean corpuscular volume, White blood cell count, Differential white blood cell co unt 
5 Need not be repeated at screening or during the Washout/PK period if done within 72 hours of dosing 1 and 2, respectively.  
6 Chemistry to include: Sodium,  Potassium, Magnesium, Chloride, Albumin, Calcium, Amylase, Phosphate, Glucose, Creatinine, Urea or blood urea nitrogen, 
Total protein, Lactate dehydrogenase, Total bilirubin, Alkaline phosphatase, Aspartate aminotransferase, and Alanine aminotransferase  
7 Tumor assessments may be performed within 28 days of first dose of study drug. Tumor assessments performed outside of the 28 day window but â‰¤ 56 days of 
the planned start of the Extension  Phase are acceptable. Tumor assessment via a CT or MRI scan of clinically indicated areas should be performed.  
8 PK sample collection for the 168 hour postdose timepoint from the first Study Drug and Wash out/PK Period and the predose for the second Study Drug and 
Washout/PK Period can occur at the same time.  
9 AEs will be collected and recorded for each patient from the time of randomization and /or treatment assignment until 30 days after the last dose of study drug. 
SAEs are required to be captured through 90 days after the last dose of study drug (or until the start of alternate anticance r therapy, whichever occurs first). All 
SAEs assessed by the Investigator as related to the study drug and AESIs will be collected and reported until study closeout (unless death or loss to follow -up 
occurs first) . Any pregnancies that occur within 180 days post -treatment will be reported. All AEs and SAEs exper ienced by a patient, irrespective of the 
suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to ba seline or normalized, until there is 
a satisfactory explanation for the changes observed, until the patient is lost to follow -up, or until the patient has died.  
Niraparib          
Clinical Study Protocol 30 00-01-004 Version 6.0    
Confidential        Page 52 of 103 Table 6: Schedule of Events: Study Drug and PK Phase â€“ Stage 2  (COMPLETED)  
Cycle/Visit  Screening  Study Drug and Washout/PK 
Period 1 
 Study Drug and Washout/PK Period 
2  EOT Safety Follow -up 
Day of Procedure  -21 to -1 1 2 3 4 5 6 8 15 
(Â±4) 16 17 18 19 20 22 +7 days of 
the decision 
to 
discontinue 
treatment for 
any reason1 30 + 7 days post - 
treatment1 
 
Informed consent  X                 
Inclusion/ exclusion criteria  review X                 
Randomization  X2                 
Demographics  X                 
Medical, surgical, cancer, and 
medication history  X                 
Laboratory assessments:                   
CBC3 X X4       X4       X X 
Chemistry5 X X4       X4       X X 
Pregnancy test  X                X 
Urinalysis  X                X 
ECG X                X 
Complete physical examination  X                X 
Symptom -directed physical examination   X4       X4         
Vital signs and weight  X X4       X4        X 
Height X                 
ECOG performance status  X X4       X4       X X 
Tumor assessment  X6                 
Niraparib          
Clinical Study Protocol 30 00-01-004 Version 6.0    
Confidential        Page 53 of 103 Cycle/Visit  Screening  Study Drug and Washout/PK 
Period 1 
 Study Drug and Washout/PK Period 
2  EOT Safety Follow -up 
Day of Procedure  -21 to -1 1 2 3 4 5 6 8 15 
(Â±4) 16 17 18 19 20 22 +7 days of 
the decision 
to 
discontinue 
treatment for 
any reason1 30 + 7 days post - 
treatment1 
 
Niraparib study drug  
administration   X       X         
Pharmacokinetic sample collection   X X X X X X X  X X X X X X X   
Concomitant medications and 
procedures  X Recorded from informed consent through EOT  
Adverse event monitoring7 X Recorded from informed consent through 30 days post -treatment  
Abbreviations: AE =adverse event; AESI =adverse events of special interest; CBC =complete blood count; CT =computed tomography; ECG =electrocardiogram; 
ECOG=Eastern Cooperative Oncology Group; EOT =end of treatment; MRI =magnetic resonance imaging; PK =pharmacokin etics; SAE =serious adverse event.  
1 Patients who do not participate in the Extension Phase of the study will proceed to the EOT visit followed by the Safety Foll ow-up Visit. Patients participatin g 
in the Extension Phase will proceed into screening for the Extension Phase directly after completing the Study drug and PK pe riod. The EOT visit will occur 
within 7 days of the decision to discontinue study treatment for any reason. Should the first dose  of a new anti -cancer therapy occur within 14 days of the 
decision to discontinue study treatment, all assessments required for the Safety Follow -up visit should occur at the EOT visit and this visit will be considered the 
Safety Follow -up visit. If the fi rst dose of the new anti -cancer therapy occurs >14 days of the decision to discontinue study, the Safety Follow -up visit will occur 
30+7 days after the last dose of the study drug, or at the start of any new anti -cancer therapy, whichever occur first.    
2 Patients to be randomized within 5 calendar days of first dose.  
3 CBC to include: Hemoglobin, Platelet count, Mean corpuscular volume,  White blood cell count, Differential white blood cell count  
4 Need not be repeated at screening or during the Washout/PK period if done within 72 hours of dosing 1 and 2, respectively.  
5 Chemistry to include: Sodium, Potassium, Magnesium, Chloride, Albumin, Calcium, Amylase, Phosphate, Glucose, Creatinine, Urea or blood urea nitrogen, 
Total protein, Lactate dehydrogenase, Total bilirubi n, Alkaline phosphatase, Aspartate aminotransferase, and Alanine aminotransferase  
6 Tumor assessments may be performed within 28 days of first dose of study drug. Tumor assessments performed outside of the 28 day window but â‰¤56 days of 
the planned start of the Extension  Phase are acceptable. Tumor assessment via a CT or MRI scan of clinic ally indicated areas should be performed.  
7 AEs will be collected and recorded for each patient from the time of randomization and/or treatment assignment until 30 days after the last dose of study drug. 
SAEs are required to be captured through 90 days after the last dose of study drug (or until the start of alternate anticance r therapy, whichever occurs first). All 
SAEs assessed by the Investigator as related to the study drug and AESIs  will be collected and reported until study closeout (unless death or loss to follow -up 
occurs first). Any pregnancies that occur within 180 days post -treatment will be reported. All AEs and SAEs experienced by a patient, irrespective of the 
suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized,  until there is 
a satisfactory explanation for the changes observed, until the patient is lost to follow -up, or until the patient h as died. 
Niraparib          
Clinical Study Protocol 30 00-01-004 Version 6.0    
Confidential        Page 54 of 103 Table 7: Schedule of Events: Study Drug and PK Phase â€“ Stage 3 
Cycle/Visit  Screening  Study Drug and Washout/  
PK Period 1  
 Study Drug and Washout/  
PK Period 2  EOT Safety Follow -up 
Day of Procedure  -21 to -1 1 2 3 4 5 6 8 15 
(+4) 16 17 18 19 20 22 +7 days of 
the decision 
to 
discontinue 
treatment for 
any reason1 30+7 days post - 
treatment1 
 
Informed consent  X                 
Inclusion/exclusion criteria review  X                 
Randomization  X2                 
Demographics  X                 
Medical, surgical, cancer, and 
medication history  X                 
Laboratory assessments:                   
CBC3   X X4       X4       X X 
Chemistry5 X X4       X4       X X 
Pregnancy test10 X                X 
Urinalysis  X                X 
ECG X                X 
Complete physical examination  X                X 
Symptom -directed physical examination   X4       X4         
Vital signs and weight11 X X4       X4       X X 
Height X                 
ECOG performance status  X X4       X4       X X 
Niraparib          
Clinical Study Protocol 30 00-01-004 Version 6.0    
Confidential        Page 55 of 103 Table 7: Schedule of Events: Study Drug and PK Phase â€“ Stage 3 (continued)  
Tumor assessment  X6                 
Confirmation of fasting  state8  X       X         
Consumption of high -fat meal, as 
applicable9  X       X         
Niraparib  study drug administration   X       X         
Pharmacokinetic sample collection   X X X X X X X  X X X X X X X   
Concomitant medications and 
procedures  X Recorded from informed consent through EOT  
Adverse event monitoring7 X Recorded from informed consent through 30 days post -treatment  
Abbreviations: AE=adverse event; AESI=adverse events of special interest; BP=blood pressure; CBC=complete blood count; CT=computed tomography; 
eCRF=electronic case report form; ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EOT=end of treatment; MRI=m agnetic resonance 
imaging; PK=pharmacokinetics; SAE=serious ad verse event.  
1  Patients who do not participate in the Extension Phase of the study will proceed to the EOT visit followed by the Safety Foll ow-up Visit. Patients participating 
in the Extension P hase will proceed into Screening for the Extension Phase directly after completing the Study Drug and PK Period. The EOT visi t will occur 
within 7 days of the decision to discontinue study drug for any reason. Should the first dose of a new anti -cancer the rapy occur within 14 days of the decision 
to discontinue study drug, all assessments required for the Safety Follow -up visit should occur at the EOT visit and this visit will be considered the Safety 
Follow-up visit. If the first dose of the new anti -cancer therapy occurs >14 days of the decision to discontinue study, the Safety Follow -up visit will occur 30+7 
days after the last dose of the study drug, or at the start of any new anti -cancer therapy, whichever occur first.   
2  Patients may be randomized wi thin 5 calendar days of first dose.  
3  CBC to include: hemoglobin , platelet count, mean corpuscular volume, white blood cell count, differential white blood cell count .  
4  Need not be repeated at Screening or during the Washout/PK Period if done within 72  hours of dosing 1 and 2, respectively.  
5  Chemistry to include: sodium, potassium , magnesium , chloride, albumin, calcium, amylase, phosphate , glucose, creatinine , urea or blood urea nitrogen, total 
protein, lactate dehydrogenase, total bilirubin, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase  
6 Tumor assessments may be performed within 28 days of first dose of study drug. Tumor assessments performed outside of the 28 day window but â‰¤56 days 
before the planned start of the E xtension Phase are acceptable. Tumor assessment via a CT or MRI scan of clinically indicated areas should be performed.  
7 AEs will be collected and recorded for each patient from the time of randomization and/or treatment assignment until 30 days after the last dose of study drug. 
SAEs are required to be captured through 90 days after the last dose of study drug (or until the start of alternate anticance r therapy, whichever occurs first). All 
SAEs assessed by the Investigator as related to the study drug an d AESIs will be collected and reported until study closeout (unless death or loss to follow -up 
occurs first). Any pregnancies that occur within 180 days post -treatment will be reported. All AEs and SAEs experienced by a patient, irrespective of the 
suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized, until there 
is a satisfactory explanation for the changes observed, until the patient is lost to follow -up, or until  the patient has died.  
8  Patient must fast for a minimum of 10 hours prior to start of visit . No food is allowed for at least 4 hours postdose in both treatment periods.  Patients should 
start the high -fat meal (if assigned) 30 minutes before administratio n of niraparib and eat the meal in 30 minutes or less. The dose of niraparib should be taken 
Niraparib          
Clinical Study Protocol 30 00-01-004 Version 6.0    
Confidential        Page 56 of 103 within 5 minutes of finishing the meal, with 240 mL (8 fluid ounces) of water. Patients taking the drug product in fasted sta te should also take it with  240 mL 
of water. Additional water is allowed except for 1 hour before and 1 hour after drug administration.  
9 Consumption of high -fat meal in either period 1 or period 2 is determined by patient randomization allocation.  
10 A negative serum or urine pregn ancy test is required within 72 hours for females of childbearing potential prior to first dose of study drug for PK period 1  and 
Extension Phase.  
11 Vital signs include BP, pulse, heart rate, and temperature .  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 57 of 103 
  Table 8: Schedule of Events: Extension Phase  
Cycle/Visit  Extension Phase 
Screening  Extension Phase  Extension Phase  EOT Safety Follow -up 
 
Day of Procedure  1-28 days1 Cycle 1  
(28 Â± 7 days)2  Cycle 2 and on  
(28 Â± 7 days)2  +7 days of the decision 
to discontinue 
treatment for any 
reason3  30 + 7 days post - 
treatment3 
 
Inclusion/exclusion criteria review  X2     
Laboratory assessments:       
CBC4 X Weekly6 Monthly X X 
Chemistry5 X Every other week6 Monthly X X 
Pregnancy test  X    X 
Urinalysis      X 
ECG     X 
Complete physical examination  
    X 
Symptom -directed physical 
examination including vital signs  X X6 (Day 1) X6 (Day 1)   
Vital signs and weight10 X Weekly X6 (Day 1) X X 
ECOG performance status  X X6 (Day 1) X6 (Day 1) X X 
Tumor assessment  X7  X (every 3  cycles)8    
Niraparib study drug dispensed   X X   
Concomitant medications and 
procedures  Recorded from informed consent through EOT   
Adverse event monitoring9 Recorded from informed consent through 30  days post-treatment  X 
Abbreviations: AE =adverse event; AESI =adverse events of special interest; BP=blood pressure; CBC=complete blood count; CT =computed tomography; 
ECG=electrocardiogram; ECOG =Eastern Cooperative Oncology Group; EOT =end of treatment; MRI =magnetic resonance imaging; SAE =serious adverse event.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confidential   Page 58 of 103 
  1 When patients complete the PK Phase of the study  (at least 7 days from the beginning of PK period 2) , they will be eligible to participate in the Extension 
Phase following re -review of selected entry criteria and completion of the screening assessments. If laboratory values are outside of the range specified in the 
inclusion criteria, the patient may con tinue to participate in the study at the discretion of the Sponsor and Investigator with consideration for a reduced dose.  
   Patients have 28 days to complete the screening assessments. The Screening Visit and Cycle 1/Day 1 Visit can occur on the sam e day dependent upon 
availability of radiographic results obtained â‰¤ 56 days of the first planned dose in the Extension Phase.  
2 The intent of the 7 -day Day 1 window is to allow flexibility in schedu ling; please note study drug is dispensed in 31 -day increments.  
3  The EOT visit will occur within 7 days of the decision to discontinue study treatment for any reason. Patient s who do not participate in the Extension Phase 
will also have an EOT visit within 7 days of the decision to discontinue study. Should the first dose of a new anti -cancer therapy occur within 14 days of the 
decision to discontinue study treatment, all asses sments required for the Safety Follow -up visit should occur at the EOT visit and this visit will be considered 
the Safety Follow -up visit. If the first dose of the new anti -cancer therapy occurs >14 days of the decision to discontinue study, the Safety Fol low-up visit will 
occur 30+7 days after the last dose of the study drug, or at the start of any new anti -cancer therapy, whichever occur first.    
4 CBC to include: Hemoglobin, Platelet count, Mean corpuscular volume, White blood cell count, Differential white blood cell count. CBC needs to obtained 
within 72 hrs prior to starting C1D1 of the Extension Phase  and monthly for the next 10 months of niraparib treatment. CBC will be obtained periodicall y after 
this time to monitor for clinically significant changes in any hematological parameter during niraparib treatment.  
5 Chemistry to include: Sodium, Potassium, Magnesium, Chloride, Albumin, Calcium, Amylase, Phosphate, Glucose, Creatinine, Urea or blood urea nitrogen, 
Total protein, Lactate dehydrogenase, Total bilirubin, Alkaline phosphatase, Aspartate aminotransferase,  and Alanine aminotransferase. Chemistry needs to 
obtained within 72 hrs prior to starting C1D1 of the Extension Phase  
6 Need not be repeated if done within 72 hours of dosing Day 1.  
7 Tumor assessment to be performed prior to the first dose of the Extension Phase (pre -Extension Phase). The pre -Extension Phase tumor assessment need not be 
performed if the baseline tumor assessment was perf ormed  â‰¤56 days before the first dose of the Extension Phase  
8 Tumor assessment via a CT or MRI scan of clinically indicated areas and evaluation of clinical signs and symptoms should be p erformed during the Extension 
Phase every three cycles (+/ - 7 days) or per the Institutionâ€™s standard practice. The Investigator will evaluate the patient scans and clinical symptoms to  
evaluate disease status and progression, discontinue niraparib and initiate s ubsequent anticancer treatment as necessary.  
9 AEs will be collected and recorded for each patient from the time of randomization and/or treatment assignment until 30 days after the last dose of study drug. 
SAEs are required to be captured through 90 days after the last dose of study drug (or until the start of alternate anticance r therapy, whichever occurs first). All 
SAEs assessed by the Investigator as related to the study drug and AESIs  will be collected and reported until study closeout (unless death or loss to follow -up 
occurs first) . Any pregnancies that occur within 180 days post -treatment will be reported. All AEs and SAEs experienced by a patient, irrespective of the 
suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized,  until there is 
a satisfactory explanation for the changes observed, until the patient is lost to follow -up, or until the patient h as died. 
10 Vital signs include BP, pulse, heart rate, and temperature. BP and heart  rate will be monitored weekly for the first 4  weeks of the Extension Phase  and monthly 
thereafter . 
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 59 of 103 
  7. SELECTION AND WITHDR AWAL OF PATIENTS  
7.1. Patient Inclusion Criteria  
7.1.1. Patient Inclusion Criteria (Stages 1 and 2)  
PK Phase:  
To be considered eligible to participate in this study, all of the following requirements must be 
met:  
1. Patient is capable of understanding the written informed consent, provides signed and 
witnessed written informed consent, and agrees to comply with prot ocol requirements.  
2. Patient has histologically or cytologically confirmed diagnosis of metastatic or locally 
advanced solid tumors that have failed to respond to standard therapy, has progressed 
despite standard therapy, or for which no standard therapy exi sts, and who may benefit 
from treatment with a PARP inhibitor as asses sed by the Investigator. Patients with 
lymphoma are eligible.  Patients with primary CNS malignancy are eligible provided they 
do not have new or progressive signs or symptoms, and are not requiring steroid dose 
exceeding the equivalent of 10 mg of prednisone daily.  
3. Patient is at least 18 years of age.  
4. Patient has an ECOG performance status of 0 to 2.  
5. Patient has adequate organ function as defined below (Note: CBC should be obtained 
without transfusion or receipt of CSFs , erythropoietin stimulating agents or platelet -
stimulating agents  within 2 weeks before first dose):  
a. Absolute neutrophil count â‰¥1,500/ÂµL  
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥ 9  g/dL (5.6 mM)  
d. Serum creatinine â‰¤1.5Ã— the upper limit of normal (ULN) or a calculated creatinine 
clearance â‰¥ 60 mL/min using the Cockcroft -Gault equation  or 24-hour urine 
creatinine clearance . 
e. Total bilirubin â‰¤1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enro ll if direct bilirubin â‰¤1.5Ã— ULN of the direct bilirubin.  
f. Aspartate aminotransferase  (AST) and alanine aminotransferase (ALT) â‰¤2.5Ã— ULN 
unless liver metastases are present, in which case, they must be â‰¤5Ã— ULN 
6. Patient has recovered to baseline or Grade 1 toxicity from prior cancer therapy (a patient 
with Grade  2 neuropathy or Grade  2 alopecia or Grade 2 hypothyroidism on a stable dose 
of thyroid replacement are an exception to this criterion and may qualify for this study).  
For patients with hemat ologic, renal or hepatic toxicity from pri or therapy , inclusion 
criterion #5 should be applied to determined eligibility.  
7. Patient is able to take oral medications.  
8. Female patient meets the following criteria:  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 60 of 103 
  a. Patient (of childbearing potential) is not brea stfeeding, has a negative serum 
pregnancy test within 72  hours prior to taking study drug and agrees to abstain from 
activities that could result in pregnancy from Screening through 180  days after the 
last dose of study drug, or is of non -childbearing pote ntial. Note: A urine pregnancy 
test may be performed if the serum pregnancy test is not available before dosing.  
b. Female patient is of non -childbearing potential (other than medical reasons) as 
defined by the following:  
i. â‰¥45 years of age and has not had mens es for >1 year). 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon 
Screening evaluation.  
iii. Had undergone a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oophorectomy, or tubal ligation must be 
confirmed in the medical records; otherwise the patient must be willing to use 
highly effective contraception (see Appendix  C) throughout the study starting 
from the Screening visit through 180  days after the last dose of study drug. 
Information must be captured appropriately within the siteâ€™s source 
documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
9. Male patient agrees to use an adequate method of contraception and not donate sperm 
starting with the first dose of study drug through 90  days after the last dose of study drug. 
Note: Abstinence is acceptable if this is the established and preferred contra ception 
method for the patient.  
7.1.2. Patient Inclusion Criteria (Stage 3  only) 
PK Phase:  
To be considered eligible to participate in this study, all of the following requirements must be 
met:  
1. Patient is capable of understanding the written informed consent, p rovides signed and 
witnessed written informed consent, and agrees to comply with protocol requirements.  
2. Patient has histologically or cytologically confirmed diagnosis of metastatic or locally 
advanced solid tumors that have failed to respond to standard t herapy, has progressed 
despite standard therapy, or for which no standard therapy exists, and who may benefit 
from treatment with a PARP inhibitor as assessed by the Investigator. Patients with 
lymphoma are eligible. Patients with CNS malignancy are eligib le provided they do not 
have new or progressive signs or symptoms and are not requiring steroid dose exceeding 
the equivalent of 10 mg of prednisone daily.  
3. Patient is at least  18 years of age.  
4. Patient has an ECOG performance status of 0 to 2.  
5. Patient has a dequate organ function as defined below (Note: CBC should be obtained 
without transfusion or receipt of CSFs in the 1 week before obtaining sample.):  
a. Absolute neutrophil count â‰¥1,000/ÂµL  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 61 of 103 
  b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM)  
d. Serum creatinine â‰¤1. 5Ã— ULN or a calculated creatinine clearance â‰¥60 mL/min using 
the Cockcroft -Gault equation.  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirub in. 
f. AST and ALT â‰¤ 2.5Ã— ULN unless liver metastases are present, in which case, they 
must be â‰¤ 5Ã— ULN 
6. Patient has recovered to baseline or Grade  1 toxicity from prior cancer therapy (a patient 
with Grade  2 neuropathy or Grade  2 alopecia or Grade 2 hypothyroidism on a stable dose 
of thyroid replacement are an exception to this criterion and may qualify for this study). 
For patients with hematologic, renal, or hepatic toxicity resulting from prior cancer 
therapy should meet inclusion criterion # 5 for eligibility.  
7. Patient is able to swallow and retain  oral medication.  
8. Female patient meets the following criteria:  
a. Female patient (of childbearing potential) is not breastfeeding, has a negative serum 
pregnancy test within 72  hours prior to taking study dru g, and agrees to abstain from 
activities that could result in pregnancy from Screening through 180  days after the 
last dose of study drug, or is of nonchildbearing potential. Note: A urine pregnancy 
test may be performed if the serum pregnancy test is not available before dosing.  
b. Female patient of nonchildbearing potential (other than medical reasons) is defined 
by the following:  
i. â‰¥45 years of age and has not had menses for >1  year. 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon 
Screening evaluation.  
iii. Had undergone a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oophorectomy or tubal ligation must be confirmed 
in the medical records, otherwise the patient must be willing to use highly 
effective contraception (see Appendix  C) throughout the study, starting with 
the Screening Visit through 180  days after the last dose of study drug. 
Information must be captured appropriately within the siteâ€™s source 
documents.  
 
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
9. Male patient agrees to use an adequate method of contraception and not donate sperm 
starting with the first dose of study drug through 90  days after the last dose of study drug . 
Note: Abstinence is acceptable if this is the established and preferred contraception metho d 
for the patient.  
10. CNS inclusion - Based on screening brain magnetic resonance imaging (MRI), patients 
must have one of the following:  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 62 of 103 
  a. No evidence of brain metastases  
b. Untreated brain metastases not needing immediate local therapy  
c. Previously treated brain m etastases not needing immediate local therapy  
d. Brain metastases previously treated with local therapy may either be stable since 
treatment or may have progressed since prior local CNS therapy  
e. Patients treated with CNS local therapy for newly identified lesi ons found on contrast 
brain MRI performed during screening for this study may be eligible to enroll if the 
following criteria are met:  
i. Time since whole brain radiation therapy (WBRT) is â‰¥21 days prior to first 
dose of study drug, time since stereotactic ra diosurgery (SRS) is â‰¥7 days prior 
to first dose of study drug, or time since surgical resection is â‰¥28 days.  
ii. Other sites of disease assessable by Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST v1.1) are present  
f. Relevant records of any CN S treatment must be available to allow for classification 
of target and non -target lesions  
11. Patient is a ble to eat a high -fat meal See Section  6.1.1. 
12. Patient is a ble to fast for a minimum of 10 hours before start of visit and for an additional 
4 hours after study visit.  See Section  6.1.1. 
7.2. Patient Exclusion Criteria  
7.2.1. Patient Exclusion Criteria (Stages 1 and 2)  
PK Phase:  
Patients will not be eligible for study entry if any of the following criteria are met:  
1. Patient has a known hypersensitivity to the components of niraparib or excipients (please 
see Appendix  B).  
2. Patient has a known diagnosis of immunodeficiency (Note: Patients with splenectomy are 
allowed).  
3. Patient has symptomatic uncontrolled brain or leptomeningeal metastases. To be 
considered â€œcontrolled,â€ the patient must have undergone treatment (e.g., radia tion or 
chemotherapy) at least 1  month prior to study entry. The patient must not have any new 
or progressive signs or symptoms related to the central nervous system disease and must 
be taking â‰¤10  mg of prednisone or equivalent per day or no steroids.  
4. Patient underwent major surgery within 3  weeks of starting the study or patient has not 
recovered from any effects of any major surgery.  
5. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder; 
nonmalignant systemic disease; or active, uncontrolled infection. Examples include, but 
are not limited to, uncontrolled ventricular arrhythmia, recent (within 90  days) 
myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord 
compression, superior vena cava syndr ome, uncontrolled hypertens ion, active 
uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that proh ibits 
obtaining informed consent.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 63 of 103 
  6. Female patient is pregnant or is expecting to conceive children while receiving study 
drug or for up  to 180 days after the last dose of study drug. Male patient is expecting to 
donate sperm or father children while receiving study drug or for up to 90 days after the 
last dose of study drug.  
a. Female patient is breastfeeding or is expecting to breastfeed wi thin 30 days of 
receiving final dose of study drug (women should not breastfeed or store breastmilk 
for use, during treatment and for 30 days after receiving the final dose of study 
treatment)  
7. Patient has a known history of myelodysplastic syndrome (MDS) or acute myeloid 
leukemia (AML). 
8. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
9. Patient is unable to refrain from any intake of grapefruit or grapefruit juice within 7 days 
of the first administration of niraparib until 2 days post-dose (Does not apply  for 
Extension Phase) . 
10. Patient is currently taking any of the following P -glycoprotein (P -gp) inhibitors: 
amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, 
cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconaz ole, 
ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, ticagrelor, and 
verapamil, unless the dose and regimen has been stable for at least 14 days prior to first 
dose and will not change during PK periods 1 and 2  (Does not apply for Extension 
Phase). 
11. Patient taking proton pump inhibitors, antacids, or histamine 2 blockers unless the dose 
and regimen is stable for at least 14 days prior to first dose and will not change during PK 
periods 1 and 2.  Patients must hold these therapies sta rting within 8  hours prior to study 
drug administration until 9 hours after study drug administration (Does not apply for 
Extension Phase).  
12. Patient has gastric, gastro -esophageal or esophageal cancer; patient is unable to swallow 
orally administered medica tion; or patient has gastrointestinal disorders or significant 
gastrointestinal resection likely to interfere with the absorption of niraparib.  
13. Patient has known active hepatic disease (known hepatic cirrhosis, hepatitis B surface 
antigen-positive status, or suspected active hepatitis C infection).  
14. Patient has a past or current history of chronic alcohol use (3 or more drinks per day for 
the 30 days prior to the Screening Visit) or dependence or is unable to abstain from 
alcohol for the duration of the stud y. 
15. Patient has had a prior cytotoxic therapy or anticancer monoclonal antibodies (mAbs) 
within 14 days prior to start of PK Phase. There is no required washout for palliative 
radiation.   For targeted small anti-cancer molecules (e.g., tyrosine kinase inhib itors), the 
required washout is 5 half-lives of the start of PK Phase. Certain hormonal agents are 
allowed and are listed in Appendix  D. For hormonal agents not listed in Appendix  D, the 
Site must consult with the Sponsor regarding allowing patient on study . For patient taking 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 64 of 103 
  hormonal agents, dose and regimen of hormonal agents should have been stable for at 
least 14 days prior to first dose and is not expected to change during PK periods 1 and 2.  
16. Patient has significant pleural effusion or ascites that is expected to require drainag e 
during the PK Phase (Does not apply for Extension Phase) . 
7.2.2. Patient Exclusion Criteria (Stage 3  only) 
PK Phase:  
Patients will not be eligible for study entry if any of the following criteria are met:  
1. Patient has a known hypersensitivity to the components  of niraparib or excipients (see 
Appendix  B).  
2. Patient has a known diagnosis of immunodeficiency (Note: Patients with splenectomy are 
allowed)  
3. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
4. Patient underwent major surgery within 3  weeks of starting the study or patient has not 
recovered from any effects of any major surgery.  
5. Patient is considered a poor medical risk due to a serious, uncontrolled  medical disorder; 
nonmalignant systemic disease; or active, uncontrolled infection. Examples include, but 
are not limited to, uncontrolled ventricular arrhythmia, recent (within 90  days) 
myocardial infarction, uncontrolled major seizure disorder, unstable  spinal cord 
compression, superior vena cava syndrome, uncontrolled hypertension, active 
uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits 
obtaining informed consent.  
6. Female patient is pregnant or is expecting to conc eive children while receiving study 
drug or for up to 180 days after the last dose of study drug. Male patient is expecting to 
donate sperm or father children while receiving study drug or for up to 90 days after the 
last dose of study drug. 
a. Female patient  is breastfeeding or is expecting to breastfeed within 30 days of 
receiving final dose of study drug (females should not breastfeed or store breastmilk 
for use, during treatment and for 30 days after receiving the final dose of study drug).  
7. Patient has a k nown history of MDS or AML.  
8. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
9. Patient is unable to refrain from any intake of grapefruit or grapefruit juice within 7 days 
of the first administration of niraparib until 2 days postdose (Does not apply for 
participation in Extension Phase of this study).  
10. Patient is currently taking any of the following P -glycoprotein inhibitors: amiodarone, 
azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, 
dronedarone, erythromycin, fe lodipine, itraconazole, ketoconazole, lopinavir and 
ritonavir, quercetin, quinidine, ranolazine, ticagrelor, and verapamil, unless the dose and 
regimen has been stable for at least 14 days prior to first dose and will not change during 
PK periods 1 and 2 (Does not apply for participation in Extension Phase of this study).  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 65 of 103 
   
11. Patient is taking a proton pump inhibitor, antacids, or H2 blocker within 48 hours of dose 
(Does not apply for participation in Extension Phase of this study).  
12. Patient has gastric, gastro esophageal or esophageal cancer; patient is unable to swallow 
orally administered medication; patient has gastrointestinal disorders or significant 
gastrointestinal resection likely to interfere with the absorption of niraparib.  
13. Patient has known active he patic disease (known hepatic cirrhosis, hepatitis B surface 
antigen positive status, or suspected active hepatitis C infection).  
14. Patient has a past or current history of chronic alcohol use (3  or more drinks per day for 
the 30 days prior to the Screening V isit) or dependence or is unable to abstain from 
alcohol for the duration of the study.  
15. <THIS EXCLUSION HAS BEEN INTENTIONALLY LEFT BLANK.>  
16. Patient has significant pleural effusion or ascites that is expected to require drainage 
during the PK Phase (Does not apply for participation in Extension Phase of this study) . 
17. Patient is currently taking a lipase inhibitor or cholesterol absorption inhibitor, such as 
orlistat or ezetimibe, respectively .  (Does not apply for participation in Extension Phase 
of this stu dy). 
7.3. Extension Study Patient Inclusion Criteria  (Stage 1 and 2)  
 
To be considered eligible to participate in the Extension study, all of the following requirements 
must be met:  
1. Patient has an ECOG performance status of 0 to 2.  
2. Patient has adequate organ function as defined below ; these criteria must be confirmed 
within 72 hours of dose 1 in Extension  (Note: CBC sho uld be obtained without 
transfusion or receipt of CSFs , erythropoietin stimulating agents or platelet stimulating 
factors within 2 weeks before  first dose) : 
a. Absolute neutrophil count â‰¥ 1,500/ÂµL  
b. Platelets â‰¥ 100,000/ÂµL  
c. Hemoglobin â‰¥ 9  g/dL (5.6 mM)  
d. Serum creatinine â‰¤1.5Ã— the ULN or a calculated creatinine clearance â‰¥ 60  mL/min 
using the Cockcroft -Gault equation or 24 -hour urine creatinine clearance  
e. Total bilirubin â‰¤1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤1.5Ã— ULN of the direct bilirubin.  
f. AST and ALT â‰¤2.5Ã— ULN unless liver metastases are present, in which case, they 
must be â‰¤5Ã— ULN 
Note:  If laboratory values at the beginning of Extension Phase are outside of the range 
specified above, the patient may continue to participate in the study only upon Sponsor 
approval and with consideration for an appropriately reduced dose.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 66 of 103 
  3. Female patient meets the following criteria:  
a. Patient (of childbearing potential) is not breastfeeding, has a negative serum 
pregnancy test within 72  hours prior to taking study drug and agrees to abstain from 
activities that could result in pregnancy from Scr eening through 180  days after the 
last dose of study drug, or is of non -childbearing potential. Note: A urine pregnancy 
test may be performed if the serum pregnancy test is not available before dosing.  
b. Female patient of non -childbearing potential (other th an medical reasons) is defined 
by the following:  
i. â‰¥45 years of age and has not had menses for >1  year). 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and a 
follicle-stimulating hormone value in the postmenopausal range upon 
Screening eval uation. 
iii. Had undergone a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oophorectomy, or tubal ligation must be 
confirmed in the medical records; otherwise the patient must be willing to use 
highly effective contraception (see Appendix  C) throughout the study, starting 
from the Screening visit through 180  days after the last dose of study drug.  
Information must be captured appropriately within the siteâ€™s source 
documents.  
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
4. Male patient agrees to use an adequate method of contraception and not donate sperm 
starting with the first dose of study drug through 90  days after the last dose of study drug. 
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
7.3.1. Extension Study Patient Inclusion Criteria (Stage 3  only) 
 
To be considered eligible to participate in the Extension Phase, all of the following requirements 
must be met:  
1. Patient has an ECOG performance status of 0 to 2.  
2. Patient has adequate organ function as defined below; these criteria must be confirmed 
within 72 hours of dose 1 in the Extension Phase (should be obtained without transfusion 
or receipt of colony -stimulating factors in the 1 week before obtaining sample ): 
a. Absolute neutrophil count â‰¥1,000/ÂµL  
b. Platelets â‰¥100,000/ÂµL  
c. Hemoglobin â‰¥9  g/dL (5.6 mM) 
d. Serum creatinine â‰¤1.5Ã— ULN or a calculated creatinine clearance of â‰¥30 mL/min 
using the Cockcroft -Gault equation.  
e. Total bilirubin â‰¤ 1.5Ã— ULN except in patients with Gilbertâ€™s syndrome. Patients with 
Gilbertâ€™s syndrome may enroll if direct bilirubin â‰¤ 1.5Ã— ULN of the direct bilirubin.  
f. AST and ALT â‰¤ 2.5Ã— ULN unless liver metastases are present, in which case, they 
must be â‰¤ 5Ã— ULN 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 67 of 103 
  Note:  If laboratory values at the beginning of Extension Phase are outside of the range 
specified above, the patient may continue to participate in the study only upon Sponsor 
approval and with consideration for an appropriately reduced dose.  
3. Female patient meets the following criteria:  
a. Patient (of childbearing potential) is not breastfeeding, has a negative serum 
pregnancy test within  72 hours prior to taking study drug, and agrees to abstain from 
activities that could result in pregnancy from Screening through 180  days after the 
last dose of study drug, or is of nonchildbearing potential. Note: A urine pregnancy 
test may be performed if the serum pregnancy test is not available before dosing.  
b. Female patient of nonchildbearing potential (other than medical reasons) is defined 
by the following:  
i. â‰¥45 years of age and has not had menses for >1  year). 
ii. Amenorrheic for <2  years without a hysterectomy and oophorectomy and 
a follicle-stimulating hormone value in the postmenopausal range upon 
Screening evaluation.  
iii. Had a hysterectomy, bilateral oophorectomy, or tubal ligation. 
Documented hysterectomy, oophorectomy or tubal ligation must be 
confirmed in the medical records, otherwise the patient must be willing to 
use highly effective contraception (see Appendix  C) throughout the study, 
starting with the Screening Visit through 180  days after the last dose of 
study drug. Information must be captured appropriately within the siteâ€™s 
source documents.  
 
Note: Abstinence is acceptable if this is the established and preferred contraception 
method for the patient.  
4. Male patient agrees to use an adequate method of contraception and not donate sperm 
starting with the first dose of study drug through 90  days after the last dose of study drug.  
Note: Abstinence is acceptable if this is the established an d preferred contraception method 
for the patient.  
7.4. Patient Withdrawal Criteria  
7.4.1. Discontinuation from Pharmacokinetic Phase  
Patients may be discontinued  from the PK Phase of the study at any time. Specific reasons for 
discontinuing include the following:  
â€¢ Unacceptable toxicity  
â€¢ Vomiting within 10 hours of dose administration  
â€¢ Loss to follow up  
â€¢ Disease progression per Investigatorâ€™s discretion  
â€¢ It is in the best interest of the patient as judged by the Investigator and/or  Sponsor 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 68 of 103 
  â€¢ Severe noncompliance with the  protocol as judged by the Investigator and/or  Sponsor  
or other reasons that would make the collected PK data non -evaluable, to include but 
not limited  to: 
âˆ’ Dosing errors  
âˆ’ Patient did not fast for a minimum of 10 hours before and for 4 hours after either 
dosing period  
âˆ’ Significant changes to the patient â€™s medical status that would potentially affect 
the PK profile as determined by the Sponsor in consultation with the Investigator 
prior to data analysis.  
â€¢ Withdrawal of consent  
âˆ’ Note: All reasonable efforts sho uld be made to encourage patients to remain on 
study even if they withdraw from treatment.  
â€¢ Patient becomes  pregnant 
â€¢ Sponsor decision to terminate  study 
â€¢ Death 
Those patients deemed to derive clinical benefit from niraparib treatment at the time of final 
analysis will have the option to continue treatment with niraparib through an alternative study, if 
available, and at the discretion of the Investigator and Sponsor.  
Patients who discontinued from the PK Phase of the study and discontinue niraparib treatme nt 
prior to the Extension Phase will continue to receive safety follow -up assessments 
(Section 6.6.1) as part of the study unless they are discontin ued from the study.  
7.4.2. Discontinuation from Treatment During Extension Phase  
Patients may be discontinued from the study drug at any time. Specific reasons for discontinuing 
include the following:  
â€¢ Unacceptable toxicity that cannot be managed by dose modificat ions 
â€¢ Loss to follow up  
â€¢ Disease progression per Investigatorâ€™s discretion  
â€¢ It is in the best interest of the patient as judged by the Investigator and/or  Sponsor 
â€¢ Severe noncompliance with the protocol as judged by the Investigator and/or  Sponsor  
â€¢ Withdrawal  of consent  
âˆ’ Note: All reasonable efforts should be made to encourage patients to remain on 
study even if they withdraw from treatment.  
â€¢ Patient becomes  pregnant 
â€¢ Sponsor decision to terminate  study 
â€¢ Death 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 69 of 103 
  Details of any required niraparib dose modifications, including interruptions, dose reductions, 
and permanent discontinuations, related to toxicity, are provided in Section  6.4. 
Patients who discontinue  from treatment will continue to receive follow -up assessments 
(Section 6.6.1) as part of the study unless they are discontinued from the study.  
7.4.3. Discontinuation from the Study  
Patients may be discontinued from the study for any of the following reasons:  
â€¢ Completion of t he required safety follow up  
â€¢ Withdrawal of consent by the patient, who is at any time free to discontinue their 
participation in the study  
â€¢ Death 
â€¢ Loss to follow -up 
â€¢ Sponsor decision to terminate study  
If a patient is lost to follow -up, attempts should be mad e to contact the patient to determine the 
reason for discontinuation. For patients who are lost to follow -up, at least 3 documented 
attempts, including one via certified mail, should be made to contact the patient before 
considering the patient lost to fol low-up. 
7.4.4. Replacement of Patients  
Patients will not be replaced during Stage 1 . During Stage s 2 and 3, the non-evaluability rate 
arising during the study conduct will be continuously monitored by the Sponsor  and the total 
number of enrolled patients  may be adjusted accordingly.   
7.5. Restrictions During Study  
Restrictions during the study include the following:  
1. No other anticancer therapy is permitted during the course of study drug for any patient. 
If the patient discontinues study drug, this restriction no longe r applies. Palliative 
radiotherapy is allowed for preexisting small areas of painful metastases that cannot be 
managed with local or systemic analgesics as long as no evidence of disease progression 
is present. Hormonal therapy is allowed provided an agent  listed in Appendix  D is used.  
For hormonal agents not listed in Appendix D, the Site must consult with the Sponsor 
regarding allowing patient on study. For patient taking hormonal agents, dose and 
regimen of hormonal agents should have been stable for at least 14 days prior to first do se 
and is not expected to change during PK periods 1 and 2.   
2. An increased risk of infection with the administration of live virus and bacterial vaccines 
has been observed with conventional chemotherapy drugs. Effects with niraparib are 
unknown, so live vi rus and bacterial vaccines should not be administered to patients in 
the study.  
3. P-glycoprotein inhibitors: amiodarone, azithromycin, captopril, carvedilol, 
clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 70 of 103 
  felodipine, itracona zole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, 
ranolazine, ticagrelor, and verapamil are not permitted per protocol unless the dose and 
regimen has been stable for at least 14 days prior to first dose and will not change during 
PK periods 1 and 2 ( does not apply for Extension Phase).  
4. Patient taking proton pump inhibitors, antacids, or H2 blocker within 48  of dose (Does 
not apply for Extension Phase).  
5. Patients who are blood donors should not donate blood during the study and for 90  days 
after the last dose of study drug.  
6. Patients must be able to fast for  10 hours before and 4 hours after dosing in the 2  PK 
dosing periods . 
7. Patients must avoid alcohol intake during the PK portion of the study.   
8. Grapefruit and grapefruit juice is not allowed 7 days before or 2 days after dosing in the 
PK portion of the study (does not apply for Extension Phase).  
9. Administration of blood or platelet transfusion should be avoided during the PK 
Phase. Should administr ation of blood products or other colloid solutions become 
necessary during the PK Phase the site must contact the Sponsor to discuss timing of 
blood (or other product) administration in relation to the timing of PK sampling.  
10. Patient is currently taking a l ipase inhibitor or cholesterol absorption inhibitor, such as 
orlistat or e zetimibe, respectively .  (Does not apply for participation in Extension Phase 
of this study) . 
7.5.1. Lifestyle Considerations  
Cases of photosensitivity have been reported for patients on n iraparib treatment. Participants 
must be informed on measures to decrease exposure to ultraviolet light, such as minimizing time 
in direct sunlight unless wearing hats and long -sleeves and application of sun protection creams.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 71 of 103 
  8. TREATMENT OF PATIENT S 
8.1. Description of Study Drug  
Table 9: Investigational Product  
 Investigational Product  
 Stage 1 and Stage 2  Stage 3 
Product Name:  Niraparib  Niraparib  Niraparib  
Dosage Form:  Capsule Tablet Tablet 
Unit Dose  100 mg per capsule  300 mg per tablet  
200 mg per tablet  
100 mg per tablet  
[200 mg and 100 mg 
tablets for use in 
Extension Phase]  300 mg per tablet for 
both PK periods  
100 mg per tablet  for 
Extension Phase  
 
Route of 
Administration  Oral Oral Oral 
Physical  
Description  Capsules may be 
packaged in high -density 
polyethylene bottles with 
child-resistant closures or 
in blister cards  Tablets will be packaged 
in high-density 
polyethylene bottles  Tablets will be 
packaged in high 
density polyethylene 
bottles with child 
resistant closures 
8.2. Concomitant Medications  
Any medication the patient takes during the study other than the study drugs, including herbal 
and other nontraditional remedies, is considered a concomitant medication. All concomitant 
medications must be recorded in the  eCRF. The following information must be recorded in the 
eCRF for each concomitant medication: generic name, route of administration, start date, stop 
date, dosage, and indication. Any changes in the dosage or regimen of a concomitant medication 
must be al so recorded in the eCRF.  
At Screening Visit, patients will be asked what medications they have taken during the last 
30 days. At each subsequent study visit, patients will be asked what concomitant medications 
they are currently taking or have taken since the previous visit.  
8.2.1. Permitted Concomitant Medications  
Denosumab and bisphosphonates are allowed while on study.  
Prophylactic antiemetics are allowed while on study. Should they be used, the same antiemetic 
prophylaxis MUST be administered in conjunction wi th Days 1 and 15 niraparib dosing in the 
PK Phase and within the same time interval from niraparib administration.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 72 of 103 
  8.2.2. Concomitant Medications Taken with Caution 
Niraparib weakly induces cytochrome P450 (CYP)1A2  in vitro and is an insensitive substrate for 
P-glycoprotein (P -gp); therefore, investigators should be advised to use caution with drugs that 
are the sensitive substrates for CYP1A2 with a narrow therapeutic range, i.e. theophylline and 
tizanidine.  
8.3. Contraception  
Niraparib is known to have properties that require the female patient of childbearing potential to 
use a highly effective form of contraception. For details on contracept ive guidelines , please refer 
to Appendix  C. 
Male patients must use an adequate method of contraception and not donate sperm starting with 
the first dose of study drug through 90  days after the last dose of study drug ( Table 10). For a 
non-pregnant woman of childbearing potential partner, contraception recommendations should 
also be considered. Abstinence is acceptable if this is the established and preferred contra ception 
method for the patient.  
Patients should be informed that taking the study drug may involve unknown risks to the fetus if 
pregnancy were to occur during the study. In order to participate in the study, both male and 
female patients must adhere to th e contraception requirement (described above) for the duration 
of the study and through 90 and 180  days, respectively, after the last study drug. This applies to 
female study patients and partners of male study patients. If there is any question that a pat ient 
will not reliably comply with the requirements for contraception, that patient should not be 
entered into the study.  
Table 10: Timing of Contraception and Sperm Donation  
Parameter  Timeframe  
Contraception use, fe male patients  Starting with the Screening Visit through 180  days 
after the last dose of study drug  
Contraception use, male patients  Starting with the first dose of study drug through 
90 days after the last dose of study drug  
Sperm donation  Starting with the first dose of study drug through 
90 days after the last dose of study drug  
8.4. Treatment Compliance  
Compliance with inclusion and exclusion criteria will be assessed as outlined in Section  7.1 
and Section 7.2, respectively.  
Niraparib will be administered by site personnel at study sites as detailed in Section  9.5. 
Study drug accountability will be monitored as detailed in  Section 9.6.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 73 of 103 
  9. STUDY DRUG MATERIALS  AND MANAGEMENT  
9.1. Study Drug  
Niraparib is a PO available, potent, highly selective PARP1 and PARP2 inhibitor. The excipients 
for niraparib are lactose monohydrate and magn esium stearate. Niraparib will be supplied as 
100 mg capsules and 300, 200, and 100 mg tablets.   
9.2. Study Drug Packaging and Labeling  
Niraparib 100  mg capsules may be packed in high -density polyethylene bottles with 
child-resistant closures or in blister card s.  
Niraparib 100 mg, 200  mg and 300  mg tablets will be provided in high -density polyethylene 
bottles. Additional information on packaging can be found in the Pharmacy Manual.  
The label text of the study drug will comply with Good Manufacturing Practice a nd the national 
legislation to meet the requirements of the United States. The study drug will be open -label and 
nonpatient -specific. 
9.3. Study Drug Storage  
All study drug supplies must be stored in accordance with the Pharmacy Manual instructions and 
package labeling. Until dispensed or administered to the patients, the study drug will be stored in 
a securely locked area, accessible to authorized personnel only.  
The pharmacist will dispense study drug for each patient according to the protocol and Pharmacy 
Manual, if applicable.  
9.4. Study Drug Administration  
The Pharmacy Manual contains descriptions of the packaging of study drug and instructions for 
administration of study drug.  
9.5. Administration  
Niraparib as 100 mg capsules and 300, 200, and 100  mg tablets will be supplied (Table 9). In the 
Stage 1 and 2 PK Phase s, patients will receive a single dose (300  mg) of the study drug 
(tablet [1Ã— 300 mg] or capsule [3 Ã— 100 mg]) in a fasted state (see Section  6.1.1) followed by a 7 -
day (+1 day) for Stage 1 of the study and a 14 -day (+/- 4 days) Washout/PK period for Stage 2 of 
the study, followed by a dose of the alternate formulation (patients receiving tablets in the first 
treatment period will receive the capsule in the second treatment period and vice versa).  
For Stage 3 during period 1, patients will receive a single 300 mg niraparib tablet either 
following a 10 hour fast or directly following consumption of a high -fat meal followed by a 14 -
day (+4 days) PK sampling and washout period. In period 2, patients will be crossed over to 
receive a single 300 mg niraparib tablet in a fasted state  or with a high -fat meal (see 
Section 6.1.1), followed by a 7 -day PK sampling period. Patients re ceiving the tablet in a fasted 
state in the first treatment period will receive the tablet with a high -fat meal in the second 
treatment period and vice versa.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 74 of 103 
  In the Extension Phase, the starting dose of niraparib will be based on the patientâ€™s baseline 
actual body weight or platelet count. Patients with a baseline actual body weight of â‰¥77 kg and 
screening platelet count of â‰¥150,000/ÂµL will take one 300 mg strength tablet or 3 x 100 mg 
tablets/capsules at each dose administration. Patients with a baseline  actual body weight of <77 
kg or screening platelet count of <150,000/ÂµL will take one 200 mg strength tablet or 2 x 100 mg 
tablets/capsules at each dose administration. For patients whose initial starting dose is 200 mg 
QD, escalation to 300 mg once daily is permitted if no treatment interruption or discontinuation 
was required during the first 2 cycles of Extension Phase therapy and with Sponsorâ€™s approval. 
Additional dose modifications will not be based upon changes in the patientâ€™s actual body weight 
during study participation. If laboratory values at the beginning of Extension Phase are outside of 
the range specified in the inclusi on criteria, the patient may continue to participate in the study 
only upon Sponsor approval and with consideration for an appropriately reduced dose. Should a 
patient start the Extension Phase at 100 mg, consideration may be given to escalate to 200 mg 
after 2 cycles  of therapy if no treatment interruption or discontinuation was required during the 
first 2 cycles of Extension Phase therapy and after approval from the Sponsor.    
9.6. Study Drug Accountability  
Accountability of the investigational study drugs is under the responsibility of the Investigator 
and can be delegated to an appropriately qualified person.  
Study drug accountability should be maintained by each site based on investigational study drug 
dispensed versus returned to the clinic at each visit an d the number days since last visit.  
Details of maintaining drug accountability, including information on the accountability log, will 
be provided in the Pharmacy Manual.  
All dispensation and accountability records will be available for Sponsor review. The study 
monitor will assume the responsibility to reconcile the study drug accountability log. The 
pharmacist will dispense study drug for each patient according to the protocol and Pharmacy 
Manual, if applicable.  
9.7. Study Drug Handling and Disposal  
At the end of study, when all patients have stopped protocol treatment, complete drug 
reconciliation per batch should be available at the site for verification in order to allow drug 
destruction or return procedure. After receiving Sponsor approval in writing, the in vestigational 
site is responsible for destruction of study drug according to local regulations. If a site does not 
have the capability for onsite destruction, the Sponsor will provide a return for destruction 
service to a third party. Both the unused and e xpired study drug must be destroyed, upon 
authorization of the Sponsor, according to local regulations and procedures, and a copy of the 
destruction form must be filed in the study binder.  
The medication provided for this study is to be used only as indica ted in this protocol and only 
for the patients entered in this study.  
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO  3DJHRI
 3+$50$&2.,1(7,&$66( 660(176 
7KHSULPDU\3.SDUDPHWHUVIRUDQDO\VLVZLOOLQFOXGH& PD[$8&WDQG$8& Â’RIQLUDSDULE 
6WDJHDQGDQG$8& WDQG$8& Â’LQ6WDJH3.SDUDPHWHUVWRE HDVVHVVHGIRUQLUDSDULE
DQG6WDJHRQO\ LQFOXGHWKHIROORZLQJ 
x$8&W
x$8&Â’
x&PD[
xWPD[
xW
x&/)QLUDSDULERQO\ 
x9])QLUDSDULERQO\ 
xWODJ6WDJHRQO\ 
SDUDPHWHUVZLOORQO\EHGHWHU PLQHGLQ6WDJHRIWKHVWXG\ $GGLWLRQDO3.SDUDPHWHUVPD\
EHHVWLPDWHGLIGHHPHGD SSURSULDWH7KH3.SDUDPHWHUVZLOOEHF DOFXODWHGIURPWKHSODVPD
FRQFHQWUDWLRQ WLPHSURILOHV7KHQRQFRPSDUWPHQWDODQD O\VLVZLOOEHSHUIRUPHG XVLQJ3KRHQL[
:LQ1RQOLQYHUVLRQRUKLJKHU3RSXODWL RQ3.DQDO\VLVPD\EH SHUIRUPHGRQ WKH3.3KDVHRI
WKHVWXG\GDWDDQGZLOOEHUHSRUWHGVHSDUDWHO\ 
)RU6WDJHL QDGGLWLRQWRWKH3.SDUDPHWHUVDERYHW ODJWKHWLPHIURPDGPLQLVWUDWLRQRIWKHGRVH
WRWKHILUVWTXDQWLILDEOHFRQFHQWUD WLRQZLOOEHGHWHUPLQHGDQ GWPD[ZLOOEHFRPSDUHGEHWZHHQWKH
IHGDQGIDVWHGVWDWHV7KHUHODWLYH ELRDYDLODELOLW\ RIWKHPJQLUDSDULEWDEOHWDGPLQLVWHUHG
ZLWKDKLJK IDWPHDOUHODWLYHWRIDVWHGGRVLQJ ZLOOEHEDVHGRQWKHUDWLRR IJHRPHWULFOHDVW VTXDUHV
PHDQVRI$8& W$8&Â’DQG&PD[
%ORRG6DPSOH&ROOHFWLRQ 
%ORRGDSSUR[LPDWHO\ P/SHUVDPSOHZLOOEHFROO HFWHGGXULQJWKHVWXG\IRU3.DVVHVV PHQWVDW
WKHIROORZLQJWLPHSRLQWVUHODWLYHWRQLUDSDULEGRVLQJ 6WDJHSUHGRVH PLQXWHVSULRUWR
GRVLQJDQGDW  DQG KRXUVSRVWGRVH 
)RU6WDJHDQG6WDJH 3.VDPSOHVZLOOEH GUDZQDWSUHGRVH PLQXWHVSULRUWRGRVLQJDQGDW
 DQG KRXUVSRVWGRVH7KHIROORZLQJ
H[FXUVLRQV DUHSHUPLWWHGUHODWLYHWRWKHSURWRFRO VSHFLILHG3.VDPSOLQJWLPHV'HYLDWLRQVRXWVLGH
RIWKHVHWLPHZLQGRZVPXVWEHGRFXPHQWHG 
x3UHGRVHÂ”PLQXWHV 
xWRKRXUVÂ“PLQXWHV 
xWRKRXUVÂ“PLQXWHV 
xKRXUVÂ“ PLQXWHV
xKRXUVÂ“PLQXWHV 
xKRXUVÂ“PLQXWHV CCI
CCI
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO  3DJHRI
 xKRXUVÂ“ PLQXWHV
xDQGKRXUVÂ“PLQXWHV
xKRXUV KRXUV
7KHDSSUR[LPDWHYROXPHRIEORRGVDPSOH VFROOHFWHGIRU3.DQDO\V LVLQWKH3.3KDVHZRXOGEH
DSSUR[LPDWHO\ P/%ORRGVDPSOHFROOHF WLRQSURFHVVLQJDQGVKLSSLQJ GHWDLOVZLOOEH
RXWOLQHGLQDVHSDUDWHODERUDWRU\PDQXDO,QEULHIEORRGZLOO EHFROOHFWHGLQWRSRWDVVLXPHWK\OHQH
GLDPLQHWHWUDDFHWLFDFLG. ('7$WXEHVSURFHVVHGDQGSODVPDDQDO\ ]HGE\DYDOLGDWHGPHWKR G
RIOLTXLGFKURPDWRJUDSK\FRXSOHGWRWDQGHPPDV VVSHFWURPHWU\GHWHFWLRQ/& 0606PHWKRG
IRUGHWHUPLQDWLRQRIDQD O\WHFRQFHQWUDWLRQV 
6DPSOH$QDO\VLV 
$QDO\VLVRIEORRGVDPSOHVLQFOXGHVWKHIROORZLQJ 
x%ORRG%ORRGVDPSOHVZLOOEHDQDO\]H GIRUWKHSODVPDFRQFHQWUDWLRQRI QLUDSDULE
6WDJHDQGDQG6WDJHRQO\XVLQJ/& 0606 CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 77 of 103 
  11. ASSESSMENT OF SAFETY  
11.1. Safety Parameters  
Safety parameters evaluated during the conduct of the study will include treatment -emergent 
adverse events (TEAEs), discontinuations due to AEs, physical examinations, vital signs, clinical 
laboratory results, and use of concomitant medications.  All AEs will be coded using the current 
version of the Medical Dictionary for Regulatory Activities (MedDR A) coding system.  
11.1.1. Demographics and Baseline Characteristics  
Demographics and baseline  characteristics consist of those variables that are assessed at 
screening/baseline.  
11.1.2. Patient Eligibility  
Compliance with inclusion and exclusion criteria will be assessed as outlined in Section  7.1 and 
Section 7.2. 
11.1.3. Patient Demography  
Patient demography consists of age at screening, race, ethnicit y, and sex.  
11.1.4. Disease History  
The following will be documented for disease history, if available:  
â€¢ Primary Cancer diagnosis  
â€¢ Date of first diagnosis  
â€¢ Stage of disease at enrollment (local versus metastatic)  
â€¢ Information on prior neoadjuvant/adjuvant treatment, i f applicable:  
âˆ’ Agents used in treatment  
â€¢ Information on previous anticancer treatments:  
âˆ’ Agents in all subsequent treatments  
â€¢ Best response for each line of therapy  
11.1.5. Medical and Surgical History  
Major medical and surgical history (including medication history), including history of 
thrombocytopenia, neutropenia, leukopenia, or anemia will be collected, if available. Details of 
any prior malignancy will be collected if available. Medical and surgical history will be obtained 
by interviewing the patient o r by reviewing the patientâ€™s medical records.  
11.1.6. Vital Signs  
Vital signs ( blood pressure [ BP], pulse, heart rate, and temperature) will be assessed according to 
the schedule of events (Section  6.6.1).  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 78 of 103 
  Body weight and height will be assessed during screening according to the schedule of events 
(Section 6.6.1). 
11.1.7. Physical Examination  
A complete physical examination and symptom -directed physical examination will be performed 
in accordance with the schedule of events.  
11.1.8. Concomitant Medications and Procedures  
Refer to Section 8.2 for a description of prior and concomitant medications. For prior 
medications, patients will be asked during the Screening Visit for the PK Phase and the 
Extension Phase what medications they have taken during the last 30  days. All concomitant 
medications wil l be recorded from the time the patient signs the ICF through completion of the 
study. Medications will be coded according to the most current version of the World Health 
Organization Drug Dictionary.  
11.1.9. Electrocardiogram  
All patients will undergo 12 -lead ECG s in accordance with the schedule of events 
(Section 6.6.1). ECGs should be performed prior to blood draws. Patients will be rested for 
approximatel y 2 minutes before ECGs are recorded.  
11.1.10. Laboratory Assessments  
The hematology, chemistry, urinalysis, and pregnancy screening will occur in accordance with 
the schedule of events (Section  6.6.1 ). These tests will be performed by the local laboratory at 
the clinical site.  
11.1.10.1.  Hematology  
Hematology will be measured in accordance with the Schedule of Events (Section  6.6.1). The 
following values will be obtained/analyzed:  
â€¢ CBC: 
âˆ’ Hemoglobin  
âˆ’ Platelet count  
âˆ’ Mean corpuscular volume  
âˆ’ White blood cell count  
âˆ’ Differential white blood cell  count 
11.1.10.2.  Chemistry  
Chemistry wil l be assessed in accordance with the Schedule of Events (Section  6.6.1 ). The 
following values will be obtained/analyzed:  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 79 of 103 
  â€¢ Sodium â€¢ Total bilirubin  
â€¢ Potassium  â€¢ Alkaline phosphatase  
â€¢ Chloride â€¢ Aspartate aminotransferase  
â€¢ Creatinine  â€¢ Alanine aminotransferase  
â€¢ Urea or blood urea nitrogen  
â€¢ Glucose  â€¢ Total protein  
â€¢ Albumin 
â€¢ Calcium  â€¢ Amylase 
â€¢ Phosphate  
â€¢ Magnesium  â€¢ Lactate dehydrogenase  
11.1.10.3.  Urinalysis  
Urinalysis will be assessed in accordance with the Schedule of Events (Section  6.6.1). The 
following values will be obtained/analyzed:  
â€¢ Specific gravity  â€¢ Protein 
â€¢ Leukocyte esterase  â€¢ Glucose 
â€¢ Nitrite â€¢ Ketones 
â€¢ Blood â€¢ Bilirubin 
11.1.10.4.  Virus Serology  
Not applicable.  
11.1.10.5.  Drug Screen  
Not applicable.  
11.1.10.6.  Pregnancy Screen  
A negative serum or urine pregnancy test is required within 72 hours prior to first dose of study 
drug for PK period 1 and first dose of Extension Phase for females of childbearing potential. 
Urine pregnancy testing will be performed in accordance with the schedule of events 
(Section 6.6.1).  
11.1.10.7.  Eastern Cooperative Oncology Group Performance Status  
Performance status will be assessed using the ECOG scale (see  Appendix  A) in accordance with 
the schedule of events (Section  6.6.1). The same observer should assess performance status each 
time. 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 80 of 103 
  11.2. Adverse Events and Special Situations  
11.2.1. Definitions  
11.2.1.1. Adverse Event (AE)  
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
medicinal product and which does not necessarily have to have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically 
significant abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of study treatment, whether or not considered related to the product.   
AEs may include the onset of new illness and the exacerbation of pre -existing medical 
conditions. An AE can include an undesirable medical condition occurring at any time after the 
time of randomization and/or treatment assignment, including baseline or washout periods, even 
if no study treatment has been administered ( see Section 11.2.3 for information about AE 
collecting and reporting.)  
11.2.1.2.  Serious Ad verse Event (SAE)  
Any untoward medical occurrence that, at any dose;  
â€¢ Results in death;  
â€¢ Is life threatening (i.e., an event in which the patient was at risk of death at the time of 
the event; it does not refer to an event that hypothetically might have cau sed death if 
it were more severe);  
â€¢ Requires inpatient hospitalization* or prolongation of existing hospitalization;  
â€¢ Results in persistent or significant disability/incapacity;  
â€¢ Is a congenital anomaly/birth defect; or  
â€¢ Is an important medical event**  
*Exception: Preplanned (at time of informed consent) hospitalization for elective procedures, for 
protocol compliance or social reasons, or for observation will not be considered criteria for an 
SAE. The reason for the planned hospitalization should be cap tured in medical history section in 
the eCRF. Complications experienced during these hospitalizations must be reported as AEs (or 
SAEs, if hospitalization is prolonged due to the AE).  
**Medical and scientific judgment should be exercised in determining wh ether situations or 
events should be considered serious adverse events: an important medical event may not be 
immediately life -threatening or result in death or require hospitalization but may jeopardize the 
patient or require intervention to prevent one o f the above outcomes. Examples of such events 
are allergic bronchospasm, blood dyscrasias, or convulsions that may require intensive treatment 
in an emergency room or at home but do not result in hospitalization, development of drug 
dependency or drug abus e, and transmission of disease associated with the administration of the 
study drug. (See Section  11.2.5 for information about SAE reporting.)  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 81 of 103 
  11.2.1.3. Treatment-Emergent Adverse Event (TEAE)  
Any event that was not present prior to the initiation of study treatment or any event already 
present that worsens in either intensity or frequency following exposure to study treatment.  
11.2.1.4. Adverse Events of Special Intere st (AESI)  
Any AE (serious or non -serious) that is of scientific and medical concern specific to the study 
treatment, for which ongoing monitoring and rapid communication by the Investigator to the 
Sponsor is appropriate.  
11.2.1.5. Special Situation: Abuse, Misuse, Medication Errors, Overdose, and Accidental 
or Occupational Exposure  
â€¢ Abuse: is the persistent or sporadic, intentional excessive use of the study treatment 
which is accompanied by harmful physical or psychological effects.  
â€¢ Misuse: medicinal product is int entionally and inappropriately used not in accordance 
with the authorized/approved product information.  
â€¢ Medication error:  is any preventable incident that may cause or lead to inappropriate 
study treatment use or patient harm while the study treatment is i n the control of the 
health care professionals or patients. Such incident may be due to health care 
professional practice, product labeling, packaging and preparation, procedures for 
administration, and systems, including the following: prescribing, order 
communication, nomenclature, compounding, dispensing, distribution, 
administration, education, monitoring, and use.  
â€¢ Overdose:  is a deliberate or accidental administration of study treatment to a study 
patient, at a dose greater than that which was assigned  to that patient per the study 
protocol and under the direction of the Investigator. If an overdose occurs, the 
Investigator and the Sponsor should be notified immediately, and the patient should 
be observed closely for AEs. Associated AEs should be treate d and monitored by the 
Investigator. The dosage of study drug administered, any associated AEs, and/or 
treatment provided to the patient because of the overdose, should be documented on 
the applicable sections within the eCRF. An overdose (including an AE or SAE 
resulting from the overdose, if any) will be reported as described in Section  11.2.5. 
â€¢ Accidental /Occupational exposure:  is the unintentional exposure to a study 
treatment as a result of oneâ€™s professional or non -professional occupation, or 
accidental exposure to a non -professional to whom exposure was not intended (i.e., 
study product given to wrong patient).  
Reporting Spe cial Situations:  All occurrences of abuse, misuse, medication error, overdose, and 
accidental or occupational exposure with any study treatment must be reported on an SAE 
Report Form [or designated Special Form] to the Sponsor regardless of whether or not an AE or 
SAE has occurred. If the abuse, misuse, medication error, overdose, or accidental / occupational 
exposure is associated with an SAE, an SAE report form must be submitted to the Sponsor 
within 24 hours of awareness. If there is no AE or SAE, the oc currence must be submitted on the 
designated Special Form (indicate â€˜no AE has occurredâ€™) as soon as possible.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 82 of 103 
  11.2.2. Assessment of Adverse Events  
11.2.2.1. Severity Assessment  
All AEs will be assessed by the Investigator for severity according to Common Terminology 
Criteria for Adverse Events (CTCAE) v4.03: 14 June 2010; National Institutes of Health (NIH), 
National Cancer Institute (NCI). The CTCAE severity grades 1 through 5 provide unique clinical 
descriptions of severity of each adverse event. The CTCAE v4.03 is availa ble on the NCI/NIH 
website. 
Please note that there is a distinction between serious and severe AEs. Severity is a measure of 
intensity whereas seriousness  is defined by the criteria in Section  11.2.1.2. For example, a mild 
degree of gastrointestinal bleeding requiring an overnight hospitalization for monitoring 
purposes may be considered an SAE but is not necessarily severe.  
11.2.2.2. Relationship to Study Inter vention 
The Investigator must provide a causality assessment regarding the relationship of the event with 
the study drug and/or study procedure for all AEs. One of the following categories should be 
selected based on medical judgment, considering all contr ibuting factors:  
â€¢ Related: A causal relationship between the medicinal product (and/or study 
procedures) and AE is a reasonable possibility. For example, the occurrence of the 
AE cannot be explained by other causative factors. The AE, however, can be 
explained by pharmacological effect of the medicinal product such as a similar event 
having been reported previously, alteration of the dose effect, or the timing or 
seriousness of the AE, etc. Positive rechallenge/dechallenge  is supportive.  
â€¢ Not Related : A causal relationship between the medicinal product (and/or study 
procedures) and AE is not a reasonable possibility: there is no temporal relationship 
between the medicinal product and event, or an alternative etiology is more 
reasonable.  
11.2.2.3. Expectedness  
The Spon sor will be responsible for determining whether an adverse event is â€˜expectedâ€™ or 
â€˜unexpectedâ€™. An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the risk information provided in the Reference Saf ety Information of 
the effective niraparib Investigator Brochure (IB).  
11.2.3. Collection and Recording of Adverse Events  
AEs may be volunteered spontaneously by the study patient, or discovered by the study staff 
during physical examinations or by asking an open,  nonleading question such as, â€œHow have you 
been feeling since your last study visit?â€ The Investigator will document the nature of AE, date 
of onset of the AE (and time, if known), date of outcome of the AE (and time, if known), 
severity of the AE, action  taken with study drug as a result of the AE, assessment of the 
seriousness of the AE, and assessment of the causal relationship of the AE to study drug and/or 
study procedure.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 83 of 103 
  AEs, including laboratory abnormalities that are assessed as clinically signifi cant or require 
intervention, should be described using a diagnosis whenever possible, rather than individual 
underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or 
symptom should be recorded as a separate AE.  
All SAEs wil l be collected from the signing of the ICF for this study through 90 days after the 
last dose of study drug (or until the start of alternate anticancer therapy, whichever occurs first) , 
and recorded in the eCRF. SAEs will also be reported on an SAE form as  described in 
Section 11.2.5 of this protocol. SAEs considered by the Investigator to be related to study 
medication are reported until study closeout.  
All AEs, regardless of the source of identification (e.g., physical  examination, laboratory 
assessment, ECG, or reported by patient), will be collected and recorded in the eCRF for each 
patient from the time of randomization and/or treatment assignment until 30 days after the last 
dose of study drug.  
Concomitant illnesses  that existed before entry into the study will not be considered AEs unless 
the illness worsens during the Treatment Period. Pre -existing conditions will be recorded as 
Medical History in the eCRF and on the SAE Report Form.  
Disease progression is an effic acy criterion and is therefore not considered an AE or SAE (even 
if fatal). Disease progression should be reported within the appropriate eCRF. If AEs/SAEs 
occur in relation to disease progression that are not consistent with the natural progression of the  
patientâ€™s disease, these AEs/SAEs must be reported per AE/SAE reporting requirements 
described in Section  11.2.5. 
11.2.4. Follow-Up of Adverse Events  
All AEs experienced by a patient, regardless of the suspected causality, will be monitored until 
the AE or SAE has resolved, until AE(s) or SAE(s) have returned to baseline or normal levels, 
until stabilized with a satisfactory explanation for the changes observ ed, until the patient is lost 
to follow-up, or until the patient has died, starts alternate anti -cancer therapy, or until the patient 
withdraws consent.  
If an Investigator becomes aware of an SAE after the specified follow -up period and considers 
the SAE related to the study drug, the Investigator should report the SAE to the Sponsor 
according to timelines for reporting SAEs described in Section  11.2.5. 
11.2.5. Reporting  
The Investigator must report all SAEs, and all follow up information to the Sponsor on an SAE 
Report Form within 24  hours of becoming aware of the initial event or follow -up information. 
The Investigator must provide a causality assessment  and must sign and date all SAE Report 
Forms. 
It is the responsibility of the Investigator to review source documentation and describe pertinent 
information on the SAE Report Form. If supporting documentation is requested (e.g., hospital 
reports, consultan t reports, death certificates, autopsy reports, etc.), the Investigator should 
highlight all relevant and pertinent information within such documents, ensure that any patientâ€™s 
personal identifiers (including Medical Record number) are removed, and submit the documents 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 84 of 103 
  with the SAE Form to the Sponsor . The Sponsor (or designee) will return a confirmation of 
receipt for all email reports (if received from other than a â€œno replyâ€ domain) within 1 business 
day.  
The minimum information required for an initial SAE report is:  
â€¢ Name of person sending the report (ie, name, address of Investigator)  
â€¢ Patient identification (screening/randomization number, initials [if permitted by local 
data privacy regulations], NOT patient name)  
âˆ’ Protocol number  
â€¢ Description of SAE wit h diagnosis if possible  
âˆ’ Causality assessment  
âˆ’ Seriousness assessment  
The Sponsor (or designee) will confirm receipt of all email reports (as long as the email is not 
coming from â€œno replyâ€ domain) within 1 business day.  
SAE REPORTING CONTACT INFORMATION  
 Email: OAX37649@gsk.com  
 Fax: +44(0) 208754 7822  
After receipt of the initial report, the Sponsor (or designee) will review the information and, if 
necessary, contact the Investigator to obtain further information. The Investigator must promptly 
respond to queries from the Sponsor.  
11.2.6. Submission and Distribution of Serious Adverse Event Reports  
Per regulatory requirements, if an event is assessed by the Sponsor as a Serious Unexpected 
Adverse Reaction (SUSAR), it is the responsibility of the Sponsor to submit  the SUSAR to 
Regulatory Authorities according to applicable regulations.  
In addition, the SUSAR will be distributed to the Investigators/sites, utilizing a Council for 
International Organizations of Medical Sciences (CIOMS) report form, or the MedWatch 35 00A 
form). The Investigator/site will submit a copy of the report to their respective Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC) per the governing institutional 
requirements and in compliance with local laws and guidelines.  
11.2.7. Adverse Events of Special Interest  
Adverse Events of Special Interest (AESI) for niraparib are the following:  
â€¢ Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)  
â€¢ Secondary cancers (new malignancies [other than MDS or AML])  
AESI should be coll ected and reported as follows:  
â€¢ MDS and AML along with other secondary cancers should be reported to the Sponsor 
until study closeout (unless death or loss to follow -up occurs first).  
â€¢  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 85 of 103 
  11.2.8. Hypertension, Including Hypertensive Crisis  
Hypertension, including hype rtensive crisis, has been reported with the use of niraparib. 
Preexisting hypertension should be adequately controlled before starting niraparib treatment. 
While receiving treatment, hypertension should be medically managed with antihypertensive 
medicinal products with or without niraparib dose adjustment.  
BP and heart rate should be monitored at least weekly for the first 2 months of niraparib 
treatment in the maintenance setting, then monthly for the first year and periodically thereafter 
during treatmen t with niraparib. Niraparib should be discontinued in case of hypertensive crisis 
or if medically significant hypertension cannot be adequately controlled with antihypertensive 
therapy. 
11.2.9. Posterior Reversible Encephalopathy Syndrome  
There have been rare repo rts of niraparib -treated patients developing signs and symptoms that 
are consistent with posterior reversible encephalopathy syndrome (PRES). PRES is a rare 
neurologic disorder that can present with the following signs and symptoms including seizures, 
headache, altered mental status, visual disturbance, or cortical blindness, with or without 
associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, 
preferably MRI. In patients developing PRES, treatment of specific symptoms includi ng control 
of hypertension is recommended, along with discontinuation of niraparib. The safety of 
reinitiating niraparib therapy in patients previously experiencing PRES is not known.  
11.2.10. Allergic Reaction  
Niraparib capsules contain tartrazine, which may cause  allergic-type reactions.  
11.2.11. Pregnancy  
The Investigator must report all pregnancies and the outcomes to the Sponsor. The Sponsor has 
the responsibility to monitor the outcome of all pregnancies reported during the clinical study.  
Each pregnancy must be report ed by the Investigator to the Sponsor on an Initial Pregnancy 
Report Form within 24 hours of becoming aware of the pregnancy. Pregnancy is not an AE, and 
therefore does not need to be reported as an AE in the eCRF unless there is a suspicion that the 
study drug may have interfered with the effectiveness of a contraceptive medication. The 
Investigator must follow -up all pregnancies, document the course and the outcome, and report 
this information to the Sponsor on a Pregnancy Outcome Report Form within 24 ho urs of 
becoming aware; even if the patient was withdrawn from the study or the study has finished.  
An elective abortion without complications should not be regarded as an AE, however, it should 
be reported as the outcome to the pregnancy on the Pregnancy O utcome Report Form . 
Therapeutic abortions should be reported as a treatment procedure; the reason for the therapeutic 
abortion should be reported on the Pregnancy Outcome Report Form  and as an AE in the eCRF. 
Hospitalization for normal delivery of a healthy newborn should not be considered an SAE.  
Any SAE that occurs during pregnancy must be recorded on the Pregnancy Outcome Report 
Form, reported as an SAE on the SAE Report Form  (e.g., maternal serious complications, 
therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, birth 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 86 of 103 
  defect) and reported to the Sponsor within 24 hours. Hospitalization for normal delivery of a 
healthy newborn should not be con sidered an SAE.  
11.2.12. Special Situations  
All occurrences of abuse, misuse, medication error, overdose, and accidental or occupational 
exposure with any study treatment must be reported on a Special Situations Report Form to the 
Sponsor within 5 calendar days of  becoming aware of the occurrence, regardless of whether it is 
categorized as an AE. If the occurrence is associated with an SAE, an SAE Report Form , along 
with the Special Situations Report Form , must be submitted to the Sponsor within 24 hours of 
awareness. 
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO  3DJHRI
 67$7,67,&6 
$VWDWLVWLFDODQDO\VLVSODQZLOOEH LVVXHGDVDVHSDUDWHGRFXPH QWSURYLGLQJGHWDLOHGPHWKRGVIRU
WKHDQDO\VHV$Q\GHYLDWLRQVIURPW KHSODQQHGDQDO\VHVZLOOEH GHVFULEHGDQGMXVWLILHGLQWKH
ILQDOLQWHJUDWHGFOLQLFDOVWXG\UHSRUW 
$QDO\VLV3RSXODWLRQV 
3.3RSXODWLRQ$OOSDWLHQWVZKRUH FHLYHDWOHDVWRQHGRVHRIQL UDSDULEDQGKD YHDWOHDVWRQH
PHDVXUDEOHQLUDSDULERUQLUDSDULERU  6WDJHRQO\FRQFHQWUD WLRQ
3.(YDOXDEOH3RSXODWLRQ $OOSDWLHQWVZKRFRPSOHWHDWOHDVWRQH3.3 HULRGDQGKDYHVXIIL FLHQW
FRQFHQWUDWLRQGDWDWRDFFXUDWHO \HVWLPDWH3.SDUDPHWHUVZLWKRXW VLJQLILFDQWQLUDSDULEFDUU\RYHU
EDVHOLQHFRQFHQWUDWLRQ !RI& PD[LQDWOHDVWRQH3HULRG 3DWLHQWVZLWKFDUU\RYHUZLOOEH
H[FOXGHGIURPWKHDQDO\VLVRI3HULRGEXWZLOOEHLQFOXGHG LQWKHDQDO\VLVRI SHULRGDVGDWDLV
DYDLODEOH
%$%((YDOXDEOH3RSXODWLRQ $OOSDWLHQWVZKRFRPSOHWHERWK3.3HU LRGVDQGKDYHVXIILFLHQW
3.VDPSOHFROOHFWLRQWR DFFXUDWHO\HVWLPDWH3.SDUD PHWHUVZLWKRXWVLJQLILFDQWQLUDSDUL E
FDUU\RYHUEDVHOLQHFRQFHQWUDWLRQ !RI& PD[LQERWK3.3HULRGV 3DWLHQWVZKRKDYH
VLJQLILFDQWQLUDSDULEFDUU\RYH ULQ3HULRGZLOOEHFRPSOHWHO\ H[FOXGHGIURPWKH%$%(
(YDOXDEOH3RSXODWL RQ

)((YDOXDEOH3RSXODWLRQ$OOSDWLHQWVZKRFRPSOHWHERWK3.3HUL RGVDQGKDYHVXIILFLHQW3.
VDPSOHFROOHFWLRQWRDFFXUDWHO \HVWLPDWH3.SDUDPHWHUVLQERWK SHULRGV3DWLHQWVPHHWLQJQRQ 
HYDOXDELOLW\FULWHULDRUKDYLQJVLJQLILFDQWQLUDSDULEFDUU\RYHU EDVHOLQHFRQFHQWUDWLRQ !RI
&PD[ZLOOEHFRPSOHWHO\H[FOXGHGIURPWKH)(3RSXODWLRQ 

7KHVDIHW\SRSXODWLRQZLOOFRQVL VWRIDOOSDWLHQWVZKRUHFHLYH GUXJ
6DPSOH6L]H&RQVLGHUDWLRQ 
6WDJH
1RIRUPDOVDPSOHVL]HFDOFXODWLRQZD VSHUIRUPHGIRU6WDJH$S SUR[LPDWHO\SDWLHQWVZLOOEH
HQUROOHGLQ6WDJH7KLVVDPSOHVL] HLVFRQVLGHUHGDGHTXDWHIR USUHOLPLQDU\DVVHVVPHQWRIWKH
UHODWLYHELRDYDLODELOLW\RIWKHWD EOHWFRPSDUHGWRWKHFDSVXOHV DQGIRUHVWLPDWLQJWKHLQWUD VXEMHFW
FRHIILFLHQWRIYDULDWLRQDIWHUDFFRX QWLQJIRUSDWLHQWGURS RXWVDQGSRWHQWLDOFDUU\RYHU 
6WDJH
%DVHGRQHVWLPDWHVIURP6WDJH %$%(HYDOXDEOHSDWLHQWVDUHUH TXLUHGLQ6WDJH:LWK
HYDOXDEOHSDWLHQWVDVVXPLQJWKHLQWUD VXEMHFWFRHIILFLHQWRIYDULD WLRQ&9LVDQGWKH
WUXHUDWLRRIPHDQVLVWKHUHLVDWOHDVWSRZHUWRGHPRQVWUD WHWKHELRHTXLYDOHQFH
ELRHTXLYDOHQFHUDQJH WRDOSKD 3RZHUFDOFX ODWLRQVZHUHDOVRSHUIRUPHG
XQGHUDOWHUQDWLYHDVVXP SWLRQVIRUWKH&9DQGPHDQUDWLR$VVXPL QJWKH&9LV DQGWKHWUXH
UDWLRRIPHDQVLVZLWKHYDOXDEOH SDWLHQWVWKHUHLV DWSRZHUWRGHPRQVWUDWH
ELRHTXLYDOHQFH$VVXPLQJWKHWUXHUDWLRLVWKHSRZHULV DQGDVVXPLQJ&9VRI
DQGUHVSHFWLYHO\ CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 88 of 103 
  The final analysis of bioequivalenc e will be based on Stage 2 BA/BE evaluable patients only, 
with a target sample size of 100 evaluable patients . Patients may be identified as non -evaluable 
due to issues arising during the study conduct, such as:  
â€¢ emesis within 9 hours of dosing,  
â€¢ dosing err ors,  
â€¢ patient did not fast prior to dosing,  
â€¢ missing critical PK sample on Day 8 ,  
â€¢ failure to complete both PK periods, and  
â€¢ significant changes to the patient medical status that would potentially affect the PK 
profile as determined by the Sponsor in consultation with the Investigator prior to PK data 
analysis.  
In this patient population, approximately 170 total patients are targeted for enrollment, assuming 
a 35% non -evaluability rate during the study conduct, and an additional 10% non -evaluabilit y 
rate during PK analysis.  The non-evaluability rate arising during the study conduct will be 
continuously monitored by the Sponsor  and the total number of enrolled patients  may be adjusted 
accordingly with the aim to target the resulting sample size of 10 0 BA/BE evaluable patients.   
Stage 3 
Assuming the true ratio of means is 1 and the intra -subject CV is 20% for AUC0-t and AUC0-âˆž, 
with 16 evaluable patients , there is approximately  83% probability  the 90% CI of the ratio of 
geometric means will be within 0.800 and 1.250. Based on the results of a FE study conducted 
using the capsule formulation, an effect of a high -fat meal on C max is possible. The sample size of 
16 patients is deemed adequate to characterize this effect. AUC0-t and AUC 0-âˆž will be the 
primary parameters for analysis.   
The primary analysis will be based on the FE Evaluable Population as it is the most conservative 
approach, which maximizes the benefits of the crossover design, where each patient serves as 
their own control. Results fo r the PK Evaluable Population will also be summarized and reported 
for this study.  
To account for non -evaluable patients, approximately 20 total patients are targeted for 
enrollment. The final analysis will be based on Stage 3 FE evaluable patients only.  Patients may  
be identified as non -evaluable due to issues arising during the study conduct, such as:  
â€¢ dosing errors ,  
â€¢ patient did not follow dietary requirements prior to dose and postdose ,  
â€¢ failure to complete both PK periods , and 
â€¢ significant changes to the patient medical status that would potentially affect the PK 
profile as determined by the Sponsor in consultation with the Investigator prior to PK 
data analysis.  
Patients who vomit within 10 hours of dosing or miss sufficient sa mples to render calculation of 
AUC unreliable will be discontinued from the PK phase; those that meet other criteria for 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 89 of 103 
  continued niraparib therapy will be eligible to be screened for the Extension Phase (see 
Section 6.1). The non-evaluability rate arising during the study conduct will be continuously 
monitored by the Sponsor  and the total number of enrolled patients  may be adjusted accordingly 
with the aim to target the resulting sample size of 16 evaluable patients.   
12.3. Safety Analyses  
Data from the Stage 1 PK Phase, Stage 2 PK Phase , Stage 3 PK Phase and Extension Phase will 
be summarized separately. Summaries will be performed by formulation , fed/fasted state and 
dosing period as applicable. The safety population will consist of all patients who receive drug.  
Demographic characteristics will be summarized descriptively and will include age, sex, race, 
height, and weight.  
Protocol deviations will b e listed by patient.  
All analysis for safety endpoints will be done in a descriptive manner. Continuous variables will 
be summarized using descriptive statistics (number of patients, mean, standard deviation [SD], 
minimum, median, and maximum). Categorical  variables will be summarized using counts of 
patients and percentages.  All AEs will be coded using the most up -to-date version of MedDRA. 
NCI-CTCAE v.4.03 will be used to grade the severity of AEs and laboratory abnormalities.  
All AEs will be listed. The  number and percent of patients who experience  a TEAE will be 
summarized by formulation , fed/fasted state and dosing period as applicable for each system 
organ class and preferred term. TEAEs will also be tabulated accordingly by intensity and 
causality.  
An analysis of AEs will include the following categories:  
â€¢ TEAEs 
â€¢ Drug-related TEAEs  
â€¢ Grade 3, 4, and 5 TEAEs (presented by grade and overall)  
â€¢ Grade 3, 4, and 5 drug -related TEAEs (presented by grade and overall)  
â€¢ TEAEs resulting in study drug discontinuation  
â€¢ Most commonly reported TEAEs  
â€¢ Treatment -emergent SAEs  
â€¢ AESIs 
Individual data listings of laboratory test results will be presented. Flags will be attached to 
values outside of the laboratory's reference limits along with the Investigator's assessment. 
Clinically significant laboratory test abnormalities that were considered AEs by the Investigator 
will be presented in the AE listing.  
In addition, for the Extension  Phase, clinical laboratory tests (observed values and changes from 
baseline) will be summa rized descriptively in tabular format. Shift tables will be presented for 
select laboratory parameters (chemistry and hematology).  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 90 of 103 
  Individual data listings of vital signs (observed and change from Baseline) will be presented for 
each patient. Individual cl inically significant vital sign findings that were considered AEs by the 
Investigator will be presented in the AE listing.  
All clinically relevant physical examination findings will be listed.  
12.4. Pharmacokinetic Analysis  
Individual and mean plasma concentrati ons over time will be plotted by formulation for the 300 -
mg dose group  in Stage 1 and 2 and by fed/fasted state in Stage 3 . Planned sampling times will 
be used to generate the mean concentration -time profiles.  
Individual patient PK parameter values will be  derived by non -compartmental methods using 
WinNonlin, version 5.1 or higher. Actual time will be used in parameter estimation.  The analysis 
of Stage 1 , Stage 2, and Stage 3 will be conducted separately.  
During the pharmacokinetic analysis, the following rules will apply : 
â€¢ Predose sample >5% of C max: profile will be excluded from PK concentration and PK 
parameters summary and inferential statistics  
â€¢ Rsq,adj <0.800: AUC 0-âˆž, Î»z, CL/F, Vz/F, and t 1/2 will be excluded from descriptive and  
inferential statistics 
â€¢ AUC0-t /AUC0-âˆž, <0.800: AUC 0-âˆž and parameters derived from it will be excluded from 
descriptive and inferential statistics   
Individual and mean plasma concentrations over time will be plotted by formulation  in Stage 1 
and 2 and by fed/fasted s tate in Stage 3 . The individual plasma concentration versus actual time 
profiles for each subject, as well as the mean plasma conce ntration versus scheduled time 
profiles for each treatment, will be presented graphically on a linear -linear and log -linear scale. 
Combined individ ual concentration versus time graphs per treatment will also be presented, 
together with  mean values. Plasma concentrations and PK parameters will be summarized in 
terms of the number of patients, arithmetic mean, median, SD, coeffic ient of variation (CV), 
geometric mean, geometric CV, minimum and maximum by formulation  in Stage 1 and 2 and by 
fed/fasted state in Stage 3 , across the PK, PK Evaluable , BA/BE Evaluable  and FE Evaluable  
populations, as appropriate . In Stage 3, differences in t max between the fed and fasted state will be 
assessed and summarized based on the FE Evaluable Population. Details will be provided in the 
Pharmacokinetic Analysis Plan.  
To assess relative bioavailability/bioequivalence, an ana lysis of variance model (ANOVA) will 
be used on logarithmically transformed  AUC0-t, AUC0-âˆž, and Cmax accounting for the following 
sources of variation: sequence, subjects nested in sequences, period and treatment. The point 
estimate and 90% CIs for the rat ios of the geometric means of the test treatment (tablet) 
compared to the reference treatment (capsule) will be obtained. Bioequivalence will be claimed 
if the 90% CI for the ratio of geometric means is between 0.800 and 1.250 for AUC 0-t, AUC0-âˆž, 
and Cmax. To assess  the effect of food for Stage 3 , the ratio of geometric means of the  test 
treatment ( high-fat meal) and corresponding 90% CI compared to the reference treatment (fasted 
state) will be obtained  for AUC0 -t, AUC0 -âˆž, and C max. 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 91 of 103 
  A population PK analysis may be performed on the PK data from the PK Phase of the study and 
will be reported separately from the study.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 92 of 103 
  13. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  
13.1. Study Monitoring  
Before an investigational site can enter a patient into the stud y, a representative of the Sponsor  
will visit the investigational study site to:  
â€¢ Determine the adequacy of the facilities  
â€¢ Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilitie s of the Sponsor  or its representatives. This 
will be documented in a Clinical Study Agreement between the Sponsor  and the 
investigator.  
During the study, a monitor from the Sponsor  or representative will have regular contacts with 
the investigational site , for the following:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that facilities remain acceptable  
â€¢ Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms (CRFs) , and that investigational product 
accountability checks are being performed  
â€¢ Perform source data verification. This includes a comparison of the data in the CRFs with 
the patientâ€™s medical records at the hospital or practice, and other records relevant to the 
study. This will require direct access to all original records for each patient (eg, clinic 
charts). 
â€¢ Record and report any protocol deviations not previously sent to the Sponsor . 
â€¢ Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs 
have been forwarded to the Sponsor  and those SAEs that met criteria for reporting have 
been forwarded to the IRB.  
The monitor will be available between visits if the investigat or(s) or other staff needs 
information or advice.  
13.2. Audits and Inspections  
Authorized representatives of the Sponsor , a regulatory authority, an IEC or an IRB may visit the 
site to perform audits or inspections, including source data verification. The purpose of a the 
Sponsor audit or inspection is to systematically and independently examine all study -related 
activities and documents to determine whether these activities were conducted, and data were 
recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice 
(GCP) guidelines of the International Council for Harmonization (ICH), and any applicable 
regulatory requirements. The investigator should contact the Sponsor  immediately if contacted 
by a regulatory agency about an inspection.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 93 of 103 
  13.3. Institutional Review Board  
The Principal Investigator must obtain IRB approval for the investigation. Initi al IRB approval, 
and all materials approved by the IRB for this study including the patient consent form and 
recruitment materials must be maintained by the Investigator and made available for inspection.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 94 of 103 
  14. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure com pliance with GCPs and all applicable regulatory requirements, the Sponsor may 
conduct a quality assurance audit. Please see Section  13.2 for more de tails regarding the audit 
process. 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 95 of 103 
  15. ETHICS  
15.1. Ethics Review  
The final study protocol, including the final version of the ICF, must be approved or given a 
favorable opinion in writing by an IRB or IEC as appropriate. The investigator must submit 
written approva l to the Sponsor  before he or she can enroll any patient/subject into the study.  
The Principal Investigator is responsible for informing the IRB or IEC of any amendment to the 
protocol in accordance with local requirements. In addition, the IRB or IEC must  approve all 
advertising used to recruit patients for the study. The protocol must be re -approved by the IRB or 
IEC upon receipt of amendments and annually, as local regulations require.  
The Principal Investigator is also responsible for providing the IRB with reports of any 
reportable serious adverse drug reactions from any other study conducted with the investigational 
product. the Sponsor  will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse dr ug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines.  
15.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are cons istent with ICH/GCP, applicable regulatory requirements 
and TESAROâ€™s policy on Bioethics.  
15.3. Written Informed Consent  
The Principal Investigator(s) at each center will ensure that the patient is given full and adequate 
oral and written information about the n ature, purpose, possible risk and benefit of the study. 
Patients must also be notified that they are free to discontinue from the study at any time. The 
patient should be given the opportunity to ask questions and allowed time to consider the 
information p rovided. 
The patientâ€™s signed and dated informed consent must be obtained before conducting any study 
procedures.  
The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF 
must be given to the patient.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 96 of 103 
  16. DATA HANDLING AND  RECORDKEEPING  
16.1. Inspection of Records  
The Sponsor  will be allowed to conduct site visits to the investigation facilities for the purpose of 
monitoring any aspect of the study. The Investigator agrees to allow the monitor to inspect the 
drug storage area, st udy drug stocks, drug accountability records, subject charts and study source 
documents, and other records relative to study conduct.  
16.2. Retention of Records  
The Principal Investigator must maintain all documentation relating to the study for a period of 
2 years after the last marketing application approval, or if not approved 2 years following the 
discontinuance of the test article for investigation. If it becomes necessary for the Sponsor  or the 
Regulatory Authority to review any documentation relating to th e study, the Investigator must 
permit access to such records.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 97 of 103 
  17. PUBLICATION POLICY  
Information regarding publication of study results is contained in the Clinical Trial Agreement 
for this study.  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 98 of 103 
  18. LIST OF REFERENCES  
1. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP -ribose) polymerase inhibitor 
niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a 
phase 1 dose -escalation trial. Lancet Oncol. 2013;14(9):882 -892. 
2. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP -ribose) polymerase in tumors 
from BRCA mutation carriers. N Engl J Med. 2009;361(2):123 -134. 
3. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP -ribose) polymerase inhibitor 
olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a 
proof-of-concept trial. Lancet. 2010;376(9737):245 -251. 
4. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high -
grade serous or poorly differentiated ovarian carcinoma or triple -negative breast cancer: a 
phase 2, multicentre, open -label, non -randomised study. Lancet Oncol. 2011;12(9):852 -
861. 
5. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with 
metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. 
Clin Cancer Res. 2012;18(6):1726 -1734. 
6. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum -
sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382 -1392. 
7. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with 
platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of 
outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852 -
861. 
8. Mirza MR, Monk BJ, He rrstedt J, et al. Niraparib Maintenance Therapy in Platinum -
Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154 -2164. 
9. Guan J, Lim KS, Mekhail T, Chang CC. Programmed Death Ligand -1 (PD-L1) 
Expression in the Programmed Death Receptor -1 (PD-1)/PD-L1 Blockade: A Key Player 
Against Various Cancers. Archives of pathology & laboratory medicine. 
2017;141(6):851 -861. 
10. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Onco l. 1982;5(6):649 -655. 
11. FDA. US Food and Drug Administration Center for Drug Evaluation and Research. 
Guidance for Industry: Food -Effect Bioavailability and Fed Bioequivalence Studies. 
2002. Accessed 08 Dec 2020. Available at: https://www.fda.gov/media/7 0945/download . 
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO  3DJHRI
 $33(1',; $($67(51&223(5$7,9( 21&2/2*<*5283
3(5)250$1&(67$786 
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which 
are protected by third party copyright laws and therefore have been excluded.
1LUDSDULE  
&OLQLFDO6WXG\3URWRFRO 9HUVLRQ  
&RQILGHQWLDO  3DJHRI
 $33(1',; %&20321(176$1'(;&,3 ,(1762)1,5$3$5,%
&$368/(6$1'7$%/(76 
CCI
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 101 of 103 
  APPENDIX  C. CONTRACEPTION GUIDEL INES 
Patients of childbearing potential who are sexually active and their partners must agree to the use 
of 2 highly effective form of contraception throughout their participation during the study 
treatment and for 180 days af ter last dose of study treatment(s). Acceptable birth control methods 
include: 
â€¢ Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation:  
âˆ’ oral route  
âˆ’ intravaginal route  
âˆ’ transdermal route  
â€¢ Progestogen -only hormonal contraception associated with inhibition of ovulation  
âˆ’ oral 
âˆ’ injectable  
âˆ’ implantable  
â€¢ Intrauterine device  
â€¢ Intrauterine hormone-releasing system  
â€¢ Bilateral tubal occlusion  
â€¢ Vasectomized partner  
â€¢ Sexual abstinence, if the preferred and usual lifestyle of the subject  
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 102 of 103 
  APPENDIX  D. PERMITTED HORMONAL T HERAPIES  
â€¢ Anastrozole  
â€¢ Letrozole  
â€¢ Exemestane  
â€¢ Fulvestrant  
â€¢ Abiraterone  acetate 
â€¢ Enzalutamide  
â€¢ Goserelin 
â€¢ Bicalutamide  
â€¢ Leuprolide  
 
Niraparib    
Clinical Study Protocol 3000 -01-004 Version 6.0   
Confident ial  Page 103 of 103 
  APPENDIX  E. GUIDANCE ON CO MPOSITION  OF HIGH -AT MEAL  
During Stage 3 PK periods, patients will receive their niraparib dose in a fasted state or directly 
after having had a high -fat meal. Below is an e xample of a high -fat meal, where â‰¥50%  of 
calories are derived from fat. Substitutions can be made to this meal if the caloric content, 
volume, and viscosity are maintained.  
Example of a high -fat meal: 
Total Calories  800-1000 
Calories from Protein  150 
Calories from Carbohydrates  250 
Calories from Fat  500-600 
An Example of a High -Fat Breakfast  â€¢ Two eggs fried in butter  
â€¢ Two strips of bacon  
â€¢ Two slices of toast with butter  
â€¢ Four ounces of hash brown potatoes  
â€¢ Eight ounces of whole milk  
Source: FDA, 2002   
 